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Tumorigenesis is a multistep process involving the alteration of genes involved in the
regulation of growth. Alteration of both positively acting oncogenes and negatively acting tumour
suppressor genes has been identified in breast tumours. The inactivation of tumour suppressor genes
often arises through a loss of genetic material which can be detected in tumours as a reduction to
homozygosity at loci that are normally heterozygous. A high rate of loss of heterozygosity (LOH) at
a specific chromosomal locus is indicative of tumour suppressor gene inactivation and has been used
to locate tumour suppressor genes involved in a number of malignancies. A high frequency of LOH
(61%) has been detected in a series of breast tumours at a site at 17pl3.3 suggesting the presence of a
tumour suppressor gene involved in breast cancer on chromosome 17p (Mackay et al, 1988a).
Following on from this work the incidence of LOH in primary breast tumours was
determined at other loci on chromosome 17p and served a two fold purpose. First, the pattern of
LOH at different loci on chromosome 17 in individual breast tumours was determined in order to
define a shortest region of overlap (SRO). Identification of such a region, commonly lost in all
tumours showing LOH, could be used to pinpoint the position of the putative tumour suppressor
gene. Secondly, as two of the probes used to investigate LOH detect loci close to the known tumour
suppressor gene p53, a potential role for the p53 gene in breast cancer development could be
investigated.
Two tumour samples showed LOH at the p53 locus and not at the more distal 17pl3.3 site,
suggesting the involvement of the p53 gene in breast tumorigenesis. Furthermore LOH at the p53
gene locus was detected in 49% of primary breast tumour samples. Exons 5-9 of the p53 gene,
which contain known mutation hotspots, were examined for mutation in 78 primary breast tumours
using the HOT (amplification and mismatch detection) technique. Twenty four (31%) of the breast
tumours were found to possess a somatically acquired p53 mutation, mostly single base substitutions
resulting in missense mutations. In tumours with data on both LOH and p53 mutation, the majority
of p53 mutations were found to be accompanied by LOH, indicating the importance of the removal
of the tumour suppressive function of the gene. The types and positions of p53 mutation occurring in
breast tumour samples in this and other studies were analysed. Mutations occurred at a number of
sites throughout the gene although no specific hotspot was identified. A preponderance of mutations
at guanine residues, suggesting exogenous factors, was also observed. p53 mutation was found to be
associated with a low level of oestrogen receptor protein suggesting an association with aggressive
tumour behaviour but not with patient age, menopausal status, family history, tumour size or lymph
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1.1.1 S tructure and development of the human breast.
The functional component of the adult female breast comprises 15-20 milk producing
lobular units connected to the nipple complex by a system of branching ducts. These functional units
are surrounded by varying amounts of fat and connective tissue which make up the bulk of the
breast. During lactation the milk produced by the lobular units drains into the duct system and is
passed out of the body through the nipple (Page and Anderson 1988). The breast duct system is
arranged in a segmental roughly radial pattern from the nipple and each branch consists of three
parts: the ductules (DTL), which are the terminal blind endings of the duct system; and the
intralobular and extralobular sections of the terminal duct (ITD and ETD), which are defined by the
specialised stroma of the lobular unit surrounding the ductules. This structure is known as the
terminal ductal lobular unit (TDLU) and is considered to be the basic functional unit of the breast
(Figure 1.1) (Wellings et al., 1975).
Major changes in the development of the breast occur during puberty. Small bundles of
duct give rise to alveolar buds which when clustered form the DTL and ITD or type 1 lobule. An
increase in the number of alveolar buds and the volume of the lobule results in the progressive
transition of these lobular units to types 2, 3 and 4. The type 4 lobule is the most developed lobule
type and is present only during pregnancy, when maximal differentiation of the breast occurs. In the
absence of child bearing the lobules decrease in both size and number and only type 1 and 2 lobules
are observed (Russo et al., 1990).
1.1.2 Origin of human breast cancer.
Breast cancer is a heterogeneous disease and a wide variety of benign and malignant lesions
of the breast have been identified. Depending upon classification there are between twenty and
thirty types of breast carcinoma (Gallager 1984). Histologically, malignant breast tumours can be
classed into numerous subgroups including lobular, tubular, medullary, mucinous, cribriform and
papillary types although most tumours are classed as either no special type (NST) (Page and
Anderson 1988) or not otherwise specified (NOS) (Fisher et al., 1984). The majority of the
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Figure 1.1
Normal terminal ductal lobular unit (TDLU).
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malignant carcinomas are thought to arise from epithelial cells in the TDLU and are thus classified
as 'ductal'. The lobular type carcinoma is thought to arise from the more differentiated type 2 lobules
and type 3 and type 4 lobules have been proposed as the site of origin for benign lesions occurring in
the breast (Russo et al., 1990).
Breast carcinomas can be further grouped into invasive (or infiltrative) and non-invasive
types depending on the presence or absence of tumour growth into the surrounding tissue. Non¬
invasive carcinomas are classed as ductal carcinoma in situ (DCIS) (or intraductal carcinoma) and
lobular carcinoma in situ (LCIS). Both forms are associated with an increased risk of developing
invasive carcinoma. 25-30% of patients with DCIS and 20-30% of patient with LCIS develop
invasive breast carcinomas within 15-20 years. (Haagensen et al., 1978; Page et al., 1982).
However, in contrast, patients with DCIS will develop invasive carcinoma at the same site as the
original DCIS (Page et al., 1982) whereas only 20% of patients possessing LCIS develop invasive
carcinomas at the same site. Indeed 50% of LCIS patients develop invasive carcinomas in a different
breast than the original LCIS (Haagensen et al., 1978). It is concluded from these observations that
DCIS is a precursor to invasive breast carcinoma despite the absence of direct evidence. Lobular
carcinoma is seen more as a marker for breast cancer than an intermediate stage.
1.1.3 Incidence and epidemiology of breast cancer.
Breast cancer is the most frequent malignancy diagnosed in women. It is thought that
nearly one in twelve women in the western world will be affected by the disease at some point in
their lifetime. An estimated 572,100 cases of breast cancer occurred world-wide in 1980 (Parkin
1988). This figure represented 18.4% of all new cancer cases diagnosed in women alone and 9% of
all new cancer cases. Estimates of the global incidence of breast cancer by the end of the century
have been as high as 1,000,000 cases per year (Millar and Bulbrook 1986). Breast cancer accounts
for 15-20% of all cancer deaths and between 2 and 5% of all deaths in developed countries of the
world (Adami et al., 1990).
Although there is a relative lifetime risk of approximately 8% of developing breast cancer,
not all women are equally at risk. Epidemiological studies have identified groups of women whose
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risk of developing breast cancer is above that of the average (Boyle and Leake 1988; Kelsey and
Berkowitz 1988; Willett 1989; Adami el al., 1990). An increased risk has been shown to be
associated with increasing age, early menarche, late menopause, high body mass index, high fat and \
or energy intake, radiation exposure, previous incidence of certain types of benign breast disease and
the occurrence of the disease in one or more relatives. However, with the exclusion of age, family
history and hormonal involvement, numerous studies have not been able to draw consistent
conclusions about the effects of various risk factors examined (Boyle and Leake 1988).
Through epidemiological analysis of geographic differences in breast cancer incidence it has
been proposed that as much as 80% of all breast cancer cases can be attributed to non-genetic
environmental factors and so is therefore theoretically preventable (Doll and Peto 1981). However,
despite extensive epidemiological study, it is thought that only 25% of breast cancer cases can be
accounted for by currently identified risk factors (Seidman 1983). In addition such studies have
failed to identify a risk factor which can offer the potential for preventative measures (Doll and Peto
1981).
1.1.4 Multistep tumorigenesis.
Cancer cells are defective in cellular growth control and differ from normal cells in that
they possess the ability to divide continuously and invade surrounding tissue. They are sometimes
able to move from their site of origin and establish secondary colonies in other organs of the body, a
process known as metastasis. It is only within the past 20 years that the processes behind tumour
generation have been elucidated.
The hypothesis of multistep tumorigenesis has now been almost universally accepted.
Tumours are believed to be monoclonal in origin, ie they arise from a single cell. The transition of a
normal cell to a malignant clone is thought to occur in a series of steps. Each step confers on the cell
a growth advantage enabling the cell to outgrow neighbouring cells, a process known as clonal
expansion (Nowell 1976). The resulting increase in cell number increases the chance of a further
alteration occurring in one of the progeny cells. Any clone obtaining an alteration conferring a
further growth advantage will again be able to outgrow the surrounding cells, thereby becoming the
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predominant clone. Successive series of clonal expansion are thought to occur until a clone showing
the malignant phenotype is produced. Further alterations are thought necessary to confer metastatic
ability onto the tumour cells (Hart and Saini 1992).
Cancer is an age related disease and the majority of human cancers increase in direct
proportion with age. This observation is in keeping with a model ofmultistep tumorigenesis and
suggests the likelihood that a cell will contain all the changes necessary to confer a malignant
phenotype increases with time. The number of events necessary for the generation of human
malignancies has been estimated from the age incidence of common cancers. Analysis of the
kinetics revealed a requirement for 5 or 6 independent rate limiting events to occur in the formation
of a tumour (Armitage and Doll 1954) although only as few as two events may be necessary for
certain childhood malignancies (Haber and Housman 1991).
Advances in molecular biology have led to the identification of some of the alterations
occurring in tumorigenic cells. These include large and small alterations at the DNA level, increased
and decreased expression of a wide variety of genes, altered methylation patterns of DNA, the loss,
gain, rearrangement and translocation of chromosomes and alteration in ploidy. Recent research has
identified genes playing a key role in the generation of a malignant phenotype which have been
shown to be altered by the mechanisms listed above. These genes are normally involved in the
control of cell growth and proliferation and, depending on their function, have been classed into two
groups: the dominantly acting oncogenes and the recessive tumour suppressor genes.
1.2 Oncogenes.
1.2.1 Oncogenes and breast cancer.
Oncogenes were first discovered through work on cancer retroviruses capable of producing
neoplastic growth in infected animals (Varmus 1984). Analysis of the viral DNA revealed the
genetic elements responsible for viral oncogenicity to be altered copies of cellular genes involved in
cell growth and proliferation. Further oncogenes have been identified through analysis of
translocation breakpoints and cell transformation by tumour derived DNA (Varmus 1984; Bishop
1985). Currently over 40 oncogenes have been identified and characterised and are known to
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function as cellular growth factors, growth factor receptors, signal transducers, protein kinases and
transcription factors (Bishop 1985; Seemayer and Cavenee 1989). In human cancers proto-
oncogenes are converted to dominantly acting oncogenes by point mutation, chromosomal
translocation or amplification. Examples include point mutation at codons 12, 13 and 61 in the
oncogene H-ras; over-expression of the oncogene myc by the promoters of the immunoglobin heavy
chain gene via translocation; and amplification of the oncogene c-erbB2/neu/Her2.
Activated oncogenes are known to play a part in the genesis ofmost solid tumours although
the specific oncogenes involved vary between malignancies. A number of oncogenes have been
implicated in the development of breast cancer and those showing the highest frequency of alteration
in breast tumours are neu, myc, int-2 and ras.
1.2.2 The neu oncogene.
The neu oncogene was initially identified from transfection studies using DNA from a
chemically induced rat neuroglioblastoma (Schechler et al., 1984). It was also cloned by virtue of its
homology to the v-erbB oncogene in avian erthyroblastosis virus and named cerbB2 and HER2 (King
et al., 1985; Semba et al., 1985). Neu belongs to a family of epithelial growth factor receptors
along with the human epithelial growth factor receptor (EGFR) or cerbBl and cerbB3 (or IIER3).
The neu gene has been mapped to 17q21 and codes for a protein of 185kD (pl85 neu).
The transforming oncogene identified in the rat neuroglioblastoma possessed a point
mutation resulting in dimerisation of the protein and an increased and constitutive activity of the
protein's intracellular kinase domain (Weiner et al., 1989). An investigation for similar transforming
mutations identified no such alterations in 100 breast tumours (Lemoine et al., 1990). However
amplification of the neu gene has been detected in breast tumours and shows good correlation with
over-expression of the normal pl85neu protein (Lacroix et al., 1989; Miller at al., 1991).
Identification of over-expression without amplification in approximately 10% of breast carcinoma
samples indicates that other mechanisms of transcriptional deregulation can occur (Slamon et al.,
1987). The neu gene has been the most intensely studied oncogene in breast cancer because of the
reported potential of neu amplification as a marker for shorter relapse time and shorter overall
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survival in breast cancer patients (Gullick 1990; Perren 1991; Borg 1992). In addition the presence
of neu amplification in DCIS of certain histological subtypes and the maintenance of gene
amplification throughout tumour development indicates that it may be one of the earliest genetic
alterations to occur in breast cancer (Van de Vijers et al., 1988). Estimates of the frequencies of
amplification/over-expression have ranged from 9% (Barnes et al., 1988) to 33% (Clark and
McGuire 1991) but the majority of studies utilising a large number of samples show a frequency
between 14 and 23% (reviewed by Clark and McGuire 1991; Perren 1991; Borg 1992).
1.2.3 The int-2 oncogene.
The int oncogenes were first described because of their activation by the MMTV (Mouse
Mammary Tumour Virus) promoter sequences in the development of mammary tumours in mice.
Although the MMTV does not contain a transduced oncogene it was shown to be inserted in the
mouse genome at specific sites, the two most frequent sites of proviral insertion being adjacent to the
int-1 and int-2 genes (Nusse 1988). The human homologue of int-2 is a member of the fibroblast
growth factor family and maps to chromosome llql3 (Dickson et al., 1990). Estimates for the
frequency of int-2 amplification in breast carcinoma range from 9% to 23% (Lidereau et al., 1988;
Varley et al., 1988; Zhou et al., 1988; Adnane et al., 1989; Ali et al., 1989a; Theillet et al., 1989;
Tsuda et al., 1989; Fantl et al., 1990; Meyers et al., 1990; Theillet et al., 1990; Borg et al., 1991).
However in contrast to neu oncogene amplification there is poor correlation between
amplification of int-2 and over-expression of the int-2 protein (Liscia et al., 1989; Theillet et al.,
1989; Fand et al., 1990). Amplification of the 1 lql3 chromosome band is not int-2 specific and has
been estimated to encompass between 2-3 Mb of DNA (Tanigami et al., 1992). Amplification
usually includes the proto-oncogene hst-1, another member of the fibroblast growth factor family
(Adelaide et al., 1988), and BCL-1, a gene associated with chromosomal breakpoints in B-cell
lymphoma. However the identification of tumours possessing amplification of the BCL-1 gene
without coamplification of the int-2 gene (Thelliet et al., 1990), int-2 gene amplification without
BCL-1 and hst-1 amplification (Ali et al., 1989a) and int-2 amplification without hst-1 amplification
(Tsuda et al., 1989) question the involvement of these genes in the selective advantage of llql3
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amplification. These observations could be explained by the involvement of an as yet unknown gene
present in the llql3 amplified region (Szepetowski et al., 1992).
1.2.4 The c-myc oncogene.
C-myc is a nuclear oncogene which codes for a transcription factor protein. The c-myc
gene is the cellular homologue of v-myc, the transforming gene of the avian myelocytomatosis virus
CM29, and maps to chromosome 8q24 (Watson et al., 1983). C-myc shows sequence homology
with two other known oncogenes, N-myc and L-myc, although only c-myc is thought to be
implicated in breast cancer (Field and Spandidos 1990). Amplification of L-myc has only been
detected in a single intraductal breast carcinoma (Varley et al., 1987). Estimates for c-myc
amplification in breast tumours range from 4% to 41% (Escot et al., 1986; Varley et al., 1987;
Biunno et al., 1988; Bonilla et al., 1988; Guerin et al., 1988; Garcia et al., 1989; Seshadri et al.,
1989; Tavassoli et al., 1989; Tsuda et al., 1989; Borg et al., 1992a; Pavelic et al., 1992). These
figures probably underestimate the involvement of c-myc in breast tumorigenesis since studies have
detected increased c-myc expression in approximately 70% of breast tumour samples (Escot et al.,
1986; Whittaker et al., 1986). In the study by Escot et al. (1986) only 6/14 tumours with elevated c-
myc expression showed corresponding amplification of the c-myc gene indicating other mechanisms
of transcriptional deregulation.
1.2.5 The ras oncogenes.
The ras proteins are a family of signal transducers involved in the transmission of growth
promoting signals from the exterior to the interior of the cell. Oncogene members of the ras family
implicated in breast carcinogenesis include Harvey ras (H-ras), Kirsten ras (K-ras) and N-ras which
map to chromosomes llpl5, 12pl2 and lpl3 respectively (Barbacid 1987). The importance of the
ras proteins has been difficult to determine due to the variation between reports on their expression in
breast carcinomas. While it is generally agreed that the activation of any of the ras genes by
mutation (Spandidos et al., 1987; Biunno et al., 1988; Rochlitz et al., 1989) or by amplification
(Theillet et al., 1986; Varley et al., 1987) is rarely seen, estimates of over-expression encompass a
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wide range of figures (reviewed by Field and Spandidos 1990). No over-expression of the Ki-ras, N-
ras or H-ras oncogenes was detected in studies by Theillet et al. (1986) and Tanaha et al. (1986). In
contrast, increased expression of H-ras was shown to occur in all breast tumours analysed by
Agnantis et al. (1986a, 1986b).
1.3 Tumour suppressor genes.
1.3.1 Tumour suppressor genes.
Oncogenes have been shown to play an important part in the genesis of hemopoetic
malignancies and sarcomas, frequently in the form of chromosome translocations (Sandberg 1991).
Cancers originating from epithelial tissue, which account for 80% of all cancers including breast,
generally show oncogene activation at a frequencies between 15-30% (Bishop 1985). It is believed
that the tumour suppressor class of genes play a more important role in the development of these
cancers.
Tumour suppressor genes are involved in the negative regulation of cell growth and
proliferation. Unlike proto-oncogenes, which are converted to a dominandy acting form by mutation
and over-expression, it is the inactivation of tumour suppressor genes which contributes to the
tumorigenic process. Initial evidence for the presence of recessive genes involved in tumorigenesis
came from somatic cell hybrid studies. The observation that the fusion of normal (N) and tumour (T)
cells generally produced non-tumorigenic (NxT) hybrids was taken as evidence for a recessive
component in the development of cancer (Stanbridge 1976). Propagation of these non-tumorigenic
hybrid lines gave rise to occasional tumorigenic revertants. Analysis of the revertants revealed that
they had lost chromosomes originally possessed by the non-tumorigenic parent hybrid and it was
deduced that these lost chromosomes harboured genes responsible for the suppression of the
malignant phenotype in the original tumour cell. By monitoring the loss of chromosomes from non-
tumorigenic hybrids it was possible to identify specific chromosomes, the loss of which correlated
with the switch to malignancy. These chromosomes were postulated to carry one or more tumour
suppressor genes (Harris 1988). Further chromosomes showing a tumour suppressor effect were
identified by the introduction of a single wild type chromosome into a tumour cell by microcell
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fusion. The formation of a non-tumorigenic hybrid indicated the presence of a tumour suppressor
gene on the donor chromosome. Human chromosomes potentially harbouring tumour suppressor
genes identified in this way include 1, 3p, 6, 9 and 11 although to date no tumour suppressor gene
has been isolated using these types of technique (Klein 1987; Sager 1989).
1.3.2 Retinoblastoma.
The paradigm for tumour suppressor genes is demonstrated by the ocular tumour
retinoblastoma. Retinoblastoma is an uncommon childhood tumour which affects approximately 5 in
100,000 children. It occurs in both inherited and sporadic forms, 40% of cases are hereditary or
define a new germline mutation, the remaining 60% are sporadic. The majority of sporadic cases are
unilateral while a high percentage of familial or germline retinoblastoma cases are bilateral
(Knudson 1971). In the familial form about 50% of the offspring develop a tumour indicating the
transmission of an autosomal dominant gene. Analysis of the number of eye tumours occurring in
the hereditary cases and comparison of age incidence graphs between bilateral (hereditary) and
unilateral (mostly sporadic) cases suggested that the formation of the tumour was dependent on two
events. From these observations Knudson postulated his 'two hit' hypothesis (Knudson 1971). It was
proposed that in the familial form the first event was inherited, and so is present in all the cells of the
carrier, and the second event occurred somatically in the target retinal cell. In the sporadic form
both events were proposed to occur somatically. In a further modification of the two hit hypothesis
the two events necessary for retinoblastoma formation involved the alteration of two alleles of a
particular gene as opposed to two alterations involving two different genes (Knudson 1978).
In an attempt to locate the gene or genes, chromosome spreads of somatic cells from
familial retinoblastoma patients were examined for any aberrations. In a small number of cases
interstitial deletions of chromosome 13 were identified which always involved the band 13ql4
(Knudson et al., 1976, Yunis and Ramsay 1978). Linkage to a known marker mapping to
chromosome 13, the esterase D gene, was found in retinoblastoma families (Sparkes et al., 1980;
Sparkes et al., 1983). These observations strongly implicated 13ql4 as a region harbouring a gene
involved in retinoblastoma development through loss of at least one allele. The loss of a copy of
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chromosome 13 and absence of esterase D activity levels in a single retinoblastoma tumour were
used to infer loss of both copies of the putative retinoblastoma gene (Rbl) (Benedict et al., 1983).
This implied that the development of retinoblastoma was dependent on the inactivation of two alleles
of the same gene and a variety of mechanisms were proposed in which recessive mutations could be
unmasked (Cavenee et al., 1983) (Figure 1.2).
Although the familial retinoblastoma is seen to be transmitted as a mendelian dominant trait
this definition is misleading, The retinoblastoma gene is recessive at a cellular level and the chance
of inactivation of the second Rbl allele in one of the 106 retinal cells in a familial patient is so high
that retinoblastoma formation nearly always occurs. Therefore the trait appears to behave as a
mendelian dominant. However it is only the susceptibility to retinoblastoma that is transmitted, an
observation in keeping with the identification of occasional individuals with a constitutional mutant
Rbl allele who do not develop tumours (Gallie et al., 1982).
The use of restriction length fragment polymorphisms (RFLPs) facilitated further
investigation of the status of the Rbl gene in retinoblastoma tumours (Cavenee et al., 1983). RFLPs
are a result of the variability naturally occurring in the human genome and are generated in two
ways. An alteration in length of a particular DNA fragment after restriction digestion can occur
either when a nucleotide base change creates or destroys a particular restriction enzyme site or when
the DNA restriction fragment contains varying numbers of tandem repeat (VNTR) sequences
(Nakamura et al., 1987). RFLPs were utilised to identify sites on chromosome 13, and the two
chromosome copies are distinguishable when they carry restriction fragments differing in length.
Comparison of the chromosomal status between normal cells from retinoblastoma patients and the
corresponding tumours revealed frequent reduction to homozygosity of a number of chromosome 13
markers in the tumours, indicating loss of genetic material including the putative Rbl gene (Cavenee
et al., 1983).
1.3.3 The retinoblastoma gene.
Eventual cloning of the Rbl gene was hampered because of the lack of a suitable positive























Potential mechanisms for the inactivation of both copies of the Rbl gene in sporadic
and hereditary retinoblastoma. The first hit (rb) is assumed to be a point mutation or
small deletion and can be either somatically acquired or inherited.
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for some (eg ras) cloning is relatively easy due to their transforming ability. Since the tumorigenic
phenotype of tumour suppressor genes is only observed when both copies of the gene are inactivated
the devising of a positive selection technique is difficult (Lee et al., 1991). The
introduction of an inactivated tumour suppressor gene into a normal or tumour cell would be
expected to have no effect at all. The introduction of a wild type tumour suppressor gene into a
tumour cell may lead to a loss of malignancy. However, in some cases the resulting reduction in
growth would make cells harbouring the wild type gene difficult to isolate from a background of
tumour cells (Eiden et al., 1991).
Isolation of the Rbl gene was achieved by undertaking a search of the 13ql4 region by
chromosome walking (Wicking and Williamson 1991). Beginning at the marker H38, a DNA
fragment shown to be deleted in 3 out of 37 retinoblastomas, this technique was used to isolate
adjacent DNA fragments in a bi-directional manner. The isolated fragments were tested for any
cross-species homology, the presence of which would indicate a conserved sequence, in the hope of
identifying an exon of a gene. A candidate sequence was identified which hybridised to an mRNA
of 4.7kb in normal retinal cells and was absent or of an altered size in retinoblastoma cell lines
(Friend et al., 1986; Fung et al., 1987; Lee et al., 1987). The putative Rbl gene was shown to be
made up of 27 exons encompassing a region of over 200 kb and coded for a protein of 293 amino
acids in length and 105kD in size (Bookstein et al., 1988; Hong et al., 1989). The sequence of the
cDNA and protein have both been elucidated although no other sequence related to the RB1 gene has
been found nor is there any other related protein of known function (Cowell 1991). The Rbl protein
is thought to regulate the activity of the transcription factors E2F and DRTF1, which in turn regulate
cellular genes involved in growth and proliferation such as c-myc (Hamel et al., 1992).
Analysis of the RB 1 gene in retinoblastoma families and tumours indicated a wide variety
of alterations at the DNA level, including large and small deletions (Fung et al., 1987; Bookstein et
al., 1988; Canning and Dryja 1989; Hashimoto et al., 1991) and missense and splicing point
mutations (Dunn et al., 1988; Horowitz et al., 1989). Individuals carrying an inherited defect in the
Rbl gene have an increased risk of developing other malignancies, most notably osteosarcoma and
soft tissue sarcomas (Draper et al., 1986). Investigation of these tumours revealed frequent alteration
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of the Rbl gene (Friend et al., 1987; Toguchida et al., 1988; Reissman et al., 1989; Stratton et al.,
1989; Wunder et al., 1991). The retinoblastoma protein is expressed in a wide variety of normal
tissues, indicating that it plays a role in cell growth regulation in many different cell types (Goddard
et al., 1988) and is found to be altered in tumours not normally associated with familial
retinoblastoma susceptibility, eg tumours of the lung (Mori et al., 1990; Murakami et al., 1991a),
prostate (Bookstein et al., 1990a), oesophagus (Boynton et al., 1991), liver (Murakami et al., 1991b),
central nervous system (Venter et al., 1991), ovary (Li et al., 1991), bladder (Horowitz et al., 1989)
and breast (Lee et al., 1988, T'Ang et al., 1988, Varley et al., 1989, Borg et al., 1992b).
Functional proof of a tumour suppressor gene is the suppression of the tumorigenic
phenotype of malignant cells (Marshall 1991; Stanbridge 1992). Expression of the wild type Rbl
gene has been shown to reduce the growth rate and suppress the ability to form tumours of
retinoblastoma and osteosarcoma cell lines (Huang et al., 1988; Madreperla et al., 1991).
Tumorigenicity and/or growth were also reduced in bladder and prostrate carcinoma cell lines after
transfection with the wild type Rbl gene (Bookstein et al., 1990b; Takahashi et al., 1991; Goodrich
et al., 1992).
1.3.4 A model for tumour suppressor gene inactivation.
The identification of mutations in the germline of familial retinoblastoma patients (Yandell
et al. 1989) and in sporadic retinoblastoma tumours (Canning and Dryja 1989) and the frequent loss
of heterozygosity observed in sporadic retinoblastomas (Cavenee et al., 1983; Dunn et al., 1988; Zhu
et al., 1992) has contributed to the currently accepted model of tumour suppressor inactivation
(Ponder 1988). In the model, the first allele is inactivated by a small alteration such as a point
mutation or small deletion. The second copy of the gene is inactivated by an event effecting a much
larger region of DNA such as chromosome loss or mitotic recombination. Evidence to support the
sequence of events occurring in the progression of a tumour is limited as it requires the identification
and isolation of sufficient tumour precursor cells for analysis.
The approach just described for tracking down the Rbl gene has been used to isolate tumour
suppressor genes involved in a variety ofmalignancies. The identification of regions potentially
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harbouring tumour suppressor genes has relied on three avenues of investigation, cytogenetics,
linkage analysis and loss of heterozygosity studies and will be discussed in the next section.
1.4 Isolation of tumour suppressor genes.
1.4.1 Cytogenetics.
The value of translocations in the identification of oncogenes involved in hemopoietic
malignancies such as leukemias and lymphomas has been well documented (Sandberg 1991).
Similarly the benefits of karyotyping normal cells from members of cancer families in order to locate
tumour suppressor genes has been demonstrated. Identification of germline abnormalities by
cytogenetic analyses has been instrumental in beginning the search for the WT1 gene (Francke et al.,
1979), the Rbl gene (Knudson 1976; Yunis and Ramsay 1978) and the APC and MCC genes
(Herrera et al., 1986). Areas implicated by cytogenetics in sporadic solid tumours include
chromosome 3p in small cell lung cancer, chromosome 9 in bladder carcinoma and chromosome 10
in prostate carcinoma (Sandberg et al., 1988).
1.4.2 Linkage analysis.
Linkage studies rely on the fact that many of the common human cancers occur in a
dominantly transmitted familial form (Knudson 1978). The inheritance of an inactivated copy of a
tumour suppressor gene, as occurs in the inherited form of retinoblastoma, is thought to be the usual
basis of familial cancer syndromes (Seemayer and Cavenee 1989). The aim behind linkage studies is
to identify known markers so close to the disease locus that they co-segregate through generations
with the susceptibility phenotype. Linkage studies are based on the LOD (log of the odds) score
which is a measurement of the frequency at which the observed distribution of marker and disease
susceptibility alleles would arise by chance (Emery 1976). A LOD score of over 3 is regarded as the
standard for positive linkage, a LOD score of -2 or less is regarded as evidence against linkage at a
stated recombination 'distance'. Information on the precise location of a putative tumour suppressor
gene can be obtained by calculating the lod score at a number of sites on the same chromosome arm
and by the analysis of any crossover events, which result in recombinant chromosomes and the non
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co-segregation of the marker and the disease. Chromosomes implicated in familial cancers by
linkage analysis include 3p in von-IIippel Lindau syndrome (Seizinger et al., 1988), 5q in familial
adenomatous polyposis (Bodmer et al., 1987), 10 in multiple endocrine neoplasia type 2 (Simpson et
al., 1987), 11 q in multiple endocrine neoplasia type 1 (Larsson et al., 1988) and 17q in
neurofibromatosis type 1 (Seizinger et al., 1987).
1.4.3 Loss of heteozygosity studies.
Loss of heterozygosity (LOH) studies, comparing constitutional (usually blood) and tumour
DNA from the same individual, are based on the assumption that the inactivation of tumour
suppressor genes is often accompanied by a loss of genetic material. Extensive searches for LOH in
a very wide variety of malignancies has been undertaken using probes detecting RFLPs in areas all
over the genome (Ponder 1988; Sager 1989; Cavenee 1991). Areas which show a high frequency of
LOH in a number of different tumour types include chromosomes 1, 3, 5, 11, 13, 17, 18 and 22.
Following identification of a locus showing frequent loss, analysis of a number of nearby markers for
LOH can be used to generate maps showing the extent of the region of loss for each tumour. By
analysing the areas of loss occurring in a group of tumours a region showing loss that is common to
each tumour, known as the shortest region of overlap (SRO), can be identified. In this way
informative samples can lead to the narrowing down of the region potentially harbouring a tumour
suppressor gene until the search for the coding sequence of the gene becomes feasible.
To date seven tumour suppressor genes have been characterised and six have been tracked
down by using either linkage analysis (NF1 on chromosome 17q), loss of heterozygosity studies
(WT1 on lip, DCC on chromosome 18q) or both (MCC and APC on chromosome 5q and Rbl on
chromosome 13q).
1.5 The search for tumour suppressor genes involved in breast cancer.
1.5.1 Breast Cancer Cytogenetics.
Karyotypic analysis of normal cells from members of breast cancer families has revealed no
chromosomal aberration associated with the transmisson of the disease. The gathering of cytogenetic
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information on breast tumour samples has been hampered by practical and technical restraints
common in many solid tumours. These include the low mitotic activity of tumour cells and their
poor growth under in vitro culture conditions, low yields of tumour cells from fresh biopsy material,
overgrowth of normal cells present in the tumour material and the fuzzy morphology of
chromosomes seen in metaphase spreads (Sandberg 1988; Teyssier 1989).
Early work analysed clinical material such as pleural effusions, metastatic breast tumours or
breast cancer cell lines which showed highly complex karyotypes featuring many chromosome
alterations (Cruciger et al., 1978; Teyssier 1989). It has been suggested that observations from
pleural effusions and metastatic breast tumours are a consequence of sampling stages late on in the
tumorigenic process and that secondary changes may well have occurred during the in vitro culturing
of the cell lines (Trent et al., 1985). Later studies, which relied on the analysis of cells taken either
directly from the tumour or cultured through one or two passages, showed a reduction in the number
and range of aberrations observed. However obtaining a sufficient quality and quantity of cells for
analysis is a problem when working with direct preparations. Techniques in which samples are
grown through a few passages on a plastic film may present a selective bias. The observation of
predominantly diploid tumours when using this type of method (Zhang et al., 1989; Geleick et al.,
1990; Wolman et al., 1985) contrasts with cytometry and cytogenetic studies which indicate that the
majority of breast tumours are aneuploid, or contain an aneuploid stemline as well as a diploid
component (Devilee and Cornelisse 1990).
No cytogenetically identifiable alteration has been reported that is common to all breast
tumours (Trent et al., 1985; Mitchell and Santibanez-Koref 1990). Although comparison between
studies is complicated by differences in technique and sample origin, many of the karyotype analyses
identify specific chromosomes frequently involved in structural rearrangements. The majority of
studies show that chromosome 1 is the most frequently involved in chromosomal aberrations
including translocations, duplication, deletions and frequent iso-chromosome formation (Cruciger et
al., 1976; Brito-Babapulle and Atkin 1981; Rodgers et al., 1984; Gerbault-Sereau et al., 1987; Hill et
al., 1987; Dutrillaux et al., 1990; Mitchell and Santibanez-Koref 1990; Ferti-Passantonopolou et al.,
1991). In a tumour sample described by Kovacs (1981) chromosome 1 was involved in 3 separate
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marker chromosomes and 9 copies of the lq arm were found per tumour cell. Of three aberrations
found in a series of 40 diploid breast tumours and 5 breast metastases analysed by Zhang et al.,
(1989) two were identified as translocations involving chromosome 1. In several studies specific
bands or regions on chromosome 1 including lqll-lq21 (Brito-Babapulle and Atkin 1981), lq22-
lq23 (Ferti-Passantonopoulou et al., 1991) and lqter-lq21 (Rodgers et al., 1984, Hill et al., 1987)
have been found to be altered in a high proportion of samples. However cytogenetic analysis has not
been able to define a region or band commonly involved in all these abnormalities.
A review of 113 breast tumour karyotypes by Mitchell and Santibanez-Koref (1990)
calculated that of 304 chromosome bands in the genome 229 where involved in cytogenetic
abnormalities. When the relative size of each band was taken into account only 5 bands, lpll, lpl3,
lp22, lq21 and lq23 were shown to be involved at a frequency greater than that expected by chance.
The lack of specificity in the chromosomal breakages and the involvement of chromosome 1 at a
high rate in nearly all neoplasms investigated (Brito-Babapulle and Atkin 1981) may well reflect
either chromosome instability or an effect, rather than a cause, of tumorigenesis. Other
chromosomes implicated in a number of studies include 8 ,11, 13, 16 and 17 (Rodgers et al., 1984;
Ferti-Passantonopoulou et al., 1987, 1991; Hill et al., 1987; Dutrillaux et al., 1990; Mitchell and
Santibanez-Koref 1990). Interestingly these chromosomes are the location of known tumour
suppressor genes and oncogenes. The oncogenes N-ras, ski, and ets map to lpl3, lq23 and 1 lq22-23
respectively. The tumour suppressor genes Rbl and p53 map to chromosomes 13q and 17p
respectively. The loss of genetic material on chromosomes 8 and 16 may indicate as yet
undiscovered tumour suppressor genes involved in human breast tumorigenesis (Rodgers et al., 1984;
Hill et al., 1987; Dutrillaux et al., 1990).
1.5.2 Linkage analysis in hereditary breast cancer.
It has been established from epidemiological studies that hereditary factors contribute to
breast cancer development (Lynch et al., 1984). Familial clustering of cancer is observed in 20% of
breast cancer patients and segregation analysis indicates that a major susceptibility gene may account
for this pattern in about 5-10% of breast cancer patients (Go et al., 1983; Goldstein et al., 1987). A
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single dominant autosomal gene with a penetrance of 57-92% best describes the observed patterns of
these cases of inherited breast cancer (Williams and Anderson 1984; Bishop et al., 1988; Newman et
al., 1988; Claus et al., 1991). Hereditary breast cancer (HBC) is generally characterised as having an
earlier onset than the sporadic form with an increased incidence ofmultiple primaries and bilateral
involvement. HBC is heterogeneous and can occur as a site specific form, as well as in association
with ovarian cancer; soft tissue sarcomas and leukaemia (SBLA or Li-Fraumeni syndrome); and
gastrointestinal cancer and cutaneous manifestations (Lynch type II) (Lynch et al., 1989).
Difficulties in the identification of families with HBC and the genetic heterogeneity of the
condition have prevented linkage studies from contributing mapping information to the same extent
that, for example, the study of the inherited colon cancer syndrome FAP has to the isolation of the
APC gene on chromosome 5q (Groden et al., 1991; Nishisho et al., 1991). However, positive
linkage scores have been reported for a number of sites including lp22 (Hall et al., 1989), lp34-36
(Ferrell et al., 1989), 6q24-27 (Zuppan et al., 1991), 8q24-ter (King et al., 1980; Ferrell et al., 1989)
and 16q (King et al., 1980). Breast cancer susceptibility shows strong linkage to a site at 17q21 in
both breast specific and breast-ovarian families (Hall et al., 1990). Initially positive LOD scores
were generated when considering early onset families only (Hall et al., 1990). However reanalysis
of the data indicates a potential role for the proposed 17q gene, named BRCA1, in late onset families
(Margaritte et al., 1992). Linkage to this site has been confirmed (Narod et al., 1991; Porter et al.,
1993) and, using data from two studies, it has been possible to locate the BRCA1 gene to an interval
of 4cM between the markers THRA1 and Mfdl88 (Hall et al., 1992; Bowcock et al., 1993).
Tumours from breast-ovarian patients inheriting the proposed mutant BRCA1 gene often show losses
of the wild type chromosome 17q, suggesting that BRCA1 acts as a tumour suppressor (Smith et al.,
1992). An absence of linkage to the 17q21 locus, ascribed to disease heterogeneity, has been
demonstrated in a number of cancer families (Sobol et al., 1992; Haile et al., 1993). Consequently,
the BCRA1 has been estimated to be involved in almost all families with breast-ovarian cancer and
half of those with site specific breast cancer (Easton et al., 1993).
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1.5.3 Loss of heterozygosity studies in breast cancer.
Areas of the genome shown to undergo LOH at greater than background levels have been
used to indicate the location of tumour suppressor genes. Due to the unstable nature of chromosomes
in cancer cells it is thought that all chromosome loci undergo LOH at a low background frequency.
Those losses resulting in a growth advantage are selected for and will therefore be detected more
frequently in LOH studies. From studies in colon cancer it has been suggested that a frequency of
LOH above 25% should be taken as significant (Vogelstein et al., 1989). Estimation of a
background frequency has been attempted in breast cancer by determining the frequency of LOH in
regions not thought to harbour tumour suppressor genes. A frequency of under 5% was found in two
studies (Mackay et al., 1988a; Chen et al., 1989) suggesting that it is possible for a specific tumour
suppressor gene to be inactivated in a subgroup of breast tumours at a frequency below 25%.
Furthermore three studies investigating all chromosome arms for LOH in breast tumours detected a
wide range of LOH frequencies occurring on various chromosome arms (Larsson et al., 1990; Sato et
al., 1990; Devilee et al., 1991a). It is therefore very difficult to determine an estimate for the
frequency of background LOH and any figure would have to be an arbitrary one.
The frequency of LOH occurring at different regions of the genome in breast tumour
samples has been determined by many independent groups (Ali et al., 1987; Lundburg et al., 1987;
Mackay et al., 1988a; Mackay et al., 1988b; Ali et al., 1989b; Chen et al., 1989; Devilee et al.,
1989; Genuardi et al., 1989; Borresen et al., 1990; Coles et al., 1990; Cropp et al., 1990; Devilee et
al., 1990; Gendler et al., 1990; Larsson et al., 1990; Sato et al., 1990; Thompson et al., 1990; Chen
et al., 1991a; Davidoff et al., 1991a; Devilee et al., 1991a; Devilee et al., 1991b; Devilee et al.,
1991c; Devilee et al., 1991d; Leone et al., 1991; Osborne et al., 1991; Sato et al., 1991a; Thorlacius
et al., 1991; Andersen et al., 1992; Bieche et al., 1992; Borg et al., 1992b; Borg et al., 1992c;
Cheickhi et al., 1992; Chen et al., 1992; Futreal et al., 1992; Hovig et al., 1992; Kallioniemi et al.,
1992; Matsumura et al., 1992; Sato et al., 1992; Takita et al., 1992; Thompson et al., 1992; Cornells
et al., 1993; Knyazev et al., 1993). Data produced from these studies can be used in two ways.
First, to determine the importance of a particular region of the genome in breast cancer development.
Loci showing a high rate of loss are potentially more important than those showing a lower rate.
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Areas of the genome showing LOH in breast tumours at a frequency of greater than 20% include lp,
7q , 8p, 8q, 9q, llq, 13q, 15q and 22q and those showing a frequency greater than 50% include lq,
3p, 6q, 16q, 17p, 17q and 18q. Second, LOH data can be used in the isolation of putative tumour
suppressor genes by the determination of a shortest region of overlap (SRO). Studies using more
than one marker on a single chromosome arm can often define a SRO region from samples showing
discordant LOH status between adjacent markers. Progress in this field has been achieved on several
chromosome arms and will be outlined in the next section.
1.5.4 Chromosome 1.
Initial LOH findings on chromosome 1 indicated two regions of loss which could be
narrowed down to lp34 - lpter (Genuardi et al., 1989) and lq23 - lq32 (Chen et al., 1989). Two
further studies indicated that a region proximal to lq24 - 31 (Devilee et al., 1991b) and lq42 - 43,
possibly near to the polymorphic epithelial mucin (PEM) locus at lq21 (Gendler et al., 1990), may
harbour a tumour suppressor gene. A SRO mapping between lp33 - 35 and lp36 has also been
determined (Borg et al., 1992c). The two initial investigations report that LOH occurs by means of a
simple deletion in all cases examined (Chen et al., 1989; Genuardi et al., 1989) while a gain in allele
intensity, suggesting an increase in chromosome copy number or sequence amplification, is reported
at a low frequency by Gendler et al. (1990) and at a much higher rate by Devilee et al. (1991b), Borg
et al. (1992c) and Cheickhi et al. (1992). These 'gain of allele' data may reflect cytogenetic
observations of over-representation of chromosome 1 in many breast cancer samples (section 1.5.1).
It has been suggested that this duplication of chromosomal material is due to the activation of one of
several oncogenes located on chromosome 1 and that the complex rearrangements observed in breast
tumours may arise through different selective pressures operating on different regions of the
chromosome (Gendler et al., 1990).
1.5.5 Chromosome 3p.
Analysis of LOH patterns on the short arm of chromosome 3 have determined two regions
of loss. One SRO defines an area encompassing 3p21 to 3p24 - 25 (Ali et al., 1989b) while another
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more proximal SRO maps between 3pl3 and 3pl4.3 (Sato et al., 1991a). Members of the c-erb
growth receptor family and the protein tyrosine phosphatase gene, which map to chromosome 3p,
have been suggested as possible candidate genes although their role in breast tumorigenesis has yet
to be investigated (Ali et al., 1989b; Croce 1991).
1.5.6 Chromosome lip.
A single SRO was determined by Ali et al. (1987) which implicated the area between the P-
globin gene at llpl5.5 and the parathyroid hormone (PTH) gene at llpl5.4. A further two studies
were unable to confirm this result. LOH mapping revealed a number of tumour samples with
complex patterns of LOH and a single SRO could not be identified (Mackay et al., 1988b; Devilee et
al., 1989). However breast tumour samples showing LOH between llpl5.5 and llpter and proximal
to 1 lpl5.5 have been identified suggesting two areas of chromosome lip as potential tumour
suppressor regions (Devilee et al., 1989). Discordant LOH status observed between markers at
llpl5.5-ter and llpl5.4-15.5 in 28 informative tumours suggested a tumour suppressor gene located
in the peritelomeric region of chromosome lip, distal to llpl5.4-15.5 (Takita et al., 1992).
1.5.7 Chromosome 13q.
LOH was first identified on chromosome 13 in 4/10 ductal breast tumours by Lundberg et
al. (1987). No breakpoints were identified although a further study by Devilee et al. (1989) revealed
an SRO between the marker xl3ql2-13ql4 and p68SR, a marker mapping to the internal part of the
RBI gene at 13ql4, strongly suggesting a role for the Rbl gene in breast cancer (Devilee et al.,
1989).
Rearranged Rbl genes were found in 2/9 breast cancer cell lines accompanied by loss of
protein expression (Lee et al., 1988). In a similar study 4/16 breast cancer cell lines and 3/41 breast
tumour samples were shown to have structurally altered Rb genes resulting in the absence or
truncation of the RBI mRNA transcript (T'Ang et al., 1988). Of 15/77 breast tumour samples
showing structural alterations to the RB 1 gene 14 had a corresponding absence of the protein in a
proportion of tumour cells (Varley et al., 1989). However, in a recent study no correlation was found
23
between allele loss at the Rbl locus and reduced Rbl protein levels suggesting that the reduction of
protein is brought about by mechanisms other than allele loss or that perhaps LOH on chromosome
13 contributes to the inactivation of another tumour suppressor gene adjacent to the Rbl gene (Borg
et al., 1992b). No mutations have been detected in exon 21 of the Rbl gene in 11 breast
carcinomas, an exon previously shown to be mutated in prostate and bladder cancers (Hovig et al.,
1992).
1.5.8 Chromosome 16q.
LOH on chromosome arm 16q has been detected in 40-57% tumour samples (Larsson et al.,
1990; Sato et al., 1990; Devilee et al., 1991a). Detailed mapping of chromosomal deletions reveals a
SRO between loci at 16q22.1 and 16q22 - 23 (Sato et al., 1990).
1.5.9 Chromosome 17p.
Following the discovery of a high incidence of LOH in colon carcinomas a single SRO was
determined between 17pl2 and 17pl3.3. Due to the tumour suppressing properties and chromosomal
position of the p53 gene it was selected as a candidate gene and subsequently found to be mutated in
colon tumours at a high frequency (section 1.6). Consequently many groups have analysed breast
tumour samples for LOH at chromosome 17p loci (detailed in chapter 3) and p53 mutation (detailed
in chapter 5).
1.5.10 Chromosome 17q.
A low frequency of LOH was detected on chromosome 17q in initial studies (Mackay et al.,
1988a; Devilee et al., 1989; Sato et al., 1990). The use of additional probes covering the 17q arm
revealed LOH in 30-40% of tumour samples (Cropp et al., 1990; Larsson et al., 1990; Thorlacius et
al., 1991; Sato et al., 1991a; Devilee et al., 1991a; Andersen et al., 1992; Futreal et al., 1992;
Knyazev et al., 1993). Information on the potential location of the putative tumour suppressor gene
was determined by several groups (Cropp et al., 1990; Sato et al., 1991a; Andersen et al., 1992;
Futreal et al., 1992). By combining these maps the SRO has been narrowed down to the
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chromosome band 17q21, the site of the BRCA1 gene. Using this localisation information an anti¬
proliferative gene called prohibitin, which shows homology to the tumour suppressor gene NF1 and
maps to 17q21, was analysed in breast tumour samples. In 23 tumours analysed 4 tumours possessed
an altered prohibitin gene with a corresponding LOH on chromosome 17q (Sato et al., 1992).
Unfortunately, these findings have not been corroborated elsewhere (Skolnick et al., unpublished
data). Recent data generated from 12 loci on chromosome 17q revealed complex patterns of LOH,
suggesting the presence of at least two putative tumour suppressor genes on chromosome 17q
(Cornelis et al., 1993).
1.5.11 Chromosome 18q.
The loss of chromosomal material on chromosome 18q in breast cancer is of special interest
as a known tumour suppressor gene, DCC, is known to map to 18q21 (Fearon et al., 1990). In a
study by Cropp et al. (1990) a high frequency of LOH was detected on chromosome 18q with an
SRO defining an area between 18q21.3 and 18q33, implicating DCC in breast cancer. However a
probe mapping to the DCC locus detected LOH in only 1 of 40 (2.5%) tumour samples in a study by
Sato et al. (1991a) and no common region of loss was found by Devilee et al. (1991c). Further
investigation of the expression and gene alteration of the DCC gene in breast tumours needs to be
carried out before the DCC gene can be excluded from a role in breast cancer development.
1.5.12 Specificity of LOH to breast cancer.
Although loci on chromosomes lp, lq, 3p, lip, 13q, 17p, 17q, and 18q have been shown to
undergo LOH in breast tumours in several studies, none of these areas appear to be breast cancer
specific. For example loci at 3p frequently undergo LOH in lung cancer and linkage to this area has
been shown for von-Hippel Lindau syndrome, which features a familial form of adrenal cancer. This
supports the observation that any one tumour suppressor gene may be involved with more than one
type of malignancy and that a breast tumour specific tumour suppressor gene may not exist. This is
advantageous since mapping information from several malignancies could potentially be used in the
isolation of tumour suppressor genes involved in breast tumorigenesis.
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1.6 The p53 gene
1.6.1 Isolation and characterisation of the p53 gene.
p53 was first identified as a cellular protein able to form stable complexes with the viral
SV40 T antigen in SV40 transformed cells (Lane and Crawford 1979). Antibodies directed against
the p53 protein were frequently detected in animals with SV40 induced tumours and in those
immunised with chemically transformed MethA cells (De Leo el al., 1979; Linzer and Levine 1979).
The p53 protein was classified as a tumour antigen following the discovery of sera containing anti-
p53 antibodies in 10% of humans with cancer (Crawford el al., 1982; Caron de Fromental el al.,
1987). The first cDNA clone for the murine p53 gene was isolated by an RNA enrichment technique
(Chumakov et al., 1983) and subsequent clones were isolated and sequenced from a variety of tissue
types. The human p53 gene was cloned through homology with the mouse gene (Matlashewski el
al., 1984; Harlow et al., 1985).
The p53 gene has been intensely studied in the mouse and human where it maps to
chromosome 11 (Czonek et al., 1984; Rotter et al., 1984) and chromosome 17pl3.1 respectively
(Benchimol et al., 1985; Isobe et al., 1986; McBride et al., 1986). The human p53 gene is
comprised of 11 exons and 10 introns spanning approximately 20kb of DNA and codes for a 2.5kb
mRNA transcription product which is translated into a protein of 393 amino acids (Harlow et al.,
1985; Lamb and Crawford 1986) (see figure 1.3).
Little is known about the promoter/enhancer region of the p53 gene. Two transcription
initiation sites have been mapped to the 5' end of the p53 gene. The first, p53pl, maps immediately
upstream of the first exon, and the second, p53p2, is located approximately lkb downstream from
exon 1 (Reisman et al., 1988). p53p2 has been shown to promote transcription 20 times more
efficiently than p53pl and transcripts from both sites have been identified in vivo (Reisman et al.,
1989). The p53pl regulatory sequences have been shown to be highly conserved between human
and mouse but are unusual as they do not contain any of the consensus sequences e.g. TATA, CAAT







































1.6.2 Evolutionary conservation of the p53 gene.
The p53 gene has been identified only in vertebrate species despite many efforts to detect an
invertebrate copy of the gene (Soussi et al., 1990; Nigro et al., 1992). Initial comparison of the
murine with human and Xenopus p53 protein sequences revealed an 81% and 57% homology
respectively (Soussi et al., 1987). The conservation of sequence is not spread evenly throughout the
molecule (Soussi et al., 1990) and five areas of high homology, ranging from 91-100%, have been
identified. These five domains, I, II, III, IV and V are positioned between codons 13-19, 117-142,
170-181, 234-258 and 270-286 respectively (Soussi et al., 1990). The conserved domains are
thought to play a central role in the function of the protein since the sequences flanking these
domains show much greater divergence, especially in the N-terminal region (Soussi et al., 1990).
Additional p53 sequences from rat (Soussi et al., 1988a), chicken (Soussi et al., 1988b), monkey
(Rigaudy and Eckhardt 1989) and trout (Caron de Fromentel et al., 1992) have been determined, all
of which show a high degree of homology in domains I to V (Soussi et al., 1990).
All the p53 proteins have a similar predicted structure consisting of three hypothetical
regions differing in charge, hydrophobicity and structure (Pennica et al., 1984; Levine and Momand
1990). The N-terminal region of the human p53 protein (residues 1-80) has a high proline content,
contains a high number of acidic residues and very few basic residues. Structurally it is composed of
a simple a-helix and carries an overall negative charge. The central region (residues 80-150) are
arranged in a (3-sheet formation containing few charged residues and three highly hydrophobic
domains which correspond to the conserved domains II, III and IV. The carboxyl end of the protein
(residues 319-393) is a negatively charged, very hydrophilic a-helix. A simple structure has been
predicted for the p53 protein consisting of the central region forming a hydrophobic core with the
amino and carboxyl terminal regions at the protein surface.
1.6.3 Expression of the p53 gene.
mRNA studies have shown that the p53 gene is expressed at low levels in most tissues
though increased levels of expression have been detected in the spleen, the thymus and during mouse
foetal development (Jenkins et al., 1984; Rogel et al., 1985). Proliferating cells show significantly
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higher levels of p53 mRNA compared with resting GO cells (Reich and Levine 1984) and high levels
of p53 protein have been found in many transformed cell lines and tumour tissues. Since the p53
mRNA levels found in transformed cell lines and tissues are often comparable with normal tissue or
non-transformed cell counterparts (Matlashewski et al., 1984) it is thought that the regulation of p53
occurs in most cases at a post-translational rather than a transcriptional level (reviewed by Levine et
al., 1989). The regulation of cellular levels of the p53 protein is thought to be achieved by protein
degradation, possibly by an ATP dependent proteolytic pathway (Gronostajski et al., 1984). p53
protein found in untransformed cells has a short half life ranging from 6-30 minutes (Jenkins and
Sturzbecher 1988). In contrast, transformed cells frequently contain a more stable p53 protein with
an increased half life of up to forty hours resulting in a 100-1000 fold increase in the cellular level of
the protein (Levine et al., 1988).
1.6.4 Biological properties of the p53 gene.
Genomic and cDNA clones from various sources were used to demonstrate that the p53
gene could immortalise rat chrondrocytes (Eliyahu et al., 1984) and, in co-operation with the ras
oncogene, could elicit full cell transformation in rat embryo fibroblasts (Jenkins, 1984; Parada et al.,
1984). Due to the positive transforming ability and nuclear localisation of the protein (Dippold et
al., 1981; Rotter et al., 1983) the p53 gene was classified as a nuclear oncogene and grouped with
the myc, myb, fos and Ela genes. However, work on Friend erythroleukemia virus infected mice
demonstrated that malignant tumours frequently contained structurally rearranged p53 genes
resulting in the loss of p53 expression altogether (Mowat et al., 1985). Similarly two tumorigenic
cell lines were shown to express no p53 protein due to the inactivation of the p53 alleles by deletion
and viral insertion (Wolf et al., 1984; Wolf and Rotter 1985). Both of these observations are more in
keeping with the role of the p53 gene as a tumour suppressor rather than an oncogene.
Further work demonstrated that the p53 gene sequences used in the transformation
experiments, many of which had been isolated from transformed cell lines, were mutant versions of
the wild type gene (Finlay et al., 1988; Levine et al., 1989). When these experiments were repeated
using the wild type p53 gene no transforming potential was observed, suggesting that the activation
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of the p53 gene occurred by mutation and not over-expression (Finlay et a/., 1988; Hinds et al., 1989;
Mercer et al., 1990). However the wild type p53 gene was found to suppress the transformation of
rat embryo fibroblasts by mutant p53, myc and the viral oncogene Ela (Finlay et al., 1989).
Transformed foci were produced in low numbers following transformation with the wild type p53
gene. However, these cells expressed either no p53 protein or an altered form of the protein,
indicating that oncogene mediated cell transformation was incompatible with wild type p53
expression (Finlay et al., 1989).
1.6.5 Alteration of the p53 gene in human malignancies.
Following the newly discovered tumour suppressor properties of the p53 gene and the high
frequency of LOII observed on chromosome 17p in colon cancer (Vogelstein et al., 1988) the p53
gene was selected as a candidate tumour suppressor gene involved in colon tumorigenesis.
Investigation of the locus revealed mutation of the p53 gene, and accompanying loss of the
remaining allele, in a high proportion of colon carcinomas, a pattern in keeping with the inactivation
of a tumour suppressor gene (Baker et al., 1989; Baker et al., 1990a). A similar pattern of mutation
and accompanying LOH was determined following studies of the p53 gene in a wide variety of
tumour types (Nigro et al., 1989). Oncogene activation often involves a specific mutational change
and the diversity of alterations of the p53 gene detected in sporadic tumours, including missense and
nonsense mutations, deletions and insertions at many different sites in the gene provided indirect
evidence that the p53 gene was undergoing a loss of function rather than a gain. In response to these
findings numerous studies demonstrated a reduction in growth rate and/or tumorigenicity following
the introduction of the wild type p53 gene into a variety of human cancer cell lines. No reduction
was observed in parallel experiments using mutant forms of the p53 gene (Baker et al., 1990b;
Mercer et ai, 1990; Casey et al., 1991; Chen et al., 1990a; Chen et al., 1991b; Shaulsky et al., 1991;
Cheng et al., 1992; Takahashi et al., 1992).
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1.6.6 Properties ofmutant p53 alleles.
Many lines of evidence suggested that the wild type p53 gene functions as a tumour
suppressor. However, if p53 mutants were simply inactivated versions of the wild type gene they
would not be expected to be capable of transforming of rat embyro fibroblasts. Mutant p53 genes
would either have to behave as dominant oncogenes or in some way be able to inactivate the
suppressive influence of the endogenous wild type protein. It has been proposed that mutant p53 can
act in a dominant negative manner, whereby the mutant protein inactivates the wild type protein by
binding to form heterologous oligomers (Herskowitz 1987). p53 forms tetrameric complexes in
solution (Stenger et al., 1992) and heterologous oligomers have been observed between mutant and
wild type p53 proteins (Milner and Medcalf 1991). Experiments cotranslating both wild type and
mutant p53 genes have shown that certain mutant p53 proteins are able to bind the wild type protein
and drive it into a structural conformation usually associated with mutant proteins (Milner and
Metcalf 1991). Although this mechanism can explain the dominant effect of p53 mutants, the
dominant nature of some p53 alleles cannot be accounted for by the inactivation of the wild type
protein. The most compelling example of this is the enhanced tumorigenicity of the cell line L12
following the introduction of a mutant p53 gene (Wolf et al., 1984). Since L12 contains no
endogenous p53 this effect cannot be explained as a consequence of the inactivation of wild type
protein and suggests that the mutant p53 protein has acquired a true 'gain of function'.
The analysis of the p53 gene has lead to the realisation that the terms oncogene and tumour
suppressor gene are notmutually exclusive and both properties can be attributed to the same gene.
The wild type p53 gene can be termed as a tumour suppressor but classification of the various p53
mutants appears to be dependent on the specific sequence alteration (Michalovitz et al., 1991).
Mutants can theoretically be split into three groups: null mutants, which simply represent an
inactivated form of the protein; the negative dominant mutants, which have the ability to interfere
with the function of wild type p53 protein and would only be classed as oncogenic in cells that co-
expressed the wild type p53 protein; and positive dominant mutants, which represent a true gain of
function, and the oncogenic nature of which is independent of the presence of wild type protein.
Variation has become apparent following the isolation and analysis ofmore mutant p53
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genes. Individual p53 proteins have been shown to differ in several biological properties including
heat shock protein 70 (hsp70) binding, transforming efficiency, immunogenicity and half life
(Halevy et al., 1990; Hinds et al., 1990; Bodner et al., 1992; Davidoff et al., 1992a; Winter et al.,
1992). For example, while colon carcinomas show frequent mutation at codons 175 and 273, the 175
His and 273 His p53 proteins have been shown to differ in transforming ability, protein conformation
and half life (Levine et al., 1991).
Alternatively, it has been proposed that the transformation properties ofmutant p53 genes
could be due to the high copy number of the introduced p53 alleles (Wang et al., 1993). Three
studies using retro-virus mediated gene transfer have shown that the introduction of a single wild
type p53 gene is sufficient to reduce the tumorigenicity of breast, rhabdomyosarcoma and
osteosarcoma cell lines (Chen et al., 1990a; Chen et al., 1991b; Wang et al., 1993). The suppression
of the malignant phenotype by the exogenous wild type p53 protein was shown to occur despite the
10 fold higher quantity of endogenous mutant p53 protein present in the cells suggesting that the
maintenance of a malignant phenotype is dependent of the removal of the p53 tumour suppressor
function in these cells.
1.6.7 Function of p53
p53 expression in normal cells appears to be cell cycle related and early evidence suggested
that the p53 protein acts at the G0/G1 phase of the cell cycle. An increase in the level of p53 mRNA
is observed in non-dividing mouse T-lymphocytes following mitogen treatment (Milner and Milner
1981). Mouse 3T3 fibroblasts arrested in GO show a dramatic increase in p53 mRNA and protein
during late G1 following serum stimulation (Reich and Levine 1984). Micro-injection of anti-p53
antibodies into serum starved GO cells leads to the failure of the cells to enter G1 (Mercer et al.,
1982). Cells expressing anti-sense p53 RNA are compromised for growth (Shobat et al., 1987) and
over-expression of the wild type protein blocks cell division in the G1 phase of the cell cycle
(Michalovitz et al., 1990). These observations suggest that the p53 protein plays a critical role in the
passage through G1 and therefore would be expected to be essential for cell viability. However,
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mice deleted for both copies of the p53 gene are developmentally normal, although they develop a
variety of tumours before they reach 6 months (Donehower et al., 1992).
Sequence motif analysis has failed to elucidate a possible function of the p53 protein (Soussi
et al., 1990). At present there are two hypotheses to explain the function of the p53 protein. The
first suggests that the protein is a transcription factor which regulates the expression of genes
involved in growth. p53 appears to bind to a specific sequence (Kern et al., 1991). A consensus p53
binding sequence consisting of two copies of a 10 base pair motif separated by 0-13 base pairs has
been determined (El-Deiry et al., 1992). Wild type p53 has been shown to increase the expression of
a reporter gene containing 3.3 kb of the upstream control sequence of the muscle-specific creatine
kinase gene (MCK), which is known to contain the proposed p53 specific binding sequence
(Wientraub et al., 1991, Levine 1992). In addition wild type p53 is known to inhibit the expression
from the interleukin 6, (3-actin, fos, major histocompatibility complex (MHC) class I (Santhanam et
al., 1991) and multidrug resistance (MDR1) promoters (Chin et al., 1992). In both of these studies
p53 mutants showed a loss or reduction in their ability to repress transcription. The highly acidic n-
terminal region of the protein has been shown to activate transcription when coupled to the GAL4
DNA binding domain, a function lost in p53 mutant proteins (O'Rourke et al., 1990; Fields and Jang
1990; Raycroft et al., 1990; Unger et al., 1992). Similarly, wild type p53 protein, but not tumour
derived mutants, has been shown to transactivate genes adjacent to a p53 DNA binding site (Kern et
al., 1992). Furthermore, deletion of the c-terminal region of the protein abolishes the ability of the
protein to bind genomic DNA (Frood et al., 1992) suggesting that the DNA binding site is located in
this region.
The second hypothesis suggests that the p53 protein is a regulator of replication or is a part
of the replication initiation complex. p53 is known to bind to SV40 T antigen, which is required in
the initiation of viral replication. Since viral genes often encode proteins that have a cellular
homologue, p53 has been proposed to regulate the cellular SV40 T homologue, a protein presumably
involved in DNA replication. In support of this hypothesis the p53 protein has been localised at sites
of viral replication in herpes infected cells (Wilcock and Lane 1991) and the wild type p53 protein
has been shown to bind to DNA sequences adjacent to the replication origin of the SV40 virus, an
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ability that has been lost in mutant forms of the p53 protein (Bargonetti et al., 1991). Although these
two hypothesis propose two different functions for p53 the fact that some origins of replication are
activated by the act of transcription near or at the origin may indicate that p53 has a dual function
within the cell (Levine 1992).
Whatever the function of the p53 protein the effects of the inactivation or activation of the
protein would seem to be far reaching. Mutant forms of the protein have been shown to increase
metastatic potential (Pohl et al., 1988), increase tumorigenicity (Wolf et al., 1984) and confer growth
factor independence (Gai et al., 1988) in transformation experiments. In addition, wild type p53 has
been postulated to involved in the control of apoptosis (Yonish-Rouach et al., 1991) and as amonitor
of DNA damage (Lane 1992).
1.6.8 Heritable p53 mutations.
Hereditary breast cancer is estimated to account for 10% of breast cancer cases and can be
associated with a number of other tumour types (section 1.5.2). Li-Fraumeni syndrome (LFS) is a
rare familial cancer syndrome which features a spectrum of malignancies including breast, brain and
adrenocortical carcinomas, osteosarcomas, soft tissue sarcomas and leukaemia (Li et al., 1988).
Breast cancer is the most frequent malignancy in the syndrome although the number of breast tumour
patients with LFS is estimated to be less than 0.001% (Vogelstein 1990). LFS family members
present with tumours at an early age, fifty percent will have cancer by the age of 30 and greater than
90% will develop cancer by the age of 70 (Malkin et al., 1990). The syndrome best fits an
inheritance model of a single dominant autosomal gene and the location of the gene responsible was
hampered by the rarity of the syndrome, the high mortality of affected LFS individuals and the
inability to distinguish between the hereditary tumours and those sporadic tumours arising in
unaffected relatives. Unlike familial retinoblastoma and adenosis polyposis coli (APC) linkage
studies and karyotypic analysis were unable to determine a possible location for the gene. Since
tumour suppressor genes are closely associated with familial cancer syndromes and the p53 gene was
known to be mutated in sporadic tumours of the types occurring in the Li-Fraumeni syndrome, it was
selected as a candidate gene. Consequently p53 germline mutations were found in Li-Fraumeni
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kindreds in a number of studies (Malkin et al., 1990; Srivastava et al., 1990; Santibanez-Koref et al.,
1991; Toguchida et al., 1992; Felix et al., 1992a). All LFS family members analysed are
heterozygous for the p53 mutations and, in keeping with the tumour suppressor hypothesis, a number
of studies report the loss of the wild type p53 allele in a number of tumours (Malkin et al., 1990;
Borresen et al., 1992; Srivastava et al., 1992; Sameshima et al., 1992a).
1.7 Aims of the project.
Genetic alterations detected in breast tumours include the over-expression and amplification
of oncogenes such as neu, int-2, c-myc and ras and the loss of genetic material from specific
chromosomal loci, indicative of the inactivation of tumour suppressor genes. This project aims to
examine the loss of genetic material occurring at sites on chromosome 17p and is a continuation of
the work of Mackay et al. (1988a), who detected a high frequency of LOH at a locus at 17pl3.3 in a
series of paired breast tumour/control DNA samples. LOH at other loci on chromosome 17 was
investigated in breast tumour samples in the hope of defining a region containing a putative tumour







All tumour, blood and lymphoblastoid cell line DNAs used in the course of this project were
obtained from a bank of matched control/tumour DNA samples established by Dr James Mackay.
All patients had presented with palpable lumps and underwent either Patey mastectomy, wide local
excision or wedge biopsy at either the Breast Unit Longmore Hospital, the Western General Hospital
or Royal Infirmary of Edinburgh.
20ml of venous blood was collected from these patients and transferred to a sterile
heparinised universal. Tumour samples were immediately frozen on dry ice after excision and stored
at -70°C. DNA was extracted from tumour and blood samples as described in section 2.2.
Lymphoblastoid cell lines were established from 10ml of blood by Dr C. M. Steel (Mackay 1989).
The diagnosis of breast cancer was confirmed and the greatest diameter of the excised
tumour was accurately measured at the University of Edinburgh Department of Pathology. The
tumours were classified into histological types (Page and Anderson 1988) and examined for in situ
carcinoma. Lymph nodes were examined histologically for metastases.
One portion of the tumour was placed on ice and immediately assayed for oestrogen
receptor protein concentration by Dr R. A. Hawkins (Lister Laboratories of the University
Department of Clinical Surgery) by an adsorption assay using Dextran coated charcoal (Hawkins el
al., 1981). The oestrogen receptor protein concentration of tumour material from patients who had
received the anti-oestrogen drug Tamoxifen was also examined by enzyme immunoassay (Leclerq
1984) using the ER-EIA Kit (Abbott Laboratories).
Information on patient age, tumour size, histological typing and lymph node involvement
was obtained from the Edinburgh Department of Pathology. Information on menopausal status and
oestrogen receptor protein levels was obtained from the Lister Laboratories. Information on family
history was obtained from the Breast Cancer Unit at the Western General Hospital (Table 1).
For control DNA, placental material was collected from the Obstetrics and Gynaecology
Department of the Western General Hospital and stored at -70°C until DNA extraction.
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1 - - - 70 - No 724
3 - - on 52 - No 0
4 - - - 79 Post No 220
6 3.2 Ductal/NST 10/23 62 - No 789
7 2.8 Ductal/NST 0/7 34 Pre No 2
8 3.2 Ductal/NST 1/6 65 Post No 122
9 9.0 Ductal/NST 4/5 73 Post No -
10 2.8 Ductal/NST 0/10 50 - No 21
11 2.0 Ductal/NST (M) 10/17 50 - No 3
12 3.4 Ductal/NST (M) 10/17 50 - No 4
13 3.8 Ductal/NST 0/9 59 Post No 15
14 1.4 Ductal/NST (M) 1/17 44 Peri Yes 51
15 3.0 Ductal/NST (M) 1/17 44 Peri Yes 39
16 2.0 (B) Ductal/NST - 60 - Yes 80
18 2.8 Ductal/NST (M) 3/10 79 Post No 0
19 1.2 Carcinoid (M) 3/10 79 Post No -
20 1.0 Ductal/NST 0/3 72 Post No -
21 3.5 Ductal/NST 7/10 66 - No 0
22 1.3 - 3/4 83 Post No 0
24 1.9 Ductal/NST 0/15 59 Post Yes -
25 5.5 Lobular variant 5/10 70 Post No 0
26 3.0 Ductal/NST 0/21 75 - No 54
27 2.5 (B) Ductal/NST - 57 Post No 364
28 - - - - No -
29 1.8(B) Ductal/NST 2/4 34 Pre No 36
30 1.0 (B) Ductal/NST - 55 Post Yes 46
32 3.9 (B) Ductal/NST 0/5 47 Post No 1
33 2.0 Ductal/NST 10/17 50 - No 71
34 2.2 (B) Ductal/NST 0/4 66 Post No 8
35 1.2 (B) Tubular 0/3 66 Post No 275
37 4.0 Squamous - 66 Post No 4
38 1.5 Ductal/NST 4/4 60 Post No 236
39 2.5 Ductal/NST 2/3 46 Peri No 31
40 7.5 Ductal/NST 4/7 49 - No 1
41 1.5 Ductal/NST 0/3 52 Post Yes -
42 1.5 Ductal/NST 1/4 47 Peri No 82
45 3.8 Ductal/NST 0/2 51 Pre No 0
46 2.5 Tubular 2/5 59 Post No 119
47 1.5 (B) Ductal/NST - 68 Post No 61
48 2.6 Ductal/NST 0/12 62 Post Yes 489
49 1.6 Mucoid 3/3 39 Pre No 23
50 - Ductal/NST 0/3 37 - Yes 3
53 2.2 Ductal/NST 5/9 54 Post No 150
54 2.8 Ductal/NST - 55 Post No 186
55 3.3 Ductal/NST 0/14 67 Post No 0
56 2.0 Ductal/NST 0/1 75 Post No 204
57 1.9 Ductal/NST 4/4 66 Post No 79



















59 2.7 (B) Ductal/NST 1/5 61 Post No 536
60 2.2(B) Ductal/NST - 59 Post No 392
61 2.6 (B) Ductal/NST - 62 Post No 225
62 -(B) Ductal/NST - 54 Post No 371
63 3.8 Ductal/NST 0/3 33 Pre No 44
64 1.7 Ductal/NST 1/3 50 Peri No 1
65 2.0 Scirrhous 3/3 45 Post No 76
67 2.2 Ductal/NST 0/4 50 - No 92
68 1.5 Ductal/NST (M) 0/8 52 - No 212
69 0.8 Ductal/NST (M) 0/8 52 - No 199
70 1.2 Ductal/NST 0/2 50 Post No -
71 1.3(B) Ductal/NST 1/1 47 Post No 436
72 1.7 (B) Ductal/NST 0/3 56 Post No 658
74 -(B) - - 62 Post No 240
75 1.9 Ductal/NST 0/7 51 Post No 3
76 3.5 Mucoid 1/10 52 Post No 62
79 1.8(B) Ductal/NST 3/15 33 Pre No 7
81 Ductal/NST 18/19 64 Post Yes 230
83 2.8 Ductal/NST 2/3 47 Pre No 36
84 4.5 Ductal/NST 3/5 55 Post No 0
85 5.5 Ductal/NST (M) 0/21 42 - No 4
86 3.0 Ductal/NST (M) 0/21 42 - No 51
87 2.5 Ductal/NST (M) 0/21 42 - No 37
88 3.5 Ductal/NST 1/4 41 - No 1
89 1.4 (B) Lobular variant 0/4 39 Pre No 35
90 1.4 Ductal/NST 1/1 56 Post No 243
91 3.2 Ductal/NST 1/11 33 Pre No 0
92 1.2 Ductal/NST 0/5 38 Peri Yes 61
93 1.4 Ductal/NST 1/4 57 - No 119
94 2.8 Ductal/NST 0/12 60 Post No 268
95 2.0 Ductal/NST (M) - 87 Post No 11
96 1.6 Ductal/NST (M) - 87 Post No -
97 1.3 Ductal/NST (M) - 87 Post No -
98 3.8 Ductal/NST 0/12 75 Post No 0
99 2.9 Ductal/NST 0/4 59 Post No 277
100 3.8 Tubular 0/12 48 Pre No 88
101 3.5 Comedo 0/12 59 Post No 0
103 2.5 Papillary 6/12 68 Post No 195
106 1.5 Ductal/NST 0/4 40 - No 21
107 2.3 Tubular (M) 3/8 64 Post Yes 149
108 1.7 Ductal/NST (M) 0/14 64 Post Yes 321
109 2.1 Ductal/NST 0/3 56 Post No 75
110 1.2 Ductal/NST 0/4 65 Post Yes 570
112 1.8 Papillary 0/10 58 - No 232
113 - Medullary 0/4 35 - No 9
114 1.4 Ductal/NST 0/12 36 Post Yes 4
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M/P - menopausal
ER - oestrogen receptor
NST - No Special Type
(B) - Biopsy
(M) - Several of the samples in the tumour bank are multiple primary breast tumours, independently
occurring tumours from in the same patient (tumours 11 and 12; 14 and 15; 18 and 19; 68 and 69; 85,
86 and 87; 95, 96 and 97; 107 and 108). During this study a mutation in the p53 gene, CGA>TGA at
codon 213, was identified in tumours 95, 96 and 97, strongly indicating a common origin for these
three tumours. Consequently the three samples have been treated as a single tumour in the present
study and are referred to collectively as tumour 95.
Summary of patient and breast tumour data:
Number of patients with primary breast cancer = 85
Number of primary breast tumours = 92
Number of tumours with information on:
Size = 67 (tumour sizes from biopsy samples have not been included)
Tumour type = 86
ER level = 84
Nodal status = 78
Number of patients with information on:
M/P status = 63
Age = 84
Family History = 85
Tumour Categorisation:





























2.2 Extraction of genomic DNA.
All chemicals unless otherwise stated were supplied by BDH Analar.
The extraction of genomic DNA followed the method of Gross - Bellard (1972). 10ml of
lysis buffer (0.1M Tris HCL, 20mM NaCl, ImM diaminoethanetetra - acetic acid (EDTA), 0.2%
sodium dodecyl sulphate (SDS» and 10ml of whole blood were mixed in a Falcon tube and
incubated overnight at 4°C. 10ml of water-saturated phenol was added and after shaking the aqueous
and phenol phases were separated by centrifugation at 3000rpm for 10 minutes. The aqueous layer
was transferred to a fresh tube, 5ml of 7.5M ammonium acetate and 20ml of isopropyl alcohol were
added and the solution was incubated overnight at -40°C. Precipitated DNA was spooled out on a
plastic rod, air dried and resuspended in 10ml of resuspension buffer (lOmM Tris HC1, 150mM
NaCl, lOmM EDTA). The DNA was treated with 500pg of RNase (Sigma) for 30 minutes at 37°C
followed by treatment with lOOpg of proteinase K in the presence of 0.2% SDS for one hour at 37°C.
10ml of water-saturated phenol was added, the mixture shaken and incubated for 20 minutes on ice.
The aqueous layer was recovered using centrifugation as before and two subsequent extraction steps
were performed using 24:1 chloroform/isoamylalcohol in lieu of phenol. The DNA was ethanol
precipitated from solution, spooled out and air dried as before. The remaining supernatant was
centrifuged at 3000rpm for 15 minutes and any precipitated DNA was air dried in the tube. The
DNA was suspended in 500p.l of TE (lOmM Tris HCL pH 7.5, 0.5mM EDTA) and stored at 4°C in
screw cap Eppendorf tubes. After 4-7 days the DNA concentration was measured using a Pye
Unicam SP-400 UV Spectrophotometer. An optical density of 1 at a wavelength of 260nm is
equivalent to a DNA concentration of 50(ig/ml.
DNA was extracted from approximately 1cm3 of solid tissue (breast tumour or placenta).
Frozen tissue was minced finely into cubes of less than 1mm using a fresh single sided razor blade
and transferred into 10ml of lysis buffer. From this point the tumour samples were treated as for
whole blood. Lymphoblastoid cell lines were used as a renewable source of control DNA.
Extraction of DNA from pellets containing lxlO7 cells was essentially the same as for whole blood.
The cell pellet was resuspended in 10ml of lysis buffer and from then on treated as for whole blood.
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2.3 Restriction enzyme digestion of DNA.
10jj.g of genomic DNA was digested with restriction enzyme in a 40|il or 60(_ii volume under
conditions recommended by the manufacturers (Boehringer Mannheim, NBL, Bio Labs) plus 25mM
spermidine (Sigma). Digestion reactions were normally left overnight at the appropriate temperature
(37°C for all enzymes except TaqI which was incubated at 65°C). Following digestion 1 Opl of
loading buffer (0.25% bromophenol blue (Sigma), 0.25% xylene cyanol FF (Sigma), 15% Ficoll
(molecular weight 4 x 106) (Sigma) or 0.25% bromophenol blue, 40% sucrose) was added and the
reaction mixture stored at 4°C until required. Details of enzymes used in this project are listed in
table 2.2.












YNZ22 D17S5 17pl3.3 1.7 TaqI 1.5-3.0
YNH37 D17S28 17pl3.3 1.6 TaqI 2.0 - 4.0
C3068 - 17pl3.2 8.8 Haelll 1.0-4.0
MCT35 D17S31 17pl3.1 2.4 Mspl 1.8, 2.4
BHp53 TP53 17pl3.1 4.1 BamHI 2.1,4.1
THH59 D17S4 17q23 - q25.3 3.8 TaqI °or-H100d
2.4 Agarose gel electrophoresis.
Agarose gel electrophoresis is used to separate DNA molecules of different sizes. The
passage of DNA through the gel is dependent on two major factors, the size of the DNA molecule
and the concentration of the agarose gel. Agarose gel electrophoresis was used for three main
purposes in this project. For the separation of restriction digested genomic DNA fragments (20 x
25cm) 500ml gels were used and were typically run at 60V for 18 hours. For the recovery of PCR
amplified DNA fragments (10x15cm) 300ml gels were used and were typically run at 70V at 4°C for
2 hours. For the estimation of DNA concentration of recovered PCR amplified fragments 30ml gels
(10 x 15cm) were used and were typically run at room temperature at 70V for 2 hours. The
concentration of the gels ranged between 0.7% - 1% depending on the size of the DNA fragments
being separated. Gels were made by heating a mixture of agarose (Sigma) and 1 x TAE (stored as 20
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x TAE: 0.8M Tris, 0.4M sodium acetate, 20mM EDTA, pH 8.2 with glacial acetic acid) in a
microwave oven until the agarose had melted. The solution was cooled to 60°C and poured into the
appropriately sized gel tray. All agarose gels were run in 1 x TAE. DNA fragments were stained by
immersing the gel in a solution of 0.5fig/ml ethidium bromide (Sigma) for 30 minutes followed by
destaining with distilled water for 10 minutes. The DNA was visualised by placing the gel on a UV
illuminator (UVP) and a record of the gel was taken either on Kodak X Pan 4147 film or by using a
video camera (UVP) and copy processor (Mitsubishi).
2.5 Southern Blotting.
The protocol used for transferring DNA fragments onto a solid support broadly follows that
of Southern (1975). Before blotting, gels were immersed in 1.25 litres of denaturing solution (0.5M
NaOH, 1.5M NaCl) for 45 minutes followed by immersion in 1.25 litres of neutralising solution (2M
NaCl, 1M Tris, pH 5.5) for 60 minutes. The blotting apparatus was prepared by placing a piece of
glass (23cm x 48cm x 0.5cm) on a plastic tray (28 x 45cm) containing 1-2 litres of 20 x SSC (3M
NaCl, 0.3M tri-sodium citrate). A 46 x 28cm piece of 17mm chromatography paper (Whatman),
pre-soaked in 20 x SSC, was placed on the glass plate with both ends immersed in the 20 x SSC
solution. Any air bubbles were removed by rolling a glass pipette over the paper. A piece of 23 x
25cm x 3mm chromatography paper (Whatman) was placed onto the 17mm paper wick, saturated
with 20 x SSC and any air bubbles removed as before. The gel was removed from the neutralising
solution and carefully placed on the 3mm paper to avoid air bubbles. The gel was cut through the
loading wells with a single sided razor blade and the agarose strip discarded. Cling film was
wrapped around the blotting apparatus in order to reduce evaporation from the 20 x SSC solution. A
23 x 20cm piece of Hybond N hybridisation membrane (Amersham) was placed on the gel and
covered by two pieces of 3mm chromotography paper, a 0.5cm layer of white kitchen towel and a
7cm layer of green paper towel (Kimberly Clark). A plastic tray and 1kg weight were placed on top
of the towels and the assembly was left overnight. The towel and filter paper layers were removed
and the Hybond filter marked with a name, the date and the position of the wells with a ball point
pen. The top right hand corner of the filter was cut in order to determine orientation. The filter was
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removed from the gel, placed DNA side down on a clean UV transilluminator and illuminated for 4
minutes in order to fix the DNA to the Hybond membrane. It was then placed between two sheets of
3mm chromotography paper and baked for 60 minutes in an 80°C vacuum oven. The gel was
removed from the blotting apparatus, stained with ethidium bromide and checked on a UV
transilluminator for efficient transfer of DNA onto the Hybond membrane. Alternatively, before
blotting, the gel was soaked for 30 minutes in denaturing solution and blotted for 4 hours onto
Hybond N+ hybridisation membrane (Amersham) using denaturing solution in lieu of 20 x SSC.
After blotting the hybond N+ filter was rinsed in 2 x SSC and air dried.
2.6 Radiolabelling of probe DNA.
All probes were supplied by Dr Y. Nakamura, Department of Biochemistry, Cancer
Institute, Tokyo 170, Japan. (Listed in Table 2.2). All probes were grown by Mrs Irene Mackenzie
using standard techniques (Sambrook et al„ 1989). Probes used for Southern hybridisation were
labelled with 32P dCTP (Amersham) using random priming kits (Amersham). Routinely 25ng of
probe DNA was denatured in lOp.1 of distilled water by heating to 100°C for 10 minutes and
immediately cooling on ice. 2jil of random prime buffer, ljil each of 0.5mM dATP, 0.5mM dGTP
and 0.5mM dTTP solutions, 5pl of 32P dCTP and l|il (2 units) of the Klenow fragment ofDNA
polymerase 1 were added. The reaction mixture was incubated at 37°C for 1 hour. The
incorporation of 32P dCTP was checked by pipetting 0.5pl of the mixture onto a circle of Whatman
GF/B filter paper and comparing the radioactive counts before and after 3 x 10 ml washes of 5%
trichloroacetic acid. If incorporation of over 40% was achieved then the probe was precipitated by
adding lpl of 3M sodium acetate and 140|il of ethanol and cooling at -40°C for an hour. The probe
was recovered by centrifugation at 13000 rpm for 30 minutes at 4°C, resuspended in lOOpl of
lOmg/ml denatured salmon sperm DNA (Sigma), heated to 100°C for 10 minutes and added to the
prehybridised filter. When using the probes MCT35.1 and c3068, which contain human DNA repeat
sequences, 1 OOp.1 of lmg/ml denatured sonicated human placental DNA was added in addition to the
denatured salmon sperm DNA. After heating at 100°C for 10 minutes these probes were incubated at
65°C for 60 minutes.
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2.7 Nucleic acid hybridisation.
Both prehybridisation and hybridisation of Hybond filters were carried out in quick-hybe
hybridisation mix (250ml 20 x SSC, 0.5g Bovine Serum Albumin (Sigma), 0.5g polyvinylpyrrolidine
(Sigma), 0.5g Ficoll, lg SDS, lg sodium pyrophosphate (Sigma), 5ml of 20mg/ml denatured salmon
sperm DNA, made up to 1 litre of solution). Filters were sealed in a plastic bag with about 1ml of
quick-hybe per 15cm^ of filter, ie typically 30ml of quick-hybe mix for a 23 x 20cm Hybond filter.
The filters were prehybridised for at least one hour in a 65°C waterbath. The radioactively labelled
probe was then added to the hybridisation mixture and sealed, ensuring no air bubbles were retained
in the bag. The filter was hybridised overnight at 65°C. The hybridisation bag was opened carefully
and the contents emptied under 500ml of 2 x SSC, 0.1% SDS wash solution. The wash solution was
discarded and the filter washed twice using 500ml of fresh 2 x SSC, 0.1% SDS wash solution and
once using either 500ml of 0.1 x SSC, 0.1% SDS wash solution or 0.2x SSC, 0.1% SDS wash
solution (depending on the probe) in a shaking oven at 65°C for 10 minutes. All wash solutions were
preheated to 65°C before use. After washing, the filters were wrapped in clingfilm, placed in an X-
ray cassette and autoradiographed at -70°C overnight with Kodak X-AR Omat film. Film was
processed in a Fuji RGB-2 Automatic film processor.
Alternatively a Hybaid hybridisation system was used which replaces hybridisation bags
with bottles. After blotting and fixation of DNA the fdter was placed between two layers of nylon
mesh and soaked in 2 x SSC. The filter/mesh sandwich was rolled up, placed in a glass screw topped
hybridisation bottle with 200ml of 2 x SSC and carefully unrolled ensuring no air bubbles were
trapped between the filter and the bottle. The 2 x SSC was discarded and replaced by 20ml of quick-
hybe. Prehybridisation, hybridisation and washing steps as described above were carried out in the
hybridisation bottle at 65°C within a specially designed rotary incubator.
2.8 PCR amplification of genomic DNA.
The oligonucleotide primers used in this project were synthesised by an Applied Biosystems
391 oligonucleotide synthesiser. Oligonucleotide stocks were stored in 30% ammonium hydroxide at
-20°C. Oligonucleotide primers were precipitated from the stock solution before use by adding 35pi
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of 3M sodium acetate pH 5.5 and 770pl of ethanol to 350pl of stock solution and cooling for 60
minutes at -20°C. The solution was centrifuged at 13000 rpm for 15 minutes at 4°C and the
supernatant discarded. The pellet was washed twice with 80% ethanol, air dried and resuspended in
200(0.1 TE. The concentration of the primers was calculated by optical density reading (section 2.2).
The molarity of the primers was calculated using the following method.
The exact extinction coefficient of a particular oligonucleotide (E) can be calculated by
adding the extinction coefficient for each base. Extintion coefficients (ml/mole) for each base are:
dATP 15.4, dCTP 7.3, dGTP 11.7, dTTP 8.8.
The concentration of the primer is calculated from the formula:
Concentration in pM = Optical density at 260nM/E.
The protocol for PCR amplification of genomic DNA is that of Saiki et al., 1988. PCR
reactions were carried out in a lOOpl reaction volume using DNA primers at 5 (iM, dNTPs (dATP,
dCTP, dGTP, dTTP) at 20mM, 0.5-lp.g of genomic DNA, 3 units of Promega Taq polymerase
enzyme and Promega Taq reaction buffer as recommended by the manufacturer. The DNA was
amplified in a Perkin Elmer Cetus thermal cycler (Model 2.2) using the cycles of 94°C for 2 minutes,
55°C for 2 minutes, 72°C for 3 minutes for 30 cycles. The sequence of the oligomers were as
follows:
p53 gene fragment III (exons 5 and 6, intron 5)
Primer III - 1. 5' TTCCTCTTCCTGCAGTACTC 3'
Primer III - 2. 5' AGTTGCAAACCAGACCTCAG 3'
p53 gene fragment IV (exons 7, 8 and 9, introns 7 and 8)
Primer IV - 1. 5' CTGTGTTATCTCCTAGGTTGG 3'
Primer IV - 2. 5' CCCAAGACTTAGTACCTGAA 3'
The amplified DNA fragments were recovered by running the reaction mixture out in a 1% low
melting point agarose (Sigma) gel as detailed in section 2.4. After ethidium bromide staining the
amplified DNA fragments were excised from the gel in an agarose slice using a single sided razor
blade and placed into labelled Eppendorf tubes.
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2.9 Purification of PCR amplified DNA fragments.
The geneclean kit (Bio 101 Inc) enables the purification of DNA molecules greater than
300bp in size from solution or agarose and was used to recover amplified DNA fragments from low
melting point agarose gel slices. Genecleaning was carried out according to the manufacturers
instructions. The volume of the gel slice was estimated by weight (lmg equals 1ml) and three times
the volume of Nal stock solution was added to the slice. The mixture was incubated at 50°C for
three minutes to ensure the agarose had completely melted. 5(il of glassmilk (silica bead solution)
was added and, after vortexing, incubated on ice with occasional shaking for 20 minutes. The
glassmilk beads were pelleted by centrifugation at 2500rpm for 7 seconds and the supernatant
discarded. The pellet was cleaned three times by vortexing in 200(il of "New wash" solution and
recovered by centrifugation as before. The glassmilk beads were suspended in 10(il of TE and
incubated at 50°C for 3 minutes to ensure dissociation of the DNA from the beads. The supernatant
was removed from the beads after centrifugation for 30 seconds. This eluting step was carried out
once more with a separate 10(il of TE to ensure maximum recovery of DNA. The concentration of
the DNA in solution was estimated by running 3(il out on a 1% agarose gel along with lp.1 of lmg/ml
Hindll/EcoRl cut lambda DNA (Boehringer Mannheim) as detailed in section 2.4.
2.10 Kinase labelling of double stranded PCR amplified products.
End labelling of DNA fragments was achieved by the use of the enzyme T4 polynucleotide
kinase which transfers the y phosphate from 32P y ATP to the 5' OH group of a dephosphorylated
oligonucleotide. lOOng of PCR amplified DNA was labelled in a reaction volume of 20fil containing
2(0.1 of 32P y ATP, 2(ol of 10 x kinase buffer and 1 (ol (9units) of T4 polynucleotide kinase. The
mixture was incubated at 37°C for 30 minutes. The DNA was precipitated by adding 20(ol of TE,
5|ol precipitating salts (3M sodium acetate pH 7.5, 7.5M ammonium acetate), 1.5(0.1 of lmg/ml
glycogen (Boehringer) and 150|ol of ethanol and incubated for half an hour at -70°C. The DNA was
pelleted by centrifugation at 13000 rpm at 4°C and then washed twice in 70% ethanol to remove
unincorporated nucleotides. The resulting pellet of end labelled DNA was dried under vacuum and
resuspended in 10|ol of TE.
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2.11 DNA heteroduplex formation.
lOng of labelled probe DNA was mixed witb lOOng of cold target DNA in a reaction
volume of lOpI containing lpl of 10 x heteroduplex salts (1M Tris, 3M NaCl, pH 8.0) and overlaid
with mineral oil (Sigma). The mixture was heated to 100°C for 5 minutes, transferred to a 65°C
waterbath and left overnight. The DNA, including the reannealed heteroduplex molecules, was
precipitated by adding 1.5pl lOmg/ml glycogen, 5pl precipitating salts and 150pl of ethanol
followed by incubation for 30 minutes at -70°C. The DNA was recovered by centrifugation for 15
minutes at 4°C, washed twice in 70% ethanol and dried for 60 seconds in a vacuum chamber. The
resulting pellet was resuspended in 13 pi TE. 6pl was transferred into a new tube and treated with
osmium tetroxide (Aldrich or Johnson Matthey), the remaining 7pl was Peated with hydroxylamine
hydroxide (Aldrich).
2.12 Chemical modification of mismatches using hydroxylamine hydroxide and piperidine.
20pl of a fresh 4M solution of hydroxylamine hydroxide (HA) titrated to pH 6 with
diethylamine (Aldrich) was added to the 7pl of heteroduplex solution and incubated at 30°C for 2
hours. The reaction was stopped by adding 200pl of 0.3M sodium acetate, O.lmM EDTA solution,
5pl of lOmg/ml dextran and 750pl of ethanol. The DNA was incubated for 10 minutes in a
methanol/dry ice bath, recovered by centrifugation at 13000rpm for 15 minutes at 4°C, washed twice
with 70% ethanol and dried for 60 seconds in a vacuum chamber. To the pellet 50pl of fresh 1M
piperidine (Aldrich) solution was added, vortexed for at least 60 seconds, and incubated at 90°C for
30 minutes. The reaction was stopped and precipitated as before but without dextran. The pellet was
resuspended in 5pl of TE and 2pl of stop solution (95% formamide, 20nM EDTA, 0.05%
Bromophenol Blue, 0.05% Xylene Cyanol FF) added. Immediately prior to denaturing
polyacrylamide electrophoresis the mixture was heated at 100°C for 2 minutes and stored on ice.
2.13 Chemical modification and cleavage ofmismatches using osmium tetroxide and piperidine.
15pl of a fresh 0.8% (1/10 dilution of a 8% solution or a 1/5 dilution of a 4% solution)
osmium tetroxide solution (Os04) (Aldrich or Johnson Matthey) and 2.5pl of osmium buffer
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(lOOmM Tris pH7.7, lOmM EDTA, 15% pyridine (Aldrich)) were added to the 6pl of heteroduplex
solution. The solution was mixed (but not spun down) and incubated for 37°C for 30 minutes. The
reaction was stopped by adding 200pl of 0.3M sodium acetate, O.lmM EDTA solution, 5)0.1 dextran
and 750|ol of ethanol and from this step, cleaved with piperidine in the same way as for HA
modification.
2.14 Sequencing of double stranded DNA amplified PCR fragments.
The sequencing of dsDNA PCR fragments was carried out using the Sequenase DNA
Sequencing Kit (USB) essentially following amodified protocol ofWinship (1989). 50ng of
template DNA, 200 - 250ng of DNA oligonucleotide primer, lpl of dimethyl sulphoxide (DMSO)
and 2|ol of sequenase reaction buffer in a volume of lOpl was heated at 100°C for 2 minutes and
immediately transferred to a dry ice/methanol water bath, lp.1 of dithiothreitol (DTT), 0.5pi 32P
dCTP, 2pl label mix (1.5pM dATP, 1.5pM dGTP, 1.5pM dTTP) and 2 units of sequenase in 1.5pi of
sequenase enzyme dilution buffer (lOmM Tris-HCl pH 7.5, 5mM DTT, 0.5mg/ml BSA) were added,
the solution mixed and incubated for 5 minutes at room temperature. 3.2pl of the mixture was
aliquoted into four tubes each containing 2pl of 80pM dATP, 80pM dCTP, 80pM dGTP, 80pM
dTTP, 50mM NaCl and either 8pM ddATP (tube A), 8pM ddCTP (tube C), 8pM ddGTP (tube G) or
8pM ddTTP (tube T). The tubes were incubated for 5 - 10 minutes at 37°C and the reaction stopped
by adding 4pl of stop solution. Immediately prior to denaturing polyacrylamide gel electrophoresis
the mixture was heated to 100°C for 2 minutes and transferred to ice.
The DNA primers used for PCR amplification (section 2.8) were used as primers for sequencing. In
addition the following primers were used:
p53 gene fragment III (for sequencing exon 6)
III - 3. 5' GACCTCAGGCGGCTCATA 3'
p53 gene fragment III (for sequencing exon 6)
III - 4. 5' CCTCTGATTCCTCACTGA 3'
p53 gene fragment IV (for sequencing exon 9)
IV - 3. 5' TAGTACCTGAAGGGTGAA 3'
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p53 gene fragment IV (for sequencing exon 8)
IV - 2A. 5' GTCCTGCTTGCTTACCTCGCT 3'
2.15 Denaturing polyacrylamide gel electrophoresis.
Denaturing polyacrylamide gel electrophoresis was carried out using the Bio rad sequi-gen
sequencing apparatus according to the manufacturers instructions. A 6% acrylamide/urea solution
was used for all polyacrylamide gel electrophoresis. 57g acrylamide (BRC), 3g N, N' -
methylenebisacrylamide (BDH) and 460g urea were dissolved at 37°C in 900ml of distilled water
and treated with 20g of 'Amberlite' MB-1 monobed mixed resin for 30 mins. 50mls of 20 x TBE
(1.8M Tris, 1.8M Boric acid, 0.04M EDTA) was added and the final volume made up to 1 litre. The
gels were made and run between two glass plates, the large plate containing the electrodes and buffer
tank, separated by two 0.4mm plastic spacers. The surface of the large plate was coated with 2%
dimethyldichlorosilane in trichloroethane to ensure that the polyacrylamide gel adhered to the small
plate only. The large and small plates were rinsed successively with tap water, distilled water and
ethanol to ensure a clean surface. The two gel plates were held together by plastic clamps and once
in place the plug of the gel was poured. The casting tray contained a strip of 23.5 x 3cm 17mm
chromatography paper resting on a 23.5cm x 3cm foam pad. 40pl of N, N, N', N' -
tetramethylethylenediamine (TEMED) (Sigma) and 240|_tl of 10% ammonium perisulphate (AMPS)
(BRL) were added to 15ml of 6% acrylamide/urea solution and immediately poured into the casting
tray. The assembled gel apparatus was placed into the casting tray and secured using plastic screws.
Once the plug was set 380|_il of AMPS and 55pl of Temed was added to 45ml of 6% acrylamide/urea
solution and poured between the two gel plates using a 50ml syringe. The appropriate comb was
inserted (a 0.4mm, 48 well Sharkstooth comb for sequencing gels or a 0.4mm, 16 well N-comb for
HOT gels (Bio - Rad)) and the gel allowed to set for 60 minutes. After setting, any excess
acrylamide was removed, the gel placed into the base apparatus and the tray and buffer tank filled
with 400ml and 450ml of 1 x TBE respectively. The gel was run at 30 Watts for 15 minutes and the
comb carefully removed. The wells were rinsed well with 1 x TBE buffer to remove urea before
loading the samples and, once loaded, the gel was run at 30 watts for up to 6 hours depending on the
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size of the fragments to be resolved. After electrophoresis the gel was fixed for 10 -15 minutes in a
10% methanol, 10% acetic acid solution, transferred to 3mm chromatography paper, covered with
cling film and dried at 80°C on a vacuum gel drier (Bio - Rad). After drying the cling film was
removed, the gel placed in an X-ray cassette and autoradiographed at -70°C overnight with Kodak X-
AR 5 film. Subsequent exposures were carried out according to the strength of the signal.
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Chapter 3
Loss of heterozygosity on chromosome 17
in primary human breast cancer
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3.1 LOH in human breast cancer.
LOH in breast tumours has been studied by many independent groups and the criteria by
which a tumour is classed as having 'lost' or 'not lost' heterozygosity at a particular locus vary
widely. Breast tumour samples often show a less than total loss of an allele due to either tumour
heterogeneity or contamination of the tumour material with normal tissue and are classed as showing
partial LOH. Recent LOH studies, discussed below, confirm that many breast tumour samples
contain more than one clone or are heavily contaminated with normal tissue.
3.2 Composition of breast tumour samples.
Unlike other solid tumours there are intrinsic difficulties associated with the study of LOH
in breast cancer. Removal of normal cells from tumour samples has been achieved in cancer of the
colon (Vogelstein et al., 1989), lung (Rabbitts et al., 1989), oesophagus (Boynton et al., 1991), brain
(Cogen et al., 1990) and pancreas (Hohne et al., 1992). However breast tumour samples are very
frequently contaminated with normal tissue in such a way that the separation of malignant and non-
malignant cells is not feasible. The extent of this contamination in breast tumour samples has been
examined by several groups by histological analysis. Almost half of the samples in the tumour series
used by Devilee et al. (1989) contained less than 60% malignant cells. The malignant cell content
ranged from 30-100% and 20-100% in two tumour series studied by Larsson et al. (1990) and
Thorlacius et al. (1991). Varley et al. (1989) reported that less than half the cells in the majority of
tumour samples were malignant and between 75-90% of cells were identified as malignant in tumour
samples used by Lundberg et al. (1987). From these reports it is clear that the composition of breast
tumour samples vary widely between different tumour banks.
3.3 Heterogeneity in breast tumour samples.
Breast cancer is a very heterogeneous disease in terms of tumour characteristics, disease
course and treatment response and this is reflected in findings at the molecular level. In addition to
the variation found between breast tumours, termed 'intertumour variation', cellular variation within
breast tumours, termed 'intratumour variation', has also been observed (Wolman and Heppner 1992).
53
Although breast tumours are thought to arise from a single cell, various sublines can develop during
the evolution of the tumour which differ in genetic characteristics (Heppner 1984). Tumour
heterogeneity, the term given to the occurrence ofmore than one type of cell in a single tumour, has
been well documented in breast cancer at cytogenetic and cytometry levels (Devilee and Cornelisse
1990). The extent of tumour heterogeneity in breast tumour samples has also been determined in
two studies at the LOH level (Larsson et al., 1990; Chen et al., 1992).
The study by Chen et al. (1992) identified tumour samples which showed complete allele
loss at one locus and a partial allele loss at a second site. Complete loss of an allele in these samples
indicated that the amount of contamination by normal tissue was very small. The partial loss
indicated that only a subset of the cells in the tumour actually showed LOH at the second site,
suggesting more than one clone of cells existed within the tumour. In 34 cases where complete LOH
was observed a partial LOH was observed at a second site in 8 tumours (24%). Since only twelve
sites on 10 chromosomes were investigated the extent of partial LOH in this tumour bank is likely to
be an underestimate.
In the study by Larsson et al. (1990) the percentage ofmalignant cells in the tumour
material had been determined by histological analysis. Thus any reduction in allele intensity could
be predicted in a tumour sample showing LOH. A decrease in the expected figure was attributed to
the tumour containing one or more clones which did not show LOH. This tumour heterogeneity was
observed in the majority (68%) of the tumours analysed. Clearly both these reports suggest that
breast tumour samples frequently contain more than one type of clone.
3.4 Criteria for LOH status in breast cancer.
Variation in allele intensity detected between blood and tumour DNA by Southern blot
analysis is thought to be due in part to experimental variation. Due to this variation, tumours
showing only partial loss of an allele are separated into groups showing 'insignificant' and
'significant' loss. Setting a level of significance has been achieved in a number of ways.
Several groups have relied on a visual evaluation of the relative allele ratios (Ali et al.,
1987; Mackay et al., 1988a; Mackay et al., 1988b; Ali et al., 1989b; Coles et al., 1990; Cropp et al.,
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1990; Gendler et al., 1990; Sato et al., 1990; Thompson et al., 1990; Leone et al., 1991; Sato et al.,
1991a; Thorlacius et al., 1991; Varley et al., 1991; Bieche et al., 1992; Borg et al., 1992b,c;
Cheickhi et al., 1992; Takita et al., 1992; Thompson et al., 1992) but this approach is highly
inaccurate unless tumour samples with very small amounts of normal tissue contamination and low
tumour heterogeneity are analysed. Other investigators have quantitatively determined the signal
imbalance by use of a scanning densitometer (Chen et al., 1989; Devilee et al., 1989; Genuardi et al.,
1989; Borresen et al., 1990; 1992; Andersen et al., 1992; Kallioniemi et al., 1992; Matsumura et al.,
1992; Knyazev et al., 1993) and then set an arbitrary value of significance. Relative signal reduction
values used to classify the 'no loss' and 'loss' states in breast tumours include 30% (Chen et al., 1992;
Kallioniemi et al., 1992; Matsumura et al., 1992), 35% (Chen et al., 1989), 40% (Devilee et al.,
1989) and 50% (Andersen et al., 1992; Knyazev et al., 1993).
Both these approaches are unsatisfactory since they do not take into account the possibility
of normal cell contamination or intratumour heterogeneity. Both these variables effect the reduction
of allele intensity observed in the southern blot assay and so can effect the estimation of the
frequency of LOH at a particular locus. Tumour samples highly contaminated with normal tissue or
containing genetically different subclones can lead to an underestimation of the frequency of LOH
when using the above criteria. Methods which take both of these factors into account have been
devised by Lundberg et al. (1987), Devilee et al. (1990) and Larsson et al. (1990). All the tumours
analysed for LOH in these studies had the amount of non-malignant tissue determined by scoring
representative histological sections at low magnification. Thus it was possible to predict the
expected imbalance in allele ratios in each tumour assuming all the malignant cells show LOH. Any
reduction in this estimated figure was attributed to tumour heterogeneity.
3.5 Determining LOH on chromosome 17 in primary breast tumours.
This series of experiments followed on from the work of Mackay et al. (1988a) investigating
the high frequency of LOH observed in primary breast tumour samples on chromosome 17. LOH
was identified in 23/38 (61%) of samples in the breast tumour bank using the VNTR probe YNZ22
(Mackay et al., 1988a). The present set of experiments determined the rates of LOH at other loci on
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chromosome 17 and had a twofold objective. Firstly LOH information on loci mapping adjacent to
the YNZ22/D17S5 locus was needed in the hope of identifying a SRO pinpointing an area of the
chromosome likely to harbour a putative tumour suppressor gene. Secondly the LOH frequency at
loci mapping close to the p53 gene itself could be used to investigate a potential role for p53 in
breast carcinogenesis.
The work was carried out on the bank of paired control/tumour DNA samples established by
Mackay et al. and detailed in section 2.1. Previous investigation of LOH at various loci had depleted
the DNA bank of certain tumour and blood DNA samples (Mackay et al., 1988a,b). Of the 92
samples of matched control/primary breast cancer DNA only 61 pairs were found to contain enough
DNA for LOH analysis. Using these samples the following probes were used to determine LOH:
BHp53, MCT35, c3068, THH59 and YNH37, which map to 17pl3.1, 17pl3.1, 17pl3.2, 17q23-25.3
and 17pl3.3 respectively (Figure 3.1). The frequency of heterozygosity observed at these loci is
shown in table 3.1.
3.6 Measurement of reduction in allele intensity.
Autoradiographs were analysed using the MRC HGU large format densitometer and tracks
unable to be analysed due to high background levels were not included in the study. Reduction in
the ratio of allele intensities was calculated after equalising one of the control alleles with the
corresponding tumour allele. The intensity of the two remaining alleles could then be compared
directly and any reduction in signal calculated. Figure 3.2 shows representative examples of
southern blot analysis in various control/tumour DNA pairs using a variety of probes. Figure 3.3
shows the densitometer scan figures used in calculating the relative signal reduction in tumour 99 at
the c3068/- locus.
In total 79 loci in 40 tumours were measured quantitatively by scanning densitometry. After
adjusting for background levels, the relative reduction of allele intensities were calculated and these
figures are shown in table 3.2. Since the LOH data on the YNZ22/D17S5 locus (Mackay et al.,
1988a) had only been analysed visually it would have been of value to re-analyse the original
















Location of the loci on chromosome 17 identified by the probes used in this study.
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Figure 3.2 Southern blot analysis of pairs of constitutional (N) and tumour (T) DNA using six

















Figure 3.3 Densitometer scans of an autoradiogram obtained following hybridisation of c3068 to an
Haelll digest of tumour 99 DNA (A) and corresponding normal DNA (B).
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other loci on chromosome 17. Unfortunately reanalysis of these autoradiographs was not possible.
Due to the decreasing amount of DNA available for LOH studies and experimental difficulty with
the YNZ22 probe only 7 informative control/tumour pairs were analysed at the YNZ22/D17S5 locus.
These results and the visual evaluation of the control/tumour pairs by Mackay et al. are shown in
table 3.2.













13 44 31 23 12
Number of
heterozygous patients
6 22 16 14 8
Frequency of
heterozygosity (%)
46 50 51 61 67
3.7 Analysis of quantitative values.
The percentage of malignant cells in the breast tumour samples had not been determined
prior to DNA extraction. Therefore, as with other studies, a level of significance was set to provide
an arbitrary cut off point of significance. Table 3.3 shows analysis of the data using 40% as a
measure of significance for LOH.
A high frequency of LOH using the probe YNZ22 has been observed in many other studies
(Mackay et al., 1988a; Devilee et al., 1989; Varley et al., 1989; Borresen et al., 1990; Cropp et al.,
1990; Larsson et al., 1990; Sato et al., 1990; Thompson et al., 1990; Chen et al., 1991a; Devilee et
al., 1991a; Osborne et al., 1991; Thorlacius et al., 1991; Andersen et al., 1992; Chen et al., 1992;
Cheickhi et al., 1992; Matsumura et al., 1992; Cornelise et al., 1993; Knyazev et al., 1993). This
frequency ranges from 17% (22/130) (Cheickhi et al., 1992) to 69% (51/74) (Varley et al., 1989).
However LOH at this locus was observed in only 14% (1/7) of informative samples in this study
(Table 3.3) and is probably a consequence of the small number of samples analysed. Other studies
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Table 3.2 Loss of heterozygosity at chromosome 17 loci in primary breast tumours expressed as a
relative percentage reduction of signal.
Tumour TTH59/ BHp53/ MCT35/ C3068/- YNH37/ YNZ22 YNZ22 data
Number D17S4 TP53 D17S31 D17S28 /D17S5 Mackay et al.
1 U U NL
3 U L
13 U
14 36 43 28 L
15 45 65 64 L
16 52 69 U
18 U 100 U U L
19 U 23 U U NL
20 2 30 u 49 U
21 100 100 U U L
22 U u L
24 U 29 U 37 24 NL






34 U u 70 25 L
35 50 37 NL
37 U 3 NL
38 U
39 2
40 72 71 76 69 U U
42 42
45 30 29 U 46 56 L
47 U U
48 U




59 U 75 U
60 U
63 7 18 40 L
64 L
65 13 4 19 U 16 NL
67 U L

























85 U 16 U
86 U 29 U
87 U U
90 U 36
91 89 U NL
92 78
93 U 20 46 NL
94 U U 68 NL




99 42 58 U 58 58 U
100 U 82 U U 5 NL
101 100 L
102 NL
103 7 26 22 8 10 16 NL
107 34 U U U U
108 29 U U U U
109 U U
U - Uninformative
NL - No LOH
L-LOH
62
have based their figures on sample sizes ranging from 19 (Osborne et al., 1991) to 130 (Cheickhi et
al., 1992) informative samples. In this study LOH is observed in 50% (4/8) of informative samples
at the YNH37/D17S28 locus (Table 3.3), which maps only 20 kb from the YNZ22/D17S5 locus
(Ledbetter et al., 1989). Although this frequency approaches those observed for the YNZ22/D17S5
loci in other studies an accurate estimation was not possible as only eight informative samples were
available for analysis.














6 25 18 15 8 7
Number of samples showing
LOH
2 11 10 8 4 1
Frequency of LOH
(%)
33 44 56 53 50 14
LOH at loci near the p53 locus, as defined by the probes BHp53 and MCT35, was observed
in 17/35 (49%) of informative samples. This figure falls within the range observed in other studies:
61% (17/28) (Davidoff et al., 1991a); 37% (26/70) (Sato et al., 1991a); 30% (6/19) (Osborne et al.,
1991); and 48% (19/42) (Andersen et al., 1992). LOH at the THH59/D17 locus on the long arm of
chromosome 17 was shown in 2/6 (17%) of informative samples. This frequency is less than that
found at this locus by Cropp et al., (1991) (29%) although, as with the YNZ22/D17S5 and
YNH37/D17S28 data, the sample size is too small to produce an accurate estimate of LOH.
While studies show a similar range of LOH frequencies for both the YNZ22/D17S5 and
BHp53/TP53 loci three studies investigating both loci show a marked difference in frequency of
LOH (Coles et al., 1990; Sato et al., 1990; Andersen et al., 1992). In the study by Sato et al. (1990)
loci at 17pl3.3 showed LOH at a higher frequency (52%) than those at 17pl3.1 (32%). In the study
by Andersen et al. (1992) loci mapping to 17pl3.3 were shown to have a frequency of LOH as high
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as 75% in comparison to a LOH frequency of 48% at 17pl3.1 loci. The data from this study, when
analysed visually and combined with the data from Mackay et al. (1988a), also indicated a difference
in the frequency of LOH between the two loci (Coles et al., 1990). However due to the limited
number of tumours available for quantitative analysis at the YNZ22/D17S5 and YNH37/D17S28 loci
these data can no longer show this difference in LOH frequency. Similar frequencies of LOH are
observed at the BHp53/TP53 (44%), MCT35/D17S31 (56%), c3068/- (53%) and YNH37/D17S28
(50%) loci (Table 3.3).
3.8 Determination of a shortest region of overlap.
The determination of a SRO involves the comparison of LOH status at adjacent loci.
Although using the 40% level of significance to determine LOH frequency is adequate when
analysing single loci, simply using this when analysing markers on the same chromosome arm would
be an unsatisfactory way of producing mapping data. For example, analysis of LOH at the 40% level
in tumour 14 would classify the tumour as showing LOH at the MCT35/D17S31 loci but not at the
BHp53/TP53 and c3068/ loci (Table 3.2). The difference in relative allele intensity reduction in this
tumour is only 7% between the BHp53/TP53 and MCT35/D17S31 loci and 15% between the
MCT35/D17S31 and c3068/- loci and could be due to experimental variation alone. For this reason,
this tumour sample would be unsuitable for determining a SRO. In order to avoid this problem, only
those tumour samples showing a difference in allele intensity ratios between adjacent loci above a
certain level would be selected for the purpose of mapping.
If the data are analysed by selecting only those tumours in which adjacent loci show a
difference in allele intensity ratios greater than a value of 40%, then only tumours 34 and 100 would
be suitable for determining an SRO. Tumours 34 and 100 show a difference in relative allele
intensity ratios between the MCT35/D17S31 and YNZ22/D17S5 markers of 55% and 78%
respectively (Figure 3.4, Table 3.2) and indicate a LOH event occurring somewhere proximal to the
YNZ22/D17S5 marker in both tumour samples. This suggests that the inactivation of a tumour
suppressor gene proximal to the YNZ22/D17S5 locus contributed to the development of both
tumours. In order to determine an SRO in these tumours other chromosome 17p loci were
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Figure 3.4 Southern blot analysis of four pairs of constitutional (N) and tumour (T) DNA using four
chromosome 17p probes. Tumours 34 and 100 show LOH with MCT35 but not with YNZ22.
Tumour 103 shows no LOH at all four loci. Tumour 99 shows LOH at all informative loci.
BHP 53 MCT 35 YNZ 22 Tumour
34
BHP 53 MCT 35 C3068 YNZ 22 Tumour
100
BHP 53 MCT 35 C3068 YNH 37 Tumour
103
BHP 53 MCT 35 C3068 YNH 37 Tumour
99
NT NT NT NT
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investigated for LOH. By using probes mapping between the YNZ22/D17S5 and MCT35/D17S31
loci and proximal to the MCT35/D17S31 locus, further data on the extent of the region of LOH
could be produced. Unfortunately the analysis of tumour 34 with the other chromosome 17p markers
was not possible due to the limited amount of tumour DNA available. Tumour 100 was analysed at
the c3068/ and BHp53/TP53 loci but was found to be uninformative for both of these markers (Table
3.2, Figure 3.4). Additional chromosome 17p probes would need to be obtained before further
mapping with tumour 100 could continue.
Following the discovery the high frequency of LOFI at the YNZ22/D17S5 locus in breast
cancer, a number of groups have attempted to define a SRO on chromosome 17p (Coles el al., 1990;
Devilee et al., 1990; Sato et al., 1991a; Andersen et al., 1992). The earlier study by Devilee et al.
(1990) determined a single SRO defined by the loci EW504/D17S67, which maps to 17pl2 and
YNZ22/D17S5. The three later studies, using additional probes, determined two SROs on
chromosome 17p, suggesting the presence of two genes involved in breast tumorigenesis. The study
by Sato et al. (1991a) implicated one of the regions between the marker LB 17.3, which maps to
17pl3.1 - 17pl3.3, and the telomere of the chromosome and the other between the marker
BHp53/TP53 and the centromere. The study by Andersen et al. (1992) further localised the
telomeric SRO between the 144D6/D17S34 and YNZ22/D17S5 loci, a region 7kb in length (Y.
Nakamura, personal communication). The second SRO was localised between the YNZ22/D17S5
loci and the centromere. Evidence for two SROs on chromosome 17p was also generated when the
data from the present study and that of Mackay et al. (1988a) were analysed visually (Coles et al.,
1990). However due to the limited number of tumours available for quantitative analysis at the
YNZ22/D17S5 locus the data are inadequate to illuminate the issue of two SROs on chromosome
17p.
3.9 Discussion.
As the location of the p53 gene falls within the more proximal SRO region determined by
both Sato et al. (1991a) and Andersen et al. (1992) it is thought that LOH in this area may indicate
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the inactivation of one copy of the p53 gene. To date the only gene sequence known to map to the
17pl3.3 region is that of the profilin gene which codes for an actin monomer binding protein
(Kwiatkowski et al., 1990). Unfortunately it is located proximal to the YNZ22 locus and is therefore
outside the SRO determined by Andersen et al. (1992). However it is possible that there is more
than one tumour suppressor gene located at 17pl3.3 and, until the gene has been screened for
alterations in tumours, a role for the profilin gene in breast tumorigenesis cannot be excluded.
Detailed studies of patterns of LOH in colon cancer have identified only a single SRO,
which contains the p53 gene (Baker et al., 1989). LOH studies of hepatocellular carcinomas
(Fujimori et al., 1991), renal cell carcinomas (Morita et al., 1991), medulloblastomas (Cogen et al.,
1992), ovarian carcinomas (Sato et al., 1990) and neuroectodermal tumours (Biegel et al., 1992)
have revealed a pattern of loss similar to that observed in breast cancer ie loss of telomeric sequences
on chromosome 17p without apparent loss of the p53 gene. This suggests that the putative tumour
suppressor gene at 17pl3.3 may play a part in the development of a number of malignancies and that
identification of this gene may not have to rely on mapping data produced from breast cancer alone.
Ideally LOH mapping in breast cancer samples requires tumour DNA derived from samples
with little contamination by normal tissue and in which tumour cells contain the same genetic
alterations. Of the 40 tumours analysed at one or more loci only three samples, tumours 18, 21 and
101, showed a complete loss of an allele (Table 3.2). This suggests that the tumour samples used in
the LOH assay were frequently contaminated by normal tissue or contained more than one type of
clone. Consequently few mapping data were able to be produced from this series of experiments. In
future, histological analysis of all tumour material before use in mapping experiments would identify
those samples containing a high level of normal cell contaminadon and would enable the
identification of samples showing tumour heterogeneity (Lundberg et al., 1987; Devilee et al., 1990;
Larsson et al., 1990).
The mapping data generated identify two tumour samples both showing LOH at a site near
to the p53 gene but not at more distal loci. LOH is observed at loci near to the p53 gene in 17/35
(49%) of samples. These two observations suggest a role for the p53 gene in breast tumorigenesis
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Detection of mutations in the p53 gene using the amplification and
mismatch detection (HOT) technique
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4.1 Mutation detection techniques.
The determination of a single SRO between 17pl2 and 17pl3.3 and the close correlation of
LOH on chromosome 17 with the mutation of the remaining p53 allele in colon and other cancers,
strongly suggested that the tumour suppressor gene inactivated during the development of those
malignancies was the p53 gene (Baker et al., 1989; Nigro et al., 1989; Baker et al., 1990a). Due to
the high frequency of LOH near the p53 locus observed in the previous set of experiments and the
detection of p53 mutations in breast cancer cell lines (Nigro et al., 1989; Bartek et al., 1990a) the
breast tumour samples were screened for the presence of p53 mutations. Early mutation studies on
the p53 gene relied on the isolation ofmRNA and the synthesis and sequencing of p53 cDNA from
tumour samples, a process both labour intensive and time consuming (Baker et al., 1989; Nigro et
al., 1989). More recent studies, especially those examining a large number of tumour samples, have
relied on non-sequencing techniques to identify p53 mutations before sequencing is attempted.
Those techniques most frequendy used are SSCP (single strand conformation
polymorphism) (Orita et al., 1989; Spinardi et al., 1991), DGGE (denaturing gradient gel
electrophoresis) (Sheffield et al., 1989) and modifications of it, CDGE (constant denaturing gel
electrophoresis) (Borresen et al., 1991) and HOT (also known as the amplification and mismatch
detection technique or chemical cleavage technique; named after the modifying chemicals used,
hydroxylamine hydroxide and osmium tetroxide). SSCP relies on the differing conformations
adopted by single stranded DNA molecules of different sequence which result in an alteration in
electrophoretic mobility. Regions of interest are simply amplified, denatured and run out on a non-
denaturing polyacrylamide gel with a normal control. DGGE/CDGE is based on strand separation of
DNA fragments in discrete sequence-dependent melting domains. Strand separation results in a
decrease in the electrophoretic mobility of the DNA fragment as it moves through a polyacrylamide
gel containing an increasing (DGGE) or constant (CDGE) gradient of denaturant. Both SSCP and
DGGE/CDGE techniques are sensitive enough to separate DNA fragments differing in only a single
base.
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4.2 The HOT technique.
The HOT technique was developed by Cotton et al., (1988) and is based on the principles of
Maxam and Gilbert sequencing (Maxam and Gilbert 1977). The basis of the technique is as follows.
Wild type and mutant DNA sequences are mixed together, denatured into single strands and allowed
to renature to form a wild type/mutant heteroduplex. Regions of mismatch are produced within the
heteroduplex molecule wherever the two sequences differ. The mismatched sequences are modified,
either by hydroxylamine hydroxide (HA) or osmium tetroxide (0s04), followed by chemical
cleavage of the sugar-phosphate backbone at these modified sites by piperidine. HA modifies across
the 5,6 double bond of cytosine bases, 0s04 modifies across the 5,6 double bond of thymine bases.
Cleaved products can be separated from full length fragments on a denaturing polyacrylamide gel
and, when using radioactively labelled DNA fragments, identified by autoradiography (Figure 4.1).
The HOT technique as described in section 2.10 is carried out by mixing radioactively end-
labelled DNA fragments (known as the probe DNA) with unlabelled fragments from a different
source (known as the target DNA). Since detection is dependent on heteroduplex formation, the
probe DNA, which can be either wild type or mutant, is mixed with approximately ten times the
amount of target DNA prior to denaturing. This ensures that nearly all of the probe DNA forms a
heteroduplex rather than a homoduplex. For convenience, when scanning a large number of DNA
samples for mutations, wild type probe DNA is used to screen the sample target DNAs. Using both
HA and 0s04 it is theoretically possible to detect all types of mutations using wild type probe DNA
with target DNA (Table 4.1).
The HOT technique has two main advantages over the other non-sequencing techniques.
Firstly, DNA fragments greater than lkb can be analysed for mutation (Cotton 1992). Both SSCP
and DGGE/CDGE techniques have a size limit of about 400bp (Grompe et al., 1989; Orita et al.,
1990). Secondly, since chemical cleavage occurs at the site ofmismatch, the size of the cleaved
fragment indicates how many bases into the fragment the mutation is located. Once a mismatch has
been detected the mutation can be located in one of two places so subsequent sequencing in order to
define the specific change is minimal. In addition, once the specific mutation has been identified it
can be confirmed by comparing the expected and observed fragment sizes following HA or 0s04
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Figure 4.1





































Detection of a GC > TA substitution using the HOT technique.
C m and T m represent bases modified by Hydroxylamine (HA) and Osmium tetroxide
(0s04) respectively.
Negative controls(-) are produced when the target and probe DNAs are identical.
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modification and piperidine cleavage. This is particularly useful when detecting mutations in
material containing both mutant and wild type sequences.






















































*N - Base on end-labelled fragment
4.3 Detection of mismatches in p53 DNA fragments amplified from primary breast tumours.
Previous work in other malignancies identified the majority of p53 mutations in exons 5-8
of the p53 gene (Nigra et al., 1989; Hollstein et al, 1991a; Caron de Fromentel et al., 1992). Breast
tumour samples were therefore screened for p53 mutations in this region of the gene.
Oligonucleotide primers were used to amplify exons 5 and 6 in a 408bp fragment (fragment III) and
exons 7, 8 and 9 in a 792bp fragment (fragment IV) from 78 primary breast tumour samples. End-
labelled wild type probe DNA was mixed with an excess of unlabelled tumour target DNA from each
tumour sample, denatured by heat and cooled to form the probe/target heteroduplex. Following HA
and 0s04 modification and piperidine cleavage the samples were loaded, with a positive control,
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onto a denaturing polyacrylamide gel. The resulting autoradiographs were analysed for the presence
of any mismatches (Figures 4.2, 4.3, 4.4, 4.5).
Mismatches were detected in 19 tumours in fragment III and 23 tumours in fragment IV.
Analysis of the cleaved fragments bands indicated that 18 of the 80 tumours contained mismatches
which could be attributed to two known polymorphisms. One of the polymorphisms was detected in
fragment IV and is known to be located in intron 7. It is are comprised of two substitutions, GC>AT
and AT>CG, which occur 72 and 92 nucleotides into intron 7 respectively (Prosser and Condie
1991). Using wild type probe DNA and tumour target DNA the polymorphism is identified by a
197bp fragment after HA modification and a 217bp fragment after 0s04 modification (Figure 4.6).
Due to the high frequency and previous characterisation of the polymorphism by the HOT technique
the corresponding lymphocyte DNA was not sequenced to confirm the presence of the
polymorphism. The polymorphism was found in 6/60 (10%) breast cancer patients in the study by
Prosser and Condie (1991) and 16/73 (22%) breast cancer patients in this study.
The second polymorphism was detected in fragment III and is located in exon 6. This
polymorphism was detected in 2 of 78 tumours and is known to correspond to a AT>GC substitution
at the third nucleotide of codon 213 (Carbone et al., 1991; Mazars et al., 1992a). It is a silent
alteration and results in no amino acid change in the p53 protein. Using wild type probe DNA and
tumour target DNA the polymorphism is identified by a 49bp cleaved fragment after 0s04
modification (Figure 4.6). The presence of the sequence alteration in somatic cells was confirmed by
sequencing fragment III amplified from the corresponding patient lymphocyte DNA (Figure 4.7).
The polymorphism was detected in 2 of 73 (3%) patients, a frequency similar to that found in other
studies: 3% (6/189) (Carbone et al., 1991); 3% (2/70) (Mazars et al., 1992a); 3% (1/34) (Hollstein et
al., 1991b); (4%) 1/26 (Osborne et al., 1991); 3% (1/33) (Bodner et al., 1992); and 5% (1/22) (von
Deimling et al., 1992).
4.4 Characterisation of the p53 mutations.
In total 24 mismatches were identified, excluding those caused by the polymorphisms in
exon 6 and intron 7. Seventeen of these mismatches were identified in fragment III, 7 were detected
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Figure 4.2 Detection of mismatches in exons 5 and 6 of the p53 gene in primary breast tumours: HA
modification and piperidine cleavage of heteroduplexes between wild type probe DNA and tumour
target DNA. Arrows indicate the positions of cleaved fragments. Tumour 34 (T34) was used as a
positive control.
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Figure 4.3 Detection of mismatches in exons 5 and 6 of the p53 gene in primary breast tumours:
0s04 modification and piperidine cleavage of heteroduplexes between wild type probe DNA and
tumour target DNA. Arrows indicate the positions of cleaved fragments. Tumour 34 (T34) was used
as a positive control.
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Figure 4.4 Detection of mismatches in exons 7, 8 and 9 of the p53 gene in primary breast tumours:
HA modification and piperidine cleavage of heteroduplexes between wild type probe DNA and
tumour target DNA. Arrows indicate the positions of cleaved fragments. Tumour 9 (9T) was used as
a positive control.
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Figure 4.5 Detection of mismatches in exons 7, 8 and 9 of the p53 gene in primary breast tumours:
0s04 modification and piperidine cleavage of heteroduplexes between wild type probe DNA and
tumour target DNA. Arrows indicate the positions of cleaved fragments. Tumour 9 (9T) was used as
a positive control.
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Figure 4.6 Detection of the intron 7 and exon 6 polymorphisms of the p53 gene by the HOT
technique. The intron 7 polymorphism is present in tumour 99. The exon 6 polymorphism is present
in tumour 74.










Figure 4.7 Sequence of the codon 213 polymorphism determined in both tumour 75 (T75) and
paired normal DNA (N75).
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in fragment IV. A greater frequency of p53 mutations has been detected in exons 7 and 8 than in
exons 5 and 6 in a number of breast cancer studies (section 5.3.5). Since fewer mutations were
detected in fragment IV than in fragment III in this tumour series, fragment IV samples were
reanalysed by the HOT technique using tumour probe DNA and wild type target DNA. An
additional mismatch was detected in a single tumour, tumour 98, which had not been identified when
using wild type probe DNA and tumour target DNA (Figure 4.8).
In order to estimate the size of the cleaved fragments, and so help pinpoint the area where
the mutations reside, the detection of the mismatches by the HOT technique was repeated. The
samples were run out on a denaturing polyacrylamide sequencing gel with either p53 fragment III or
IV sequencing reaction products as a size marker (Figures 4.9, 4.10, 4.11). Once the fragment sizes
were determined, sequencing was carried out from either end and the appropriate area examined for
mutation. Mismatch analysis and sequencing were performed on independently amplified PCR
fragments to ensure that the mutations identified had not arisen from infidelity of the taq polymerase
enzyme. A change in sequence was identified in 24 of the 25 tumour samples identified by the HOT
technique (Figure 4.12, Tables 4.2, 4.3, 4.4).
In one case, tumour 85, a mismatch was detected in fragment IV resulting in a cleaved
fragment length of approximately 80bp after HA modification (Figures 4.4, 4.13). Sequencing of the
fragment detected no mutation 80bp from either end of the fragment (Figure 4.14). Reanalysis of
two further independently amplified fragments confirmed the presence of the 80bp fragment. In an
effort to identify the possible type of base change present in the p53 gene of this tumour, mutation
detection by the FIOT technique was performed using tumour probe DNA and wild type target DNA.
No cleaved bands were observed on the resulting autoradiograph (Figure 4.13). This pattern is
consistent with a CG>TA substitution. The 80bp cleaved fragment is generated from a CA mismatch
when the wild type fragment is end labelled. The absence of any cleaved product when the mutant
fragment is labelled can be explained by the insufficient modification of a GT mismatch (section
4.5). However, repeated sequencing of independently amplified samples detected no mutation at any
site on the fragment.
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Figure 4.8 Detection of mismatches in exons 7, 8 and 9 in the p53 gene in primary breast tumours:
HA modification and piperidine cleavage of heteroduplexes between tumour probe DNA and wild
type target DNA. The 585bp cleaved fragment represents the intron 7 polymorphism in tumours 98
and 99. The 721bp fragment represents the AT>GC substitution present in tumour 98.
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Figure 4.9 Detection of mismatches in exons 5 and 6 of the p53 gene in primary breast tumours:
size determination of HA modified and piperidine cleaved fragments. p53 fragment III sequencing
reaction products, used as size markers, are indicated by G, A, T, C.
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Figure 4.10 Detection of mismatches in exons 5 and 6 of the p53 gene in primary breast tumours:
size determination ofOs04 modified and piperidine cleaved fragments. p53 fragment III sequencing
reaction products, used as size markers, are indicated by G, A, T, C.
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Figure 4.11 Detection of mismatches in exons 7, 8 and 9 of the p53 gene in primary breast tumours:
size determination of HA and 0s04 modified and piperidine cleaved fragments. T8H, T12H, etc
indicate heteroduplexes modified by HA, T8°, T92°, etc represent heteroduplexes modified by 0s04.
p53 fragment IV sequencing reaction products, used as size markers, are indicated by G, A, T, C.
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Table 4.2 Chemical modification of mismatched bases detected in exons 5 and 6 of the p53 gene in
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A - single base deletion
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Table 4.3 Chemical modification ofmismatch bases detected in exons 7, 8 and 9 of the p53 gene in
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NK - Not Known
A - single base deletion
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Table 4.4 Chemical modification of mismatch bases detected in exons 7, 8 and 9 of the p53 gene in
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Figure 4.12 Sequence characterisation of p53 mutations detected in eight breast tumours by the
HOT technique.
GATC GATC GATC GATC
T8 T12 T34 T57
GATC GATC GATC GATC
T67 T84 ~ T95 T101
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Figure 4.13 Mismatch detection in tumour 85 using the HOT technique. An 80bp fragment is
detected using wild type probe and tumour target DNA. No cleaved fragments are detected using
tumour probe and wild type target DNA.
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In order to determine whether any of the 25 mutations were uncharacterised polymorphisms
or hereditary mutations, patient lymphocyte DNA was examined either by the HOT technique or by
sequencing for the base change present in the tumour (Figures 4.15, 4.16). In all 25 cases the change
in sequence was found only in the tumour DNA, confirming that the mutations were somatically
acquired.
4.5 Sequence confirmation of p53 mutations by analysis of modified fragments.
Once the mutation was identified by sequencing, the fragment sizes produced by both HA
and 0s04 modification and piperidine cleavage were checked to see if they concurred with the
expected fragment sizes. Unexpected bands can be explained by the modification of bases adjacent
to the site of mismatch. Adjacent base pairs, though not mismatched themselves, can also be
disrupted and are sometimes modified along with the mismatched bases (Cotton and Duncan
Campbell 1989). Tables 4.2, 4.3 and 4.4 show the confirmatory cleaved bands observed with the p53
mutations and polymorphisms identified.
By comparing the mismatches detected by the HOT technique using either wild type or
tumour probe DNA, it is apparent that although the HOT technique is able to detect some GT
mismatches, eg the codon 213 polymorphism (Table 4.2), a number of GT mismatches are not
detected by this technique, eg mutations in tumours 98 (Table 4.3), 101 and 110 (Table 4.4). The
distortion of the double helix created by various mismatches is thought to depend on the bases
involved. Mismatches such as CA and CC are thought to create the most distortion while GT
mismatches are thought to cause the least (Cotton 1989). It is perhaps for this reason that the Os04
modification of mismatched thymine in GT mismatches is sometimes not sufficient for mutation
detection.
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Figure 4.15 Detection ofmismatches in exons 7, 8 and 9 of the p53 gene in patient control DNA:
HA modification and piperidine cleavage of heteroduplexes between wild type probe DNA and




Figure 4.16 Detection of mismatches in exons 7, 8 and 9 of the p53 gene in patient control DNA:
Os04 modification and piperidine cleavage of heteroduplexes between wild type probe DNA and




Analysis of p53 mutations in primary human breast cancer
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5.1 Frequency of p53 mutations in primary breast cancer.
5.1.1 Estimating the incidence of p53 mutations in primary breast tumours.
Using the HOT technique 25 somatically acquired sequence alterations were detected in
exons 5-9 of the p53 gene in 78 primary breast tumour samples. Twenty four of these alterations
were identified by sequencing. The nucleotide and amino acid alterations together with LOH data
are shown in Table 5.1.













8 208 GAC>GTC Asp > Val - - -
10 194 CTT>CGT Leu > Arg - - -
11 140 GAC>GAC Frameshift - - -
18 179 CAT>TAT His > Tyr L U
21 192 CAG>TAG Gin > Stop! L L
25 186 GAT>TAT Asp > Tyr - - -
34 182 TGC>TGA Cys > Stop! u L N
57 175 CGC>CAC Arg > His L L -
64 213 CGA>TGA Arg > Stop! - U
67 163 TAC>AAC Tyr> Asn U U
71 141 TGC>TAC Cys > Tyr - - -
72 194 CTT>CGT Leu > Arg L U -
95 213 CGA>TGA Arg > Stop! U u
113 194 CTT>CGT Leu > Arg - - -
114 175 CGC>CAC Arg > His - - -
8 285 GAG>AAG Glu > Lys - - -
12 276 GCC>CCC Ala > Pro - - -
61 273 CGT>CAT Arg > Leu - - -
84 273 CGT>CTT Arg > Leu - - -
85 ND ND ND N - -
88 237 ATG>ATT Met > lie - - -
92 255 ATC>AAA lie deletion U - -
98 239 AAC > GAC Asn > Asp - u -
101 245 GGC>GAC Gly > Asn L u L
110 282 CGG>CTG Arg > Leu - - -
L - LOH
U - uninformative
N - No LOH
ND - Not determined
A - single base deletion
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One of the tumour samples, number 8, contained two mutations, one in exon 6 and another
in exon 8. For the purposes of estimating the frequency of breast tumours containing p53 mutations
these two mutations effectively count as a single mutation. When estimating p53 mutation frequency
from this data, a number of points must be considered. The estimate will be affected by the
efficiency of the HOT mutation detection technique, the incidence of mutations occurring at sites
other than in exons 5-9 of the p53 gene and, because of the design of the primers used, the inability
of the technique to detect mutations at a number of bases in exons 5, 6, 7 and 9. These will be
discussed in the following section.
5.1.2 Factors effecting the estimation of p53 mutation frequency in breast tumours.
Non-sequencing mutation detection techniques are now widely used, although little work
has been done on the relative efficiencies of the different techniques. Theophilus et al. (1989)
compared the use of RNase A protection, chemical cleavage and DGGE techniques and concluded
that DGGE was the most reliable and informative method. In a recent study by Condie et al. (1993),
a direct comparison was made between the three techniques most commonly used to detect p53
mutations in breast tumour samples, SSCP, CDGE and HOT (Prosser et al., 1990; Borresen et
al., 1991; Mazars et al., 1992b; Osborne et al., 1991; Runnebaum et al., 1991; Thompson et al.,
1992). The efficiency of each technique was determined by the analysis of DNA samples containing
known p53 mutations. Both SSCP and CDGE techniques were found to detect 90% of all p53
mutations. The HOT technique, when using both wild type probe DNA with mutant target DNA and
mutant probe DNA with wild type target DNA, had a detection efficiency of 100%. In this way any
GT mismatches missed using one type of probe DNA would be detected through a CA mismatch
when using the other type.
The HOT technique was carried out using both wild type and tumour probe DNA to detect
p53 mutations in exons 7-9 in this study (section 4.4). However only wild type probe DNA with
tumour target DNA fragments were used to detect p53 mutations in exons 5 and 6. Theoretically
therefore AT>GC substitutions occurring in this region may not be detected and indeed, no AT>GC
mutations were detected in exons 5-6 (Table 5.1). By analysing the mutations identified by other
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detection techniques of p53 in breast cancer it can be seen that 3/20 (15%) of mutations in exons 5-6
are AT>GC substitutions (section 5.3.5). Therefore, the 15 mutations found in exons 5 and 6 of the
p53 gene could represent an actual incidence of 18 mutations, giving a total of 27 mutations in exons
5-9.
Although the majority of mutations found in the p53 gene have been found within exon 5-9,
a significant number of mutations have been identified outside this region. In a study of compiled
p53 alterations from a wide variety of cancers, 22 out of 368 mutations (6%) were recorded outside
exons 5-9, in exons 1-4, 10 and 11, and in introns 3, 4, 5, 6, 7 and 9 (Caron de Fromentel and Soussi
1992). This frequency is probably an underestimate due to the heavy bias in the majority of studies
towards mutation detection in exons 5-8 or 5-9 alone. However no base changes were detected in
this study in introns 5, 7 and 8 which were included in the PCR fragments screened by the HOT
technique. No mutations were detected in exon 4 in 15 (Chen et al., 1991a) and 24 (Osborne el al.,
1991) breast tumours or in exon 2 in 96 breast tumours (Mazars et al., 1992b). Five of 59 (8%)
breast tumours analysed by multiplex PCR showed aberrant bands in exons 2-4 and 10 and 11
(Runnebaum et al., 1991). If a figure of 10% is allowed for mutations occurring outside exons 5-9
then the 27 mutations in exons 5-9 would represent 30 mutations in the entire gene.
Ideally, the oligonucleotide primers used to amplify exons 5-6 and 7-9 should be located
within the intron sequences flanking the exons. Due to the incorporation of the primers into the
fragment during amplification any base change occurring within the primer sequence would not be
detected. Due to the lack of information on the intron sequences of the p53 gene at the time of the
oligonucleotide primer design, it was necessary to include five oligonucleotide bases at the beginning
of exons 5 and 7 and at the end of exons 6 and 9 in the primer sequences. Therefore any mutations
occurring in codons 126, 224, 225 and 310, in the first two bases of codons 127 and 226 or in the last
two bases of codons 223 and 311 would not be detected. However, other studies detecting p53
mutations in breast tumour samples have not identified mutations occurring at any of these sites.
Indeed mutations at these codons have not been identified in any type of tumour sample (Hollstein et
al., 1991a; Caron de Fromentel et al., 1992). Therefore the estimate of p53 frequency has not been
modified to allow for potential mutations at these sites.
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After allowing for mutations outside exons 5-9 and the mutation detection efficiency of the
HOT technique the 24 primary breast tumours containing p53 mutations would represent an
estimated incidence of 38% (30/78). Table 5.2 compares this figure with published data from other
studies on p53 mutation frequency in breast tumours. Due to differing approaches of analysis the
different sets of data have been modified in order to allow direct comparison. The estimated
incidence of p53 mutation range from 16 to 46% although most of the estimates fall between 35%
and 46%. On the strength of these figures it is estimated that approximately 40% of primary breast
tumours contain a p53 mutation.
5.1.3 Immunohistochemical estimates of p53 mutation frequency in breast tumours.
The p53 mutation frequency in breast tumours has been estimated on the basis of
immunohistochemical analysis, involving the staining of tumour tissue sections with p53 specific
antibodies in order to detect over-expression of the p53 protein. Due to the short half life and low
level of expression of the wild type p53 protein in normal cells, the p53 protein is virtually
undetectable by immunohistochemical methods. p53 mutation can result in a stable protein with an
increased half life, resulting in expression at a level detectable by immunohistochemistry. Thus any
cell staining with p53 specific antibodies may indicate the expression of a mutant form of p53.
Estimation of p53 mutation frequency in primary breast tumours by immunohistochemical
detection has been attempted by many groups (Table 5.3). Comparison of 20 immunohistochemical
studies reveals estimates ranging between 14% (41/289) and 67% (18/27) (Isobe et al., 1992; Moll et
al., 1992). Variation between studies, discussed below, could be due in part to the type and
condition of the sample used, the use of different antibodies detecting different p53 epitopes and
varying criteria used for the definition of a positively staining sample.
The study by Bartek et al. (1990b) detected antibody staining in 56% of frozen samples
while only 20% of paraffin embedded tissue samples showed positive staining with the same
antibodies. Chang et al. (1991) observed that 58% of breast tumour samples stained with PAbl801
while only 21% stained with PAb421 (Table 5.3). The majority of studies reveal different expression
patterns of the p53 protein and have been unable to classify tumours into positive or negative
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Cattoretti et al., 1988
PAb 1801, PAb240,.PAb421 on
frozen sections
81 45 56 Bartek et al., 1990b
PAb 1801, PAb240, PAb421 on
paraffin embedded sections
94 19 20 Bartek et al., 1990b
CM - 1 on paraffin embedded
sections
42 26 62 Bartek et al., 1991
PAb 1801, PAb240, PAb 421 on
frozen sections
49 11 22 Davidoff et al., 1991a
PAb 1801, PAb240 on frozen
sections
73 42-48 58-66 Varley et al., 1991
PAb240 on frozen and paraffin
sections
111 59 53 Horack et al., 1991
PAb240, CI9, PAb 1801, JG8
and PAb421 on frozen sections














Chang et al., 1991
PAb 1801 on frozen sections 184 50 27 Davidoff et al., 1991c
PAb 1801 on frozen sections 90 32 36 Ostrowski et al., 1991
PAb421 on FNA smears 37 19 51 Koutselini et al.,
1991
OM-11-918 on frozen sections 32 6 19 Borresen et al., 1991
PAb 1801 on frozen sections 44 13 30 Thompson et al.,
1992
PAb 1801 on formalin fixed
sections













PAb 1801 on frozen sections 27 18 67 Moll etal., 1992
PAbl801 on methacarn fixed
samples
46 17 37 Porter etal., 1992a
CM-1 on formalin fixed sections 289 41 14 Isolaeia/., 1992
PAb 1801 on paraffin embedded
and frozen sections
498 110 22 Thor etal., 1992
PAb 1801 and PAb240 on
frozen samples
700 362 52 Allred et al., 1993
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staining groups (Bartek et al., 1990b; Bartek et al., 1991; Chang et al., 1991; Davidoff et al., 1991c;
Midgley et al., 1992; Moll et al., 1992; Porter et al., 1992a). Most studies identify three or four
basic patterns: intense nuclear staining in the majority of tumour cells; variable staining in only a
proportion of tumour cells ranging from 90% to single isolated cells or cell clusters; cytoplasmic
staining; and absence of cell staining. Consequently the criteria for defining a positively staining
tumour vary widely. For example, those tumours showing antibody staining in any cell are scored as
positive by Thor et al. (1992) while only those showing staining in greater than 20% of cells are
scored positive by Isola et al. (1992). Similarly cytoplasmic staining is counted as positive in studies
by Horak et al. (1991) and Moll et al. (1992) but not in those by Poller et al. (1992) and Varley et al.
(1991).
In spite of this, several of the studies detect over-expression of p53 protein in 50-66% of
breast tumour samples, a figure 10-20% in excess of the mutation frequency observed at the DNA
level (Bartek et al., 1990b; Varley et al., 1991; Horak et al., 1991; Walker et al., 1991; Chang et al.,
1991; Koutselini et al., 1991; Moll et al., 1992; Allred et al., 1993). This may be due to an over
estimated efficiency of mutation detection by DNA based techniques or a greater than expected
number of mutations occurring at sites other than exons 5-9.
Alternatively, there is evidence to suggest that over-expression of the p53 protein may not
necessarily indicate the presence of a mutated p53 gene. p53 protein levels are known to be affected
by factors such as differentiation state (Linzer and Levine 1979; Reich et al., 1983), cell cycle
progression (Reich and Levine 1983) and complex formation with other proteins such as the SV40 T
antigen (Lane and Crawford 1979). High levels of apparently wild type p53 have been found to be
expressed by 4 neuroblastoma derived cell lines (Davidoff et al., 1992b). A high level of p53 protein
has been found in most epithelial and mesenchymal cells from two individuals who do not have a
constitutional p53 mutation and an alteration in the degradation of the p53 protein has been
suggested as a possible mechanism (Barnes et al., 1992). Evidence for the expression of wild type
protein in a mutant configuration has been found in a number of studies (Gamble and Milner 1988;
Milner and Watson 1990; Cook and Milner 1990). Taken together, these observations suggest that
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over-expression of the p53 protein or reactivity with a mutant specific antibody such as pAb240 may
not be indicative of a mutated p53 gene.
Despite this evidence, data from several studies have indicated a close correlation between
p53 over-expression and p53 mutation. Of 43 positively staining breast tumours and cell lines, 39
have been shown to possess mutations in the p53 gene (Bartek et al., 1990a; Davidoff et al., 1990;
Davidoff et al., 1991a; Varley et al., 1991; Borresen et al., 1991; Sommer et al., 1992; Thor et al.,
1992). A close correlation has also been reported in lung, colon, ovary and oesophagus tumours and
cell lines (Bennet et al., 1991; Iggo et al., 1990; Rodrigues et al., 1990; Marks et al., 1991;
Gusterson et al., 1991). However, no correlation was found between p53 mutation and p53 over-
expression in breast tumour samples in a study by Thompson et al. (1992). In one study tumour
samples were split into either nuclear or cytoplasmic staining groups (Moll et al., 1992) and p53
mutations were associated with tumour samples showing nuclear staining. Antibody staining
therefore could be indicative of a p53 mutation in only a specific subset of tumours. Furthermore the
two distinct patterns of p53 expression suggested cytoplasmic exclusion as a mechanism for p53
protein inactivation. In a comparison of antibody staining and mutation detection by SSCP in exons
5-9 in 171 breast tumours concordance between the two tests was found in only 108 (62%) samples
(Allred et al., 1993). Of the remaining 63 discordant cases, 58 were SSCP negative and
immunohistochemically positive and 5 were immunohistochemically negative and SSCP positive.
Even after considering the possibility ofmutations occurring outside exons 5-9 and the less than
100% detection rate of the SSCP technique these results strongly suggest that over-expression of the
p53 protein can occur without mutation of the p53 gene.
In addition, there are reasons to suggest that the immunohistochemical methods would not
detect all mutations. For example, the majority of p53 genes with stop codons truncating the protein
before codon 370 would go undetected by the antibody Ab421, which detects an epitope between the
amino acids 370 and 378, and indeed p53 mutations have been found in negatively staining breast
tumour material in several studies (Bartek et al., 1991; Borresen et al., 1991; Sommer et al., 1992;
Thompson et al., 1992).
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Overall, while immunohistochemical analysis provides some indication on how frequently
the p53 protein is over-expressed in tumours it cannot, for several reasons, be relied upon to
determine the p53 mutation frequency. Until a large study of mutations detected at both the protein
and DNA sequence levels is undertaken, no conclusions can be drawn about the mutation detection
efficiency of immunohistochemical analysis.
5.1.4 Incidence of p53 constitutional mutations in sporadic breast cancer patients.
Following the identification of p53 mutations in Li-Fraumeni syndrome (LFS) patients the
possibility that constitutional p53 mutations could be involved in other hereditary cancer syndromes
or a proportion of sporadic cancers was proposed (Marx 1990; Vogelstein 1990). Screening for
constitutional p53 mutations focused on patients with breast and adrenocortical carcinomas,
sarcomas and leukemias since these tumour types figure predominantly in the LFS cancer spectrum.
Several investigations selected patients showing early onset of cancer or multiple tumours, features
characteristic of hereditary disease, in the hope of increasing the chances of detecting a p53
mutation.
A mutation frequency of 6.8% (4/59) was determined in children and young adults with
second cancers (Malkin el al., 1992). Two p53 mutations were found in two families from a cohort
of patients with childhood adrenocortical carcinoma (Sameshima et al., 1992a). Two constitutional
p53 mutations in two LFS families were detected following analysis of the p53 gene in 17
osteosarcoma patients (Porter et al., 1992b). Four of 25 (16%) paediatric lymphoblastic leukemia
patients were found to possess a constitutional p53 mutation with LFS indicated in only one of the
kindreds (Felix et al., 1992a). Similarly, a total of 8 constitutional p53 mutations were detected in a
set of 196 (4%) sarcoma patients. Five of these mutations originated in 15 patients having multiple
tumours or a family history of cancer. Only one of the patients had a family history fully consistent
with the LFS in its strictest definition (Toguchida et al., 1992). Both these studies indicate that a
high proportion of non-LFS familial sarcoma patients (4/15, 27%) and non-LFS paediatric
lymphoblastic leukemia patients (12%) possess a constitutional p53 mutant allele.
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It is possible that a small subset of sporadic breast cancers patients (estimated to be less than
5%) and a proportion of HBC families may possess constitutional p53 mutations (Vogelstein 1990).
A total of 30 HBC families have been screened for p53 mutations in two studies (Prosser et al., 1992;
Warren et al., 1992) with neither detecting any constitutional p53 mutation. In addition, 30 women
with at least one first degree relative with breast cancer also had no detectable p53 mutation
(Borresen et al., 1992). One study detected no constitutional p53 mutations in 126 patients who had
developed breast cancer before the age of 40 (Sidransky et al., 1992a), while a similar study by
Borresen et al. (1992) detected one p53 mutation in a set of 40 women who had developed breast
cancer before the age of 35. No mutations were found in patients selected on the basis of bilateral
breast cancer (Lidereau and Soussi 1992). One of 167 (0.6%) sporadic breast tumour patients was
found to possess the mutation CGC > CAC at codon 181, resulting in an amino acid change of Arg >
His (Borresen et al., 1992). However since the mutant p53 protein has been shown to possess wild
type p53 properties when compared with other constitutional p53 mutant proteins (Frebourg et al.,
1992) it has been suggested that it is functionally silent and may impart no increased cancer risk
(Borresen et al., 1992).
In this study twenty five mutations were identified in 78 sporadic primary breast tumours
from 73 patients using the HOT technique. No mutation occurring in any of the 25 tumours was
detected in the corresponding lymphocyte DNA as described in section 4.4. A similar study from
another series of Scottish patients detected a constitutional p53 mutation in 1/60 sporadic breast
cancer patients (Thompson et al., 1992). The mutation was a GC>AT substitution at the second
nucleotide of codon 267 and occurred in a non-LFS cancer family. When both sets of data are
combined, the constitutional p53 mutation frequency in sporadic breast cancer patients is estimated
as 1/133 (0.7%) (Prosser et al., 1992), a similar figure to that found by Borresen et al. (1992). These
series of experiments indicate that constitutional p53 mutation is a rare etiological factor in sporadic
breast cancer.
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5.2 Relationship between p53 mutation and LOH on chromosome 17p in primary breast
cancer.
5.2.1 p53 mutation and allelic loss in primary breast cancer.
The p53 gene has been shown to possess the characteristics of both oncogene and tumour
suppressor gene (section 1.5.6). Data on p53 mutation and LOH enable speculation on the state of
the two p53 alleles and suggest mechanisms by which the p53 gene may contribute to the
maintenance of a malignant phenotype. If the p53 gene is simply acting as a tumour suppressor then,
in accordance with Knudson's two hit hypothesis, p53 mutation should frequently be accompanied by
LOH, indicating the inactivation of both copies of the gene. If the mutant p53 gene is behaving as a
dominant oncogene then p53 mutation need not be accompanied by the loss of the second wild type
allele.
Various studies have attempted to correlate the LOH on chromosome 17p and p53 mutation
in breast cancer (Nigro et al., 1989; Prosser et al., 1990; Borresen et al., 1991; Chen et al., 1991a;
Davidoff et al., 1991a; Osborne et al., 1991; Varley et al., 1991; Thompson et al., 1992). However
care must be taken when using LOH data as an indicator for the loss of the wild type p53 allele in
tumour samples. Evidence implicating two independent areas of loss on chromosome 17p has been
found in a number ofmalignancies. One is at 17pl3.1, the site of the p53 gene, and the other is
more telomeric at 17pl 3.3 (Section 3.9). Thus, unless the pattern of allele loss on chromosome 17p
determines a single locus, as has been shown in colon cancer (Baker et al., 1989), LOH at the p53
locus cannot be predicted by LOH at the more telomeric site, eg when using the probe YNZ22
(Nigro et al., 1989; Chen et al., 1991a; Varley et al., 1991).
5.2.2 Association of p53 mutation with LOH.
There are 30 tumours in this study which are informative at the BHP53/TP53 or
MCT35/D17S31 loci, which map near the p53 gene at 17pl3.1, and have been screened for p53
mutations in exons 5-9 using the HOT technique. The precise codon changes and LOH data in
tumours with a p53 mutation are shown in table 5.1. Six of the 7 (86%) tumours (tumours 18, 21, 34,
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57, 72 and 101) which possess a p53 mutation in exons 5-9 show LOH at nearby loci. Other breast
cancer studies report that p53 mutations are accompanied by LOH, at loci near the p53 gene, at a
high frequency: 100% (10/10) (Borresen et al., 1991); 57% (4/7) (Davidoff et al., 1991a); 56% (5/9)
(Osborne et al., 1991); and 75% (9/12) (Thompson et al., 1992).
In addition to determining LOH at the p53 gene locus, several investigators have directly
determined the presence or absence of the wild type allele using sequence data and SSCP
autoradiographs. Using these methods, a high frequency of loss is also observed in breast tumours
and cell lines: 100% (8/8) (Runnebaum et al., 1991); 100% (4/4) (Osborne et al., 1991); 100% (2/2)
(Kovach et al., 1991); 57% (4/7) (Davidoff et al., 1991a); and 93% (13/14) (Sommer et al., 1992). A
similar high frequency of homozygous and hemizygous mutations has been detected in tumours of
the ovary, oesophagus, brain, liver, uterus, gut, as well as in leukemia (Gaidano et al., 1991; Hensel
et al., 1991; Hsu et al., 1991; Mashiyama et al., 1991; Okamoto et al., 1991a; Okamoto et al.,
1991b; Shaw et al., 1991; Tamura et al., 1991).
In this study 24 p53 mutations have been characterised. Direct comparison between the
intensities of the mutant and wild type sequencing bands showed that the mutant allele was at least
twice the intensity of the wild type allele in 11 (46%) tumours, suggesting that the p53 mutation was
accompanied by loss of the wild type copy of the p53 gene. However, in the remaining 13 (54%)
mutations the wild type sequencing band was either equal to or greater than the intensity of the
mutant sequencing band. While these may reflect genuine p53 mutations without loss of the wild
type allele, the relative intensities of the mutant and wild type bands may simply be due to the
contamination of the tumour sample by normal tissue or the presence of tumour heterogeneity. This
problem is highlighted in a study by Mazars et al. (1992b) which found that only 2/16 breast tumours
with p53 mutations were accompanied by loss of the wild type allele. Previous data suggest that the
breast tumour samples used in this present study are frequently contaminated with normal tissue or
show tumour heterogeneity (section 3.9) and could explain the low frequency of loss observed when
analysing the mutations using sequence data.
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5.2.3 p53 mutation without LOH
The loss of the wild type allele in the majority of breast tumour samples with a p53
mutation indicates the importance of the removal of the tumour suppressing function of wild type
p53 in breast cancer development. However one of the 7 (14%) tumours with a p53 mutation
showed no accompanying LOH (tumour 85). A number of similar tumours have been identified in
other breast cancer studies: 3/7,43% (Davidoff et al., 1991a); 4/9, 44% (Osborne et al. 1991); 1/14,
7% (Sommer et al., 1992), 3/12, 25% (Thompson et al., 1992). These tumours show no LOH at the
p53 locus and so suggest that the mutant p53 gene is acting as an dominant oncogene. However, the
remaining allele may be inactivated by mechanisms other than mutation in exons 5-9 and deletion
(section 5.2.4). Alternatively these tumours may simply represent a stage following p53 mutation
and before allele loss, as has been suggested in colon carcinomas (Baker et al., 1990a).
Certain mutant p53 genes are known to be able to act as oncogenes (Hinds et al., 1990;
Halevy et al., 1990; Milner and Metcalf 1991) and may influence tumorigenesis in a dominant
manner. An interesting hypothesis would be that while weakly or non-oncogenic p53 mutants
require loss of the remaining wild type allele, strongly oncogenic mutations would require no loss to
effect a growth advantage. Although p53 mutants are known to possess different properties the
relative oncogenicity of only a few has been determined. Hinds et al. (1990) and Halevy et al.
(1990) have compared p53 mutations on the basis of their ability to transform primary rat cells in
culture while Milner and Metcalf (1991) have compared mutant proteins for their ability to drive
wild type p53 protein into the mutant conformation. From these three studies, a number of p53
mutations have been categorised as either strongly oncogenic (132 Phe, 135 Val, 151 Ser, 175 His,
247 lie and 273 Pro) or weakly oncogenic (248 Trp, 270 Cys, 273 His and 281 Gly).
Only one breast tumour sample in this study possessed any mutation of measured
oncogenicity. Tumour 57 possesses the strongly oncogenic 175 His mutation and so might be
expected to show retention of the normal wild type allele. This tumour however shows LOH at the
MCT35/D17S31 locus and sequencing of this mutation shows a near complete absence of the wild
type allele (Figure 4.12). Other breast cancer studies identifying tumours containing p53 mutations
of known oncogenicity show either LOH or loss of the wild type allele upon sequencing regardless of
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the proposed strength of the mutation (Nigro et al., 1989; Borresen et al., 1991; Chen et al., 1991a;
Kovach et al., 1991; Varley et al., 1991; Thompson et al., 1992). The oncogenic properties of the
various p53 proteins therefore do not seem to determine the loss of the remaining allele in breast
tumours.
5.2.4 LOH without p53 mutation.
LOH at the p53 locus without apparent alteration in the remaining p53 allele has been
determined in a proportion of samples. Of 16 tumours in this series with LOH near the p53 locus, 10
(63%) apparently have wild type p53 DNA only, suggesting that many tumours show loss of a p53
allele without mutation of the remaining copy. The occurrence of LOH without apparent mutation
has been identified in breast tumours (Davidoff et al., 1991a; Osborne et al., 1991; Sommer et al.,
1992; Thompson et al., 1992) and in other malignancies (Baker et al., 1990a; Okamoto et al.,
1991a,b: Frankel et al., 1992; Miller et al., 1992; Seruca et al., 1992) and several possible
explanations have been suggested.
The alteration of the remaining wild type p53 can potentially occur at the DNA and
protein levels via mechanisms other than mutation in exons 5-9 and deletion. These include
rearrangement (Mowat et al., 1985), promoter mutation (Rovinski et al., 1987; Bookstein et al.,
1990a), altered transcription (Mulligan et al., 1990; Thompson et al., 1990), inactivation of the wild
type protein by mutant forms (Milner and Metcalf 1991), altered conformation (Cook and Milner
1990; Milner and Watson 1990), altered degradation (Barnes et al., 1992), hypermethylation (Sakai
et al., 1991), alteration of intronic sequences (Beenken et al., 1991), localisation to the cytoplasm
(Shaulsky et al., 1991; Moll et al., 1992) and binding of the p53 protein to cellular proteins such as
the murine double minute 2 (MDM2) protein (Oliner et al., 1992; Momand et al., 1992) and viral
proteins (Lane and Crawford 1979). None of these types of alteration would be detected in either the
LOH or p53 mutation analyses.
Loss or deletion of chromosomes are thought to occur randomly in the tumorigenic process,
with those changes conferring a growth advantage being selected. However LOH on 17p in a
proportion of tumours may represent a random or non-selected loss, an alteration that provides no
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selective advantage or disadvantage to the clone. Another possibility is that the mutation detection
technique used may not have detected the corresponding p53 mutation. This is especially relevant
were the mutation techniques do not detect 100% of the mutations eg SSCP and CDGE both have a
detection rate of 90%. The mutation may have occurred outside the regions screened as frequently
only exons 5-8 or 5-9 are screened for the presence of mutations. There may be a selective
advantage resulting in the deletion of only one copy of the p53 gene although this mechanism does
not conform to the pattern expected of either a tumour suppressor gene or an oncogene (Bishop
1990). Finally, the allele loss at the p53 locus may involve a second tumour suppressor gene. Since
LOH on chromosome 17p at the p53 locus frequently involves 17pl3.3 loci and occasionally whole
chromosome loss (Andersen et al., 1992) it may simply reflect the inactivation of other tumour
suppressor genes on the long or short arms of chromosome 17 (Osborne et al., 1991).
5.2.6 Discussion
High frequencies of LOH on chromosome 17p and p53 gene mutation were initially
detected in colon carcinomas and are thought to play integral parts in colon tumorigenesis
(Vogelstein et al., 1988; Baker el al., 1990a). Following these studies many groups have analysed a
wide range of tumour types for similar alterations. The main aim of the series of experiments
described in sections 5.1 and 5.2 was to determine the prevalence, and therefore the potential
importance, of these genetic abnormalities in primary human breast cancer. LOH on
chromosome 17 at loci near the p53 gene and p53 gene mutation are estimated to occur in 49% and
40% of breast tumour samples respectively. These figures suggest that alteration of the p53 gene is
not as frequent, and therefore not as important, in breast tumorigenesis as it is in the development of
other common solid tumours. Colon carcinomas show a frequency of LOH on chromosome 17p of
64-76% and a frequency of p53 gene mutation of 64-71% (Vogelstein et al., 1988; Baker et al.,
1990a; Shaw et al., 1991; Cunningham et al., 1992). LOH on chromosome 17p and p53 gene
mutation are observed in 88-100% and 45-85% of lung cancer samples respectively (Yokota et al.,
1987; Weston et al., 1989; Chiba et al., 1990; Hensel et al., 1991; D'Amico et al., 1992; Miller et
al., 1992; Sameshima et al., 1992b; Tsuchiya et al., 1992). These observations indicate that the
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alteration of the p53 gene is an important step in colon tumorigenesis and perhaps an essential one in
the development of lung cancer.
However, the results of the current study in breast tumours can only indicate the importance
of the alteration of the p53 gene by the mechanisms of mutation and allelic loss. Alteration of wild
type p53 can potentially occur at the DNA and protein levels via many different mechanisms (section
5.2.4). Studies in most types of cancer have concentrated on the mutation and loss of the p53 gene
and have barely investigated the role ofmany other potential mechanisms of alteration. For example
it is thought that the p53 protein is often inactivated in sarcomas through binding with the MDM2
protein, possibly as a result of amplification of the MDM2 gene (Oliner et al„ 1992; Vogelstein
1992). Similarly the binding of the viral protein E6 to the p53 protein, resulting in p53 protein
degradation, has been found in HPV (human papilloma virus) associated cervical tumours
(Schneffner et al., 1990). The p53 gene could therefore be altered in many breast tumours by
mechanisms not yet investigated. The higher frequency of p53 protein alteration found in some p53
antibody staining studies compared to those using DNA based methods of mutation detection might
suggest other mechanisms of alteration, such as p53 protein inactivation by complexing with other
proteins or by a change in conformation, which could lead to the loss of the tumour suppressor
function of the p53 protein. Further studies investigating p53 at the DNA, mRNA and protein levels
should give a greater insight into the mechanisms by which p53 contributes to a malignant phenotype
in breast tumours.
Overall, p53 mutations found in breast tumour samples are frequently accompanied by loss
of the wild type allele suggesting a role as a tumour suppressor gene in the majority of breast
tumours. While there is evidence to suggest that the p53 acts as an oncogene in a small proportion of
breast tumours, the identification of tumour samples with p53 mutations and no concurrent LOH
many simply reflect either the composition of the tumour material or the inactivation of p53 by
mechanisms other than LOH.
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5.3 p53 mutation analysis in breast cancer.
5.3.1 Mutagenesis of the p53 gene.
Mutations in the growth regulating proto-oncogenes and tumour suppressor genes are
critical steps in tumorigenesis. Both internal (endogenous) and external (exogenous) factors are
thought to play a part in the mutation of these genes. Endogenous factors include damage caused by
free oxygen radicals (Lutz et al., 1990), deamination of 5-methylcytosine to thymine (Ehrlich et al.,
1990), DNA depurination and DNA polymerase infidelity (Loeb and Cheng 1990). Exogenous
factors include environmental carcinogens, many of which possess mutagenic properties, such as N-
nitrosamines, polycyclic aromatic hydrocarbons and fungal toxins (Zeiger 1987).
Studies using prokaryotic and simple eukaryotic systems have shown that carcinogenic
agents can show specificity for both the type and the location of the DNA mutation they induce
(Skandalis and Glickman 1990). This has been demonstrated in mammals by the work done on the
mutation of the ras oncogene by chemical carcinogens (reviewed in Harris 1991). Chemical
treatment of test animals leads to a carcinogen-specific pattern of mutation of the ras gene in
resulting tumours. For example, in a study by Zarbl et al. (1985) the ras mutations detected in the
tumours of rodents exposed to methylating N-nitroso-N-methylurea were all GC>AT base
substitutions, a result of the methylation of deoxyguanine followed by the mispairing of thymine
during DNA synthesis. Although there are several deoxyguanine residues that would produce a
transforming ras protein, all the mutations were located in the second nucleotide base of codon 35.
This carcinogen-specific alteration of a defined DNA sequence establishes a direct link between the
tumorigenic process and the influence of exogenous carcinogens.
Theoretically, therefore, the type of mutations observed in cancer cells can be linked to
specific mechanisms of mutation. Analysing the type and locations of mutation identified in tumours
may offer insight into the origins of the mutations (Vogelstein and Kinzler 1992). While many of the
investigations of this type have concentrated on the ras oncogene, their use in implicating specific
mutation mechanisms in tumours is limited due to the low mutation frequency of ras in the majority
of human solid tumours and the limited number of codons which can be mutated to give an
oncogenic form of the protein (Bos et al., 1989). In contrast the p53 gene is ideally suited for this
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type of analysis. p53 mutations can occur at many sites within the gene (Hollstein et al., 1991a,
Caron de Fromentel and Soussi 1992), thus potentially producing more informative mutation spectra,
and are detected in many different tumour types, often at high frequencies (Baker et al., 1990a;
Chiba et al., 1990; Hollstein et al., 1991b; Mazars et al., 1991; Sidransky et al., 1991; Tamura et al.,
1991; D'Amico et al., 1992; Frankel et al., 1992).
5.3.2 Mutation spectra of the p53 gene in solid tumours.
The mutation spectrum of the p53 gene has been determined in two studies using p53
mutations detected in a range ofmalignancies (Hollstein et al., 1991a; Caron de Fromentel and
Soussi 1992). Mutations were found in over 100 of the 393 codons of the gene, with the majority
located in exons 5-8. The mutation spectrum of the p53 gene was shown to differ significantly
between tumour types, indicating that the origins of mutations are distinct in different malignancies.
The mutations were analysed by type and position to determine whether any feature of the spectrum
could indicate possible factors responsible for the generation of the p53 mutations observed. In this
respect the most notable features of the mutation spectrum are observed in hepatocellular, lung, skin
and oesophageal cancers.
The mutational spectrum in hepatocellular carcinoma (HCC) contains a high proportion of
GC>TA base changes. In three initial studies, 11 of 21 p53 mutations were found to be GC>TA
changes in the third nucleotide of codon 249. Since mutations occur at many sites within the p53
gene in the majority of tumour types this positional specificity is exceptional. All of the codon 249
mutations were recorded in two of the studies using tumour material from two areas, Qidong, China
and southern Africa (Bressac et al., 1991; Hsu et al., 1991). Both of these areas have a high
frequency of HCC thought to be caused in part by the prevalence of hepatitis B virus (FIBV) and
aflatoxin B1, both known risk factors for the disease. Aflatoxin B1 is a fungal carcinogen found as a
contaminant in damp-stored cereals, which forms N7 deoxyguanosine adducts and induces base
substitutions, mostly GC>TA transversions (McMahon et al., 1990). No GC>TA changes at codon
249 were found in the third study (Murakami et al., 1991b) which used tumour material from
Japanese patients, who have a low risk of dietary aflatoxin B1 intake.
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Further studies strengthened the proposed link between HBV, aflatoxin B1 exposure and
p53 mutation by looking specifically for base changes at codon 249 (Hayward et al., 1991; Ozturk et
al., 1991; Scorsone et al., 1992). No such mutations were found in HCCs from Australian patients,
who have a low risk of exposure to aflatoxin Bl, (Hayward et al., 1991) while 21 of 36 (58%) of
HCCs from a second series of patients from Qidong contained codon 249 mutations (Scorsone et al.,
1992). The presence of the codon 249 mutation was correlated with high risk exposure to HBV and
aflatoxin Bl in HCCs from patients in 14 different countries (Ozturk et al., 1991). Comparison of
two similar populations of HBV positive patients from neighbouring countries indicated that
exposure to aflatoxin B1 was strongly associated with the presence of the codon 249 base change
(Ozturk et al., 1991) while HBV infection alone did not seem to correlate with the codon 249
mutation (Hayward et al., 1991; Ozturk et al., 1991).
From these observations, it was proposed that while aflatoxin B1 was strongly associated
with the 249 mutation the absence of the 249 mutation in any non-HBV related HCC analysed
implicated HBV as a necessary co-factor (Ozturk et al., 1991). The absence of the 249 mutation in
aflatoxin Bl-induced tumours in non-human primates (Fujimoto et al., 1992a) and in aflatoxin Bl-
induced hepatic hyperplastic nodules in rats (Hulla et al., 1993) also suggested a role for HBV.
However the identification of 249 mutations in HBV negative patients from areas of low risk of
aflatoxin B1 exposure questions the role of both risk factors in the generation of this specific change
(Oda et al., 1992).
Of 15 p53 mutations identified in squamous cell carcinomas of the skin (SCC), 3 were
double CC>TT base changes and the remaining mutations, mainly C>T transitions, occurred at
dipyrimidine sequences (Brash et al., 1991). Similarly 7 mutations found in 14 basal cell carcinomas
of the skin were all GC>AT transitions (Rady et al., 1992). These types of change are characteristic
of UV mutagenesis (Miller 1985) and UV exposure is a well documented disease risk factor for skin
cancer. Analysis of p53 mutations in lung and oesophageal cancer, two malignancies associated with
tobacco smoking, reveals a high frequency ofGC>TA transversions. Tobacco smoke contains
benzo(a)pyrene, a carcinogen able to induce GC>TA base changes (Chen et al., 1990b; Andersson
1992). However, although lifetime cigarette consumption has been shown to be associated with non-
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small cell lung tumours containing p53 mutations in Japanese patients (Suzuki et al., 1992), no such
association was found in U.S. patients (Chiba et al., 1990).
A study of lung tumours from miners exposed to radon, an inert gas which decays to two
alpha particle-emitting radioisotopes, revealed a p53 spectrum different to that determined in other
lung tumour studies. Despite all the patients being smokers, the most common mutation type seen in
lung cancer, GC>TA in the non-coding strand, was not found in any of the tumours examined. The
spectrum observed was assumed to be influenced by the exposure to radon with the most frequent
base substitution being GC>TA in the coding strand (Vahakangas et al., 1992). Oesophageal
tumours have one of the highest frequencies of AT>TA transversions in any solid tumour type and
this has been linked to exposure to urethan (Harris 1991), a carcinogen contaminant of alcoholic
beverages known to be able to induce AT>TA base changes (Bonham et al., 1989). These examples
demonstrate that it is possible for this type of analysis to implicate external carcinogens in the
mutation of the p53 gene and thus in the development of solid tumours (Vogelstein and Kinzler
1992).
5.3.3 Determining a p53 mutation spectrum in breast cancer.
In order to determine the types of changes prevalent in sporadic breast cancer 125 tumour
and cell line p53 mutations from this and other studies were combined and analysed (Nigro et al.,
1989; Bartek et al., 1990a; Prosser et al., 1990; Borresen et al., 1991; Chen et al., 1991a; Devilee P.,
unpublished data; Davidoff et al., 1991a; Davidoff et al., 1991b; Kovach et al., 1991; Osborne et al.,
1991; Varley et al., 1991; Mazars et al., 1992b; Moll et al., 1992; Runnebaum et al., 1991; Sommer
et al., 1992; Thompson et al., 1992; Thor et al., 1992) (Table 5.4). Since this study aims to
determine factors influencing the types of somatic change occurring within breast tissue, constitutive
p53 mutations should not be included. However, the majority of the above studies do not report the
screening of the corresponding lymphocyte or normal tissue DNA for the presence of the p53
mutation. Following the identification of 40 mutations in sporadic breast tumours only one was
found to be constitutional (Prosser et al., 1990; Coles et al., 1992; Prosser et al., 1992; Thompson et
al., 1992). Therefore it could be expected that few of the remaining 85 mutations detected by other
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Table 5.4 Codon number and specific alteration for breast tumour mutations
Codon Codon Nucleotide CpG Source Reference
Number Change Change Dinucleotide
128 CCT > CCG T > G Tumour Borresen et al., 1991
128 CCT > TCT C > T non Tumour Borresen et al., 1991
132 AAG > CAG A > C Cell line Bartek et al., 1990
132 AAG > AAT G > T Tumour Mazars et al., 1992b
134 TTT > CTT T > C Tumour Borresen et al., 1991
134 TTT>TTA T > A Tumour Thor et al., 1992
135 TGC > TGG C > G Tumour Mazars et al., 1992b
136 CAA > GAA C > G Tumour Prosser et al., 1991
138 GCC > GTC C > T non Tumour Moll et al., 1992
138 GCC > GTC C > T non Tumour Moll et al., 1992
139 AAG > AAT G > T Tumour Mazars et al., 1992b
141 TGC > TAC G > A non Tumour This study
149 CCC > TCC C > T non Tumour Thor et al., 1992
151 CCC > TCC C > T non Tumour Chen et al., 1991a
152 CCG > TCG C > T non Tumour Prosser et al., 1991
157 GTC > TTC G > T Tumour Prosser et al., 1991
157 GTC > TTC G > T Cell line Kovach et al., 1991
157 GTC > TTC G > T Tumour Mazars et al., 1992b
163 TAC > AAC T > A Tumour This study
163 TAC > TGC A > G Tumour Davidoff et al., 1991a
L 163 TAC > AAC T > A Tumour Sommer et al., 1992
164 AAG > CAG A > C Tumour Prosser et al., 1991
164 AAG > GAG A > G Tumour Thor et al., 1992
165 CAG > CTG A > T Tumour Mazars et al., 1992b
175 CGC > CAC G > A CpG Tumour This study
175 CGC > CAC G > A CpG Tumour This study
175 CGC > CAC G > A CpG Tumour Varley et al., 1991
175 CGC > CAC G > A CpG Tumour Borresen et al., 1991
175 CGC > CTC G > T Tumour Prosser et al., 1991
175 CGC > CAC G > A CpG Cell line Kovach et al., 1991
175 CGC > CAC G > A CpG Tumour Sommer et al., 1992
175 CGC > CAC G > A CpG Tumour Thor et al., 1992
176 TGC > TTC G > T Tumour Mazars et al., 1992b
179 CAT > GAT C > G Tumour Prosser et al., 1991
179 CAT > TAT C > T non Tumour This study
179 CAT > GAT C > G Tumour Kovach et al., 1991
182 TGC > TGA C > A Tumour This study
186 GAT > TAT G > T Tumour This study
187 GGT > TGT G > T Tumour Prosser et al., 1991
192 CAG > TAG C > T non Tumour This study
193 CAT > CCT A > C Tumour Devilee, P.*
194 CTT > CGT T > G Tumour This study
194 CTT > CGT T > G Tumour This study
194 CTT > CGT T > G Tumour This study
194 CTT > TTT C > T non Cell line Nigro et al., 1989
196 CGA > CCA G > C Tumour Devilee, P.*
196 CGA > TGA C > T CpG Tumour Mazars et al., 1992b
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Table 5.4 (continued)
Codon Codon Nucleotide CpG Source Reference
Number Change Change Dinucleotide
208 GAC > GTC A > T Tumour This study
213 CGA > TGA C > T CpG Tumour This study
213 CGA > TGA C > T CpG Tumour This study
213 CGA > TGA C > T CpG Tumour Sommer et al., 1992
232 ATC > AGC T > G Tumour Mazars et al., 1992b
234 TAC > TAA C > A Cell line Runnebaum et al., 1991
238 TGT > TTT G > T Tumour Osborne et al., 1991
238 TGT > TTT G > T Tumour Borresen et al., 1991
238 TGT > TCT G > C Tumour Thor et al., 1992
237 ATG > ATT G > T Tumour This study
237 ATG > AAG T > A Tumour Borresen et al., 1991
237 ATG > ATA G > A non Tumour Davidoff et al., 1991a
239 AAC > GAC A > G Tumour This study
241 TCC > GCC T > G Tumour Mazars et al., 1992b
242 TGC > TTC G > T Tumour Thompson et al., 1992
245 GGC > GAC G > A non Tumour Davidoff et al., 1991a
245 GGC > GTC G > T Tumour Borresen et al., 1991
245 GGC > GAC G > A non Tumour This study
245 GGC > TGC G > T Tumour Moll et al., 1992
248 CGG > TGG C > T CpG Tumour Borresen et al., 1991
248 CGG > CAG G > A CpG Tumour Davidoff et al., 1991a
248 CGG > CAG G > A CpG Tumour Davidoff et al., 1991b
248 CGG > CAG G > A CpG Tumour Sommer et al., 1992
248 CGG > TGG C > T CpG Tumour Mazars et al., 1992b
248 CGG > TGG C > T CpG Tumour Mazars et al., 1992b
249 AGG > AGC G > C Cell line Bartek et al., 1990
249 AGG > AGT G > T Tumour Moll et al., 1992
249 AGG > AGC G > C Tumour Mazars et al., 1992b
250 CCC > GCC C > G Tumour Thompson et al., 1992
254 ATC > AAC T > A Tumour Davidoff et al., 1991b
255 ATC > AAC T > A Tumour Mazars et al., 1992b
265 CTG > CCG T > C Tumour Thompson et al., 1992
266 GGA > GTA G > T Tumour Davidoff et al., 1991b
272 GTG > ATG G > A non Tumour Mazars et al., 1992b
272 GTG > ATG G > A non Tumour Mazars et al., 1992b
273 CGT > CAT G > A CpG Cell line Nigro et al., 1989
273 CGT > CTT G > T Tumour This study
273 CGT > CAT G > A CpG Tumour This study
273 CGT > CAT G > A CpG Tumour Borresen et al., 1991
273 CGT > CAT G > A CpG Tumour Sommer et al., 1992
273 CGT > CCT G > C Tumour Sommer et al., 1992
275 TGT > TGG T > G Tumour Sommer et al., 1992
276 GCC > CCC G > C Tumour This study
278 CCT > GCT G > C Tumour Davidoff et al., 1991a
280 AGA > ACA G > C Tumour Osborne et al., 1991
280 AGA > ACA G > C Tumour Kovach et al., 1991












280 AGA > AAA G > A non Cell line Bartek et al., 1990
280 AGA > ACA G > C Tumour Sommer et al., 1992
281 GAC > GGC A > G Tumour Borresen et al., 1991
281 GAC > GGC A > G Tumour Thompson et al., 1992
282 CGG > CTG G > T Tumour This study
282 CGG > CCG G > C Tumour Varley et al., 1991
282 CGG > CTG G > T Tumour Davidoff et al., 1991a
283 CGC > CCC G > C Tumour Thompson et al., 1992
285 GAG > AAG G > A non Tumour This study
285 GAG > AAG G > A non Tumour Osborne et al., 1991
285 GAG > AAG G > A non Cell line Bartek et al., 1990
285 GAG > AGG G > A non Tumour Moll et al., 1992
306 CGA > TGA C > T CpG Tumour Mazars et al., 1992b
307 GCA > ACA G > A non Tumour Thompson et al., 1992
342 CGA > TGA C > T CpG Tumour Moll et al., 1992
intron 9 Splice mutation G > A non Tumour Sommer et al., 1992
Codon Codon Change Deletion Source Reference
140 GAC > GAC AT base pair Tumour This study
144 AGC codon deletion 3 base pairs Tumour Sommer et al., 1992
167 CAG > CAA GC base pair Tumour Varley et al., 1991
172 GTT > GT TA base pair Tumour Borresen et al., 1991
175 -180 Deletion 6 codons 18 base pairs Tumour Davidoff et al., 1991a
201 TTG > TTA GC base pair Tumour Prosser et al., 1991
233 - 235 Frameshift deletion 8 base pairs Tumour Sommer et al., 1992
235 - 239 Frameshift deletion 14 base pairs Tumour Kovach et al., 1991
241 TCC codon deletion 3 base pairs Tumour Moll et al., 1992
252 - 254 Deletion 3 codons 9 base pairs Tumour Sommer et al., 1992
255 ATC codon deletion 3 base pairs Tumour This study
265 - int8 Frameshift deletion 11 base pairs Tumour Mazars et al., 1992b
279 - 287 Frameshift deletion 23 base pairs Tumour Mazars et al., 1992b
329 ACC > ACA CG base pair Tumour Kovach et al., 1991
exon 11 Deletion 30 bp 30 base pairs Tumour Osborne et al., 1991
CpG - GOAT transition at a CpG dinucleotide site
non - GC>AT transition at any non-CpG dinucleotide
*
- unpublished data
A - single base deletion
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studies would be constitutive.
5.3.4 Analysis of base changes in the breast cancer p53 mutation spectrum.
As seen in a wide range of malignancies, the most frequent type of mutation occurring in
the p53 gene is a single base pair substitution (Hollstein et al., 1991a; Caron de Fromentel and Soussi
1992). This is observed in breast cancers alone where 110/125 (88%) of mutations are single base
pair substitutions and the remaining 15/125 (12%) are deletions (Table 5.4). Substitutions resulting
in a missense mutation, producing a protein differing in a single amino acid, account for 81%
(101/125) of changes. Those resulting in a stop codon, producing a truncated mRNA and p53
protein, account for 7% (9/125).
The p53 base substitutions identified in breast tumours have been grouped into mutation
types and compared with those from other solid tumours (Tables 5.5 and 5.6). The mutations
identified from other solid tumours originate from carcinomas of the colon (Baker et al., 1989; Nigro
et al., 1989; Baker et al., 1990a; Rodrigues et al., 1990; Skirasawa et al., 1991; Cunningham et al.,
1992), lung (N-SCLC) (Nigro et al., 1989; Takahashi et al., 1989; Chiba et al., 1990; Iggo et al.,
1990; Lehman et al., 1991; Bodner et al., 1992; Kishimoto et al., 1992; Miller et al., 1992;
Mitsudoni et al., 1992), lung (SCLC) (Nigro et al., 1989; Takahashi et al., 1989; Hensel et al., 1991;
Lehman et al., 1991; Bodner et al., 1992; D'Amico et al., 1992; Miller et al., 1992; Sameshima et
al., 1992b), oesophagus (Hollstein et al., 1990; Bennet et al., 1991; Carson et al., 1991; Hollstein et
al., 1991a), liver (Bressac et al., 1991; Hsu et al., 1991; Murakami et al., 1991; Challen et al., 1992;
Oda et al., 1992; Sheu et al., 1992), ovary (Marks et al., 1991; Mazars et al., 1991; Okamoto et al.,
1991a; Yoginuma and Westphal 1992), brain (Nigro et al., 1989; Mashiyama et al., 1991; Frankel et
al., 1992; Fults et al., 1992; Sidransky et al., 1992b; von Deimling et al., 1992) and bladder
(Hollstein et al., 1991a; Sidransky et al., 1991; Fujimoto et al., 1992b). Constitutional p53
mutations occurring were also analysed (Malkin et al., 1990; Srivastava et al., 1990; Law et al.,
1991; Metzger et al., 1991; Santibanez-Koref et al., 1991; Borresen et al., 1992; Felix et al., 1992a;
Iavarone et al., 1992; Kovar et al., 1992; Malkin et al., 1992; Prosser et al., 1992; Sameshima et al.,
1992a; Sidransky et al., 1992a; Toguchida et al., 1992; Malkin and Friend 1993).
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Table 5.5 Frequency of specific types of p53 mutation in breast tumours, constitutive cancer
syndromes and other solid tumours.
GC>CG GC>TA GC>AT AT>GC AT>CG AT>TA Total
CpG Non
Breast p53 mutations 1 5 10 1 3 2 22
identified in this study 6 4
Breast p53 mutations 5 9 12 4 4 2 36
identified from Scottish 6 6
patients
Total breast p53 17 22 45 8 10 8 110
mutations 23 22
Colon p53 mutations 2 0 36 8 0 2 48
30 6
Lung p53 mutations 19 49 37 8 5 8 126
(N-SCLC) 12 25
Lung p53 mutations 6 25 11 4 5 4 55
(SCLC) 6 5
Brain p53 mutations 2 4 30 6 1 0 43
20 10
Oesophagus p53 0 9 16 4 3 5 37
mutations 7 9
Bladder p53 mutations 5 2 8 3 3 021
6 2
Liver p53 mutations 4 30 13 14 4 14 79
6 7
Ovary p53 mutations 4 3 8 1 2 1 19
2 6
Total p53 mutations in 59 144 204 56 33 42 538
solid tumours 113 91
Constitutive mutations 1 2 20 2 2 1 28
(mainly Li-Fraumeni) 17 3
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Table 5.6 Frequency of specific types of base substitution in breast tumours, constitutive cancer
syndromes and other solid tumours expressed as a percentage.
GC>CG GC>TA GC>AT AT>GC AT>CG AT>TA Total
CpG Non
Breast p53 mutations 5 23 46 5 17 9 100
identified in this study 28 18
Breast p53 mutations 14 25 34 11 11 5 100
identified from Scottish 17 17
patients
Total breast p53 16 20 41 7 9 7 100
mutations 21 20
Colon p53 mutations 4 0 75 17 0 4 100
63 12
Lung p53 mutations 15 39 30 6 4 6 100
(N-SCLC) 10 20
Lung p53 mutations 11 46 20 7 9 7 100
(SCLC) 11 9
Brain p53 mutations 5 9 70 14 2 0 100
47 23
Oesophagus p53 0 24 43 11 8 14 100
mutations 19 24
Bladder p53 mutations 24 10 38 14 14 0 100
28 10
Liver p53 mutations 5 38 16 18 5 18 100
7 9
Ovary p53 mutations 21 16 42 5 11 5 100
10 32
Total p53 mutations in 11 27 38 10 6 8 100
solid tumours 21 17
Constitutive mutations 4 7 71 7 7 4100
(mainly Li-Fraumeni) 60 11
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One of the most notable features of the p53 mutational spectra is the preponderance of base
substitutions at GC base pairs. If all alterations occurred randomly then the frequency of the changes
seen at GC base pairs would be expected to reflect the GC content of the gene. While the overall
content of GC in the p53 gene sequence is 56% (Chumakov P.M. EMBL access number X54156 for
HSP53G), 76% of the base substitutions in all solid tumours occur at GC base pairs. A similar figure
of 77% is observed when analysing breast tumours alone (table 5.6). The most frequent types of
base pair substitution observed in breast tumours all occur at GC base pairs: GC>AT transitions
(41%) and GC>TA (20%) and GC>CG (16%) transversions.
GC>AT transitions in breast cancer occurs at approximately equal frequency at both CpG
dinucleotides (21%) and at cytosine and guanine residues not contained in this sequence
conformation (20%). 5-methylcytosine is present in the genome at a frequency of 1% and occurs
mainly at CpG dinucleotide sequences. GC>AT transitions at CpG dinucleotides are thought to arise
by the deamination of 5-methylcytosine to thymine (Bird et al., 1980). Although it is not known
which CpG residues are methylated in breast tissue, the CpG dinucleotides at codons 170, 175, 181,
185/6 and 273 have been shown to be methylated in white blood cell, sperm, liver, muscle,
urothelium and cultured skin fibroblast DNA (Rideout et al., 1990). In accordance with this, 7/8
mutations at codon 175 and 4/6 mutations at codon 273 are consistent with the deamination of 5-
methylcytosine to thymine at a CpG dinucleotide. Although 21% of the base substitutions in breast
cancer could be due to this endogenous mechanism it is clearly not as important a factor as it appears
to be in colon (63%) and brain (47%) tumours or constitutional cancer syndromes (60%).
The highest frequencies of GC>TA transversions are seen in oesophageal (24%), liver
(38%) and lung (41%) cancers and a similar preponderance is found in breast cancer (22/108, 20%).
As previously noted, external carcinogens are thought to play an important part in the generation of
these tumours. The nucleotide G is known to be a preferential target for most chemical carcinogen-
induced mutations (Kriek et al., 1984). Therefore the prevalence of GC>TA base changes implies
that external carcinogens have a role in the development of breast tumours.
Of 84 base substitutions at GC base pairs 59 occur with the guanine residue in the non-
coding strand. This strand bias is seen in GC>CG, GC>TA and GC>AT mutation types although it
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is most pronounced for GC>TA transversions (table 5.7). It is possible that 59/125 (47%) of all
mutations in breast tumours are point mutations occurring at the guanine residues in the non-coding
strand. However 14/27 GC>AT transitions occurring at CpG dinucleotides could more realistically
be viewed as alterations caused by the deamination of 5 methylcytosine to thymine in the coding
strand. Nevertheless the remaining 45/125 (36%) mutations occurring at guanine in the non-coding
strand is in excess of expectation.
Table 5.7 Strand bias in GC base pair substitutions.
GC > CG GC > TA GC> AT
G in the non coding strand 12 20 27
C in the non-coding strand 5 2 18
Total 17 22 45
Mutagenesis experiments in mammalian cells have shown that the non-transcribed strand is
more frequently the site of damage and this is thought to be due to either the preferential repair of the
coding over the non-coding strand (Mellon et al., 1987) or increased susceptibility of the non-coding
strand to damage. This bias is also seen in lung tumours of both the small cell and non-small cell
types (Hollstein et al., 1991a). All of the N-SCLC and 23/25 SCLC GC>TA mutations involved
nucleotide base pairs containing guanine in the non-coding strand. This strand bias was also
observed with GC>CG transversions in N-SCLC and SCLC and with GC>AT transitions in SCLC.
The number of changes seen at AT base pairs is too small to indicate any strand bias in this type of
mutation (table 5.5).
5.3.5 Analysis of position in the breast cancer p53 mutation spectrum.
The preponderance of a particular type of base substitution in a spectrum can implicate
many potential origins, eg GC>TA transversions can arise thought DNA polymerase infidelity (Loeb
and Cheng 1990), 8-hydroxyguanine adduct formation by oxy-radical damage (Wood et al., 1990)
and N2 -BPDE deoxyguanine adduct formation by benzo(a)pyrene (Chen et al., 1990b). Therefore it
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is the positional specificity of mutations that will provide the most information on specific factors
involved in p53 mutagenesis (Hollstein et al., 1991a).
The 125 breast cancer p53 mutations occur between exons 5 and 11: 43/125 (34%) in exon
5; 14/125 (11%) in exon 6; 32/125 (25%) in exon 7; 31/125 (25%) in exon 8; 2/125 (2%) in exon 9;
1/125 (1%) in intron 9; 1/125 (1%) in exon 10; and 1/125 (1%) in exon 11. The missense mutations
are found in 54 different codons and the deletions involve a further 69 codons. Four regions of the
p53 gene showing high frequency of mutation, known as hotspot regions (HSRs), have been
determined (Nigra et al., 1989). These four HSRs (A to D) show good correlation with four of the
five highly conserved domains (HCDs II-V) found in the gene (Soussi et al., 1990). Seventy five of
110 (68%) point substitutions and 5/9 (56%) deletions are found within these four HCDs. Of the
remaining missense mutations, 20/34 are found at codons conserved from Xenopus to mammals and
13/34 are found at codons conserved between mammals. A fifth HSR, HSR A', has been determined
between the codons 151 and 159 (Caron de Fromentel and Soussi 1992). This HSR, however, is the
location of only 5/125 (4%) breast cancer mutations.
Hotspot codons are particularly interesting as they can indicate the influence of a potent
factor on the mutation spectrum of the p53 gene. The determination of a hotspot at codon 249
strongly suggested a role for aflatoxin B1 in the development of HCC. Over 50% of mutations occur
at codons 175, 248, 273 and 282 in colon tumours. These codons contain CpG dinucleotide sites and
all of the changes at these sites are GC>AT transitions, implicating 5-methylcytosine as an
endogenous mutagen involved in the generation of a high number of colon p53 mutations.
The most frequent sites for breast cancer mutations are codons 175 (8), 194 (4), 245 (4), 248
(6), 273 (6), 280 (5) and 285 (4). Together they account for only 37/125 (30%) of the mutations
identified. Codons 175, 245, 248 and 273 are found to be mutated in a wide variety of malignancies
including cancers of the colon, brain, oesophagus, liver and cervix (Hollstein et al., 1991a; Caron de
Fromentel and Soussi 1992). Mutations at codon 194 have only been identified in two oesophageal
carcinomas (Hollstein et al., 1991b), one small cell lung tumour (Takahashi et al., 1989) and a B-cell
chronic lymphocytic leukemia (B-CLL) (Gaidano et al., 1991). Codon 280 has been shown to be
mutated in an oesophageal tumour (Hollstein et al., 1991b), a non-small cell lung tumour (Kishimoto
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et al., 1992), a rhabdomyosarcoma cell line (Felix et al., 1991b) and a pancreatic carcinoma cell line
(Barton et al., 1991). Mutations at codon 285 have been detected in four non-small cell lung
tumours (Bodner et al., 1992; Mitsudoni et al., 1992). Identification of three codons mutated in
breast (13/110, 12%), oesophageal (3/37, 8%) and non-small cell lung tumours (5/126, 4%), but
rarely in other malignancies, may indicate a common mechanism ofmutation altering the p53 gene
in these types of tissue. Although this kind of analysis is limited due to the number of mutations
identified in certain tumour types the characterisation of further p53 mutations will aid in the
identification of common sites of mutation in different malignancies.
5.3.6 Discussion
Analysis of the p53 mutation spectrum in breast cancer reveals a high frequency of
mutations at G residues, suggesting the involvement of external carcinogens. However it must be
remembered that the p53 spectrum may not simply be the product of the interaction between
exogenous factors and DNA. The differences observed between mutation spectra of different tumour
types could be due largely to endogenous factors. Recent studies have proposed that exogenous
factors, in the doses normally encountered, would have little or no discernible effect when added to
the huge carcinogenic load originating from endogenous factors (Rudiger 1990). Thus differences
between p53 mutation spectra could be accounted for by variation in endogenous factors such as 5-
methylcytosine content (Ehrlich et al., 1982), type and efficiency of DNA repair mechanisms (Harris
1989) and concentration of various endogenous mutagenic compounds such as reducing sugars (Lee
and Cerami 1990), lipids and lipid precursors (Esterbauer el al., 1990) and amino acid derivatives
(Glatt 1990) between tissue types.
A second consideration is that the p53 spectra could simply be an effect of tissue specific
mutation selection. Mutant p53 proteins have differing properties (Hinds et al., 1990; Halvey et al.,
1990) and it has been hypothesised that the growth advantage conferred by certain p53 proteins is
dependent on the cell type in which the mutation occurs (Levine et al., 1991). Mutations not
appearing in the spectrum of a particular tumour type may be lethal or may not offer any selective
advantage to that cell type. Thus the hotspot codons, 175, 248, 273 and 282, which are frequently
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mutated in colon cancer, could reflect strong cell-specific selection, rather than the deamination of 5-
methylcytosine at these sites. The codon 249 mutation occurring in HCCs could also be hepatocyte
specific rather than mutagen specific (Vogelstein and Kinzler 1992).
A possible example of a non-selectable mutation is demonstrated by GC>AT substitutions
occurring at the CpG dinucleotide at codon 175 (Caron de Fromentel and Soussi 1992). Twenty two
transitions found at this site in a range of cancers exclusively involve the G residue of the
dinucleotide, resulting in an amino acid change of arginine to histidine. Transitions involving the C
residue would produce an arginine to cysteine substitution. The CpG dinucleotides at codons 248
and 273, which are mutated at a high frequency in human tumours, are mutated at the C and G
residues at equal frequencies suggesting that the codon 175 Arg to Cys mutation does not confer any
growth advantage.
The constitutional p53 mutations found so far in familial cancer syndromes such as LFS
could be the result of a specific type of selection. These mutations show unusual clustering in exon
seven and 68% (23/34) are located between the codons 241 and 286. The mutation spectrum reveals
two hotspots, one at codon 245 (4/34, 12%) and another at codon 248 (7/34, 21%) and 57% (16/28)
of base substitutions occur at CpG dinucleotides. The mutant p53 proteins have been shown to have
distinct properties, such as differences in growth suppression (Frebourg et al., 1992), protein
expression (Srivastava et al., 1992) and ability to drive the wild type p53 protein into the mutant
conformation (Milner and Metcalf 1991), when compared to somatically acquired p53 mutants.
These distinct characteristics suggest that only certain p53 mutations will be tolerated when present
constitutively. The spectrum of constitutional p53 mutations might therefore reflect selection for
these characteristics rather than the influence of exogenous and endogenous mechanisms of
mutation.
The analysis of p53 mutations in solid tumours can only implicate external carcinogens if
these have a direct effect on p53 mutation. Less than half of the chemicals shown to be carcinogenic
in rats actually show mutagenic properties in Salmonella (Ames and Gold 1990). The remaining
chemicals are thought to act as mitogens or cytotoxins (Hoel et al., 1988), and influence DNA
mutation by an increase in cell division. This increase has been postulated to enhance mutation
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formation by endogenous factors in several ways: by allowing adducts to be converted into
mutations; by increasing the incidence of mitotic recombination, gene conversion and non¬
disjunction events, which are important factors in tumour suppressor gene inactivation; and by
allowing gene duplication, which can lead to the increased expression of oncogenes. An increase in
DNA replication is also accompanied by an increase in the level of ssDNA, which is more
susceptible to damage than dsDNA (Ames and Gold 1990). Thus it is possible that a carcinogen
acting on breast epithelial cells, because it increases the frequency of mutations caused by
endogenous factors and does not effect the DNA directly, will not induce carcinogen-specific
mutations.
Identification of specific exogenous and endogenous factors through p53 mutation spectrum
analysis relies on the presumption that the mutations arising in the tumour samples have similar
origins. The p53 mutations used to determine the breast cancer p53 mutation spectrum originated
from patients in Scotland, England, France, the Netherlands, Norway and the USA. The origins of
p53 mutations in different patient populations might be expected to reflect exposure to differing
carcinogens and variation in internal endogenous factors. Quantitative differences in DNA repair,
DNA adduct formation and carcinogen metabolism between individuals have been described and
may modify the pattern of p53 mutation (Harris 1989). An example of this might be seen in the
analysis of breast cancer where the mutation CTT>CGT at codon 194 accounts for 3/110 (3%) single
base substitutions, all of which are found in Scottish patients (3/36, 8%) (0.1 > P > 0.05, Fisher's
exact test). A higher frequency of p53 deletions, 5/14 (36%) compared to 10/111 (9%) in all other
breast tumour studies, has been detected in breast tumours from patients in Rochester, USA (Sommer
et al., 1992) (0.05> P > 0.01, Fisher's exact test). Similarly a prominent mutation hotspot at codon
273 found in SCLC samples from American patients was not detected in SCLC samples from
Japanese patients (Chiba et al., 1990; Mitsodomi et al., 1992; Suzuki et al., 1992). Thus specific
factors inducing p53 mutations in one population may not be present in another and therefore might
not be apparent in an analysis using p53 mutations occurring in differing populations.
For the spectra of p53 mutations to be of any use in determining specific causal factors, the
type and positions of p53 mutations induced by specific carcinogens need to be determined. While
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most of this kind of work has been done on the ras oncogene in rodents, similar studies in humans
would need to rely upon in vitro treatment of human cells with chemical carcinogens. Studies
similar to those investigating the mutation spectra of the hypoxanthine-guanine phosphoribosyl
transferase (HPRT), adenine phosphoribosyl transferase (APRT) and thymidine kinase (TK) genes
would be ideal although, unlike these genes, there is no convenient selection test for mutated p53
genes (Clive et al., 1972; Albertini and DeMars 1973; Jones and Sargent 1974). Experimental
systems in which immortalised cells arising after chemical treatment are tested for p53 mutation on
the basis of immunohistochemistry (Maehle et al., 1992) or transcriptional activation (Frebourg et
al., 1992) could be utilised. However, p53 mutations occurring in vitro would perhaps not reflect
those occurring in vivo (Harvey and Levine 1991; Rittling and Denhardt 1992). The feasibility and
productivity of such an approach must be considered before further studies in this direction are
undertaken. Characterisation of the p53 mutations induced by a single chemical would be a major
task, even when using non-sequencing methods such as the SSCP and HOT techniques. Considering
that more than 50% of all chemicals tested are carcinogenic (Ames and Gold 1990) the effort needed
for the characterisation of even a small number would be enormous.
Given that the p53 spectrum in breast cancer, as it stands, shows no features as notable as
the hotspots in HCC and colon cancer, identification of exogenous or endogenous factors by this
method may not be particularly efficient. In addition, those exogenous factors implicated in the
carcinogenic process by p53 mutation analysis (benzo(a)pyrene in lung cancer, aflatoxin B1
exposure in HCC, urethan in oesophageal cancer and UV exposure in skin cancers) had previously
been identified as risk factors by epidemiological approaches (Selikoff et al., 1968; Yeh et al., 1989;
Yu et al., 1980) and mutagenesis studies (Miller 1985, McMahon et al., 1990; Chen et al., 1990b).
This suggests that any exogenous factor potent enough to affect the mutation spectrum of the p53




Correlation of p53 mutation and LOH with
pathological/clinical parameters
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6.1 Prognostic makers in breast cancer.
To date the most informative factors for predicting disease recurrence and overall survival
in breast cancer patients are the metastatic spread of the tumour to axillary lymph nodes (Shek and
Godolphin 1988) and tumour stage (TNM), which combines information on spread to axillary lymph
nodes with tumour size and occurrence of distant metastases (Donegan 1992). Disease recurrence in
the 10 years following primary treatment occurs in 20-30% of patients without histologically
involved axillary nodes in comparison to 75% of patients with histologically involved axillary nodes
(Fisher 1984). Oestrogen (ER) and progesterone receptor (PR) levels, tumour grade and histological
type can also be used as indicators of prognosis (Knight et al., 1977; Gallager 1984; Pari et al., 1984;
Le Doussal et al., 1989). In addition ER and PR levels can be used to identify tumours with a high
probability of response to endocrine or hormone therapy. A favourable response to such treatment is
found in three quarters of patients with ER and PR positive tumours and in 14% of patients with ER
and PR negative tumours (McGuire et al., 1978).
The search for a marker capable of predicting disease recurrence and overall survival
independently of lymph node involvement has been the aim of many studies. As metastatic breast
cancer is incurable, this is particularly important in axillary node negative (ANN) breast cancer
where such a marker could be used to identify those patients at high risk of recurrence (McGuire et
al., 1992). Adjuvant endocrine therapy and chemotherapy have been shown to increase disease free
survival significantly in node negative patients (Mansour et al., 1989; Fisher et al., 1989; Nayfield el
al., 1991). A marker capable of predicting the risk of recurrence could be used to separate patients
into high and low risk groups. High risk patients could benefit from adjuvant therapy while low risk
patients could avoid unnecessary and expensive treatment along with potential side effects.
Since tumorigenesis is a process resulting from an accumulation of genetic alterations
affecting cellular growth control, tumour behaviour might therefore be expected to reflect these
underlying genetic changes. Determination of these changes and their association with pathological
and clinical characteristics could indicate the origins of certain tumour characteristics. Ultimately
these associations may be able to divide tumours into subgroups whereby their clinical behaviour can
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be reliably predicted and the appropriate treatment more successfully applied (McGuire et al., 1991;
Wolman et al., 1992).
Many studies have attempted to associate tumour and patient characteristics with alterations
of specific oncogenes or LOH at specific sites of the genome in the hope of identifying a reliable
clinical marker (Callahan 1989). The over-expression of c-myc has been correlated with oestrogen
receptor level, (Mizukami et al., 1992), patient age (Escot et al., 1986; Spandidos et al., 1989),
progesterone receptor level (Adane et al., 1989), metastatic spread to lymph nodes (Guerin et al.,
1988), and poor prognosis (Varley et al., 1987). Over-expression of the ras oncogene has been
correlated with oestrogen receptor level (Muzukami et al., 1992), histological grade (Agnantis et al.,
1986a) and tumour invasion (Horan Hand et al., 1984). Alteration of the int-2 gene has been
correlated with oestrogen receptor level (Fantl et al., 1990; Borg et al., 1991; Berns et al., 1992),
progesterone receptor level (Adane et al., 1989) and metastatic spread to lymph nodes (Adane et al.,
1989). The oncogene on which most work has been done is the neu/c-erbB2/HER oncogene, the
amplification/overexpression of which has shown correlation with poor prognosis in node positive
and, in some studies, node negative tumours (Gullick 1990; Perren 1991; Borg 1992).
The following parameters have been shown to be significantly associated with LOH on
specific chromosomes: tumour size with LOH on 13 and lip (Mackay et al., 1988b; Andersen et al.,
1992); metastatic spread to lymph nodes with LOH on lq, lip and 6q (Ali et al., 1987; Devilee et
al., 1991a; Chen et al., 1989); histological tumour type with LOH on 13q (Devilee et al., 1991a);
menopausal status with LOH on 17q (Borresen et al., 1991); age at disease onset with LOH on 17q
(Devilee et al., 1991a); oestrogen receptor level with LOH on lip, 13q, 17q and 18q (Ali et al.,
1987; Mackay et al., 1988b; Cropp et al., 1990; Devilee et al., 1991a); high grade tumours with LOH
on 3p, 11 and 18q (Ali et al., 1987; Ali et al., 1989b; Cropp et al., 1990); and disease free interval
and overall survival with LOH on 7q (Bieche et al., 1992).
The associations determined by the oncogene/LOH studies are not consistently found in
every investigation. This variability has been attributed to a number of factors: sampling errors due
to small numbers of tumours; different compositions of the patient and tumour populations; varying
fractions of normal cell contamination within tumour samples, which is especially relevant in LOH
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and mRNA studies; limited periods of post-surgical follow-up; differences in experimental
techniques and data analysis; and the failure to consider the effects of post-surgical treatment.
Consequently, studies of the above type have been criticised for their approach and guidelines for the
setting up of future studies have been recommended (McGuire et al., 1991). Under these guidelines
the present attempt to correlate p53 mutation and LOH on chromosome 17p with
pathological/clinical parameters, considering the small sample size and limited patient and tumour
information, would qualify as 'pilot study'. The results could only be used as an initial indication of
the potential of these genetic alterations as a useful prognostic markers.
6.2 Correlation of LOH on chromosome 17 and p53 mutation with pathological/clinical parameters.
In the present study six clinical/pathological parameters were examined for correlation with
either LOH on chromosome 17 or p53 mutation. The pathological/clinical parameters were tumour
size, metastatic spread to lymph nodes, age of patient at presentation, patient menopausal status,
family history of breast disease and tumour oestrogen receptor protein level. Seventy eight tumour
samples analysed for mutations in the p53 gene have information on three or more
pathological/clinical parameters (Table 6.1). Thirty five tumour samples analysed for LOH using
markers near the p53 gene have information on three or more pathological/clinical parameters (Table
6.2) The relationships between the molecular alterations and pathological/clinical parameters were
analysed statistically by the %2 or Fishers exact (2x2) test using C-stat, an IBM computer statistics
package. Tables 6.3 and 6.4 show the probability levels (P value) for the association of LOH and
p53 mutation with the pathological/clinical parameters. P values of less than 0.05 were considered
statistically significant.
p53 mutation was found to be associated with two pathological/clinical parameters,
menopausal status and low levels of oestrogen receptor protein (Table 6.3). No pathological/clinical
parameter was associated with LOH at the p53 locus (Table 6.4). This is perhaps not unexpected
considering that tumour heterogeneity and normal cell contamination would mask the actual LOH
status of the breast tumour samples analysed (sections 3.2 and 3.3).
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wt 4 - - - 79 Post No 220
wt 6 3.2 Ductal/NST 10/23 62 - No 789
wt 7 2.8 Ductal/NST 0/7 34 Pre No 2
wt 9 9 Ductal/NST 4/5 73 Post No -
wt 14 1.4 Ductal/NST 1/17 44 Peri Yes 51
wt 15 3.0 Ductal/NST 1/17 44 Peri Yes 39
wt 16 2.0 (B) Ductal/NST - 60 - Yes 80
wt 20 1 Ductal/NST 0/3 L 72 Post No -
wt 22 1.3 - 3/4 83 Post No 0
wt 24 1.9 Ductal/NST 0/15 59 Post Yes -
wt 26 3.0 Ductal/NST 0/21 75 - No 54
wt 27 2.5 (B) Ductal/NST - 57 Post No 364
wt 32 3.9 (B) Ductal/NST 0/5 47 Post No 1
wt 33 2 Ductal/NST 10/17 50 - No 71
wt 37 4.0 Squamous - 66 Post No 4
wt 40 7.5 Ductal/NST 4/7 49 - No 1
wt 41 1.5 Ductal/NST 0/3 52 Post Yes -
wt 42 1.5 Ductal/NST 1/4 47 Peri No 82
wt 45 3.8 Ductal/NST 0/2 51 Pre No 0
wt 46 2.5 Tubular 2/5 59 Post No 119
wt 49 1.6 Mucoid 3/3 39 Pre No 23
wt 50 - Ductal/NST 0/3 37 - Yes 3
wt 53 2.2 Ductal/NST 5/9 54 Post No 150
wt 54 2.8 Ductal/NST - 55 Post No 186
wt 55 3.3 Ductal/NST 0/14 67 Post No 0
wt 56 2.0 Ductal/NST 0/1 75 Post No 204
wt 58 KB) Ductal/NST 1/6 57 - No -
wt 59 2.7 (B) Ductal/NST 1/5 61 Post No 536
wt 60 2.2 (B) Ductal/NST - 59 Post No 392
wt 62 -(B) Ductal/NST - 54 Post No 371
wt 63 3.8 Ductal/NST 0/3 33 Pre No 44
wt 65 2 Scirrhous 3/3 45 Post No 76
wt 68 1.5 Ductal/NST 0/8 52 - No 212
wt 69 0.8 Ductal/NST 0/8 52 - No 199 _j
wt 70 1.2 Ductal/NST 0/2 50 Post No -
wt 74 -(B) - - 62 Post No 240
wt 75 1.9 Ductal/NST 0/7 51 Post No 3
wt 76 3.5 Mucoid 1/10 52 Post No 62
wt 79 1.8 (B) Ductal/NST 3/15 33 Pre No 7
wt 81 j - Ductal/NST 18/19 64 Post Yes 230
wt 83 2.8 Ductal/NST 2/3 47 Pre No 36
wt 86 3.0 Ductal/NST 0/21 42 - No 51
wt 87 2.5 Ductal/NST 0/21 42 - No 37
wt 89 1.4 (B) Lobular variant 0/4 39 Pre No 35
wt 90 1.4 Ductal/NST 1/1 56 Post No 243
wt 91 3.2 Ductal/NST 1/11 33 Pre No 0





















wt 99 2.9 Ductal/NST 0/4 59 Post No 277
wt 100 3.8 Tubular 0/12 48 Pre No 88
wt 106 1.5 Ductal/NST 0/4 40 - No 21
wt 107 2.3 Tubular 3/8 64 Post Yes 149
wt 108 1.7 Ductal/NST 0/14 64 Post Yes 321
wt 109 2.1 Ductal/NST 0/3 56 Post No 75
wt 112 1.8 Papillary 0/10 58 - No 232
mut 8 3.2 Ductal/NST 1/6 65 Post No 122
mut 10 2.8 Ductal/NST 0/10 50 - No 21
mut 11 2.0 Ductal/NST 10/17 50 - No 3
mut 12 3.4 Ductal/NST 10/17 50 - No 4
mut 18 2.8 Ductal/NST 3/10 79 Post No 0
mut 21 3.5 Ductal/NST 7/10 66 - No 0
mut 25 5.5 Lobular variant 5/10 70 Post No 0
mut 34 2.2(B) Ductal/NST 0/4 66 Post No 8
mut 57 1.9 Ductal/NST 4/4 66 Post No 79
mut 61 2.6 (B) Ductal/NST - 62 Post No 225
mut 64 1.7 Ductal/NST 1/3 50 Peri No 1
mut 67 2.2 Ductal/NST 0/4 50 - No 92
mut 71 1.3(B) Ductal/NST 1/1 47 Post No 436
mut 72 1.7(B) Ductal/NST 0/3 56 Post No 658
mut 84 4.5 Ductal/NST 3/5 55 Post No 0
mut 85 5.5 Ductal/NST 0/21 42 - No 4
mut 88 3.5 Ductal/NST 1/4 41 - No 1
mut 92 1.2 Ductal/NST 0/5 38 Peri Yes 61
mut 95 2.0 Ductal/NST - 87 Post No 11
mut 98 3.8 Ductal/NST 0/12 75 Post No 0
mut 101 3.5 Comedo 0/12 59 Post No 0
mut 110 1.2 Ductal/NST 0/4 65 Post Yes 570
mut 113 - Medullary 0/4 35 - No 9
mut 114 1.4 Ductal/NST 0/12 36 Post Yes 4
NST - No Special Type
(B) - Biopsy
M/P - menopausal
wt - wild type
mut - mutant
ER - oestrogen receptor
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L 14 1.4 Ductal/NST 1/17 44 Peri Yes 51
L 15 3.0 Ductal/NST 1/17 44 Peri Yes 39
L 16 2.0(B) Ductal/NST - 60 - Yes 80
L 18 2.8 Ductal/NST 3/10 79 Post No 0
L 21 3.5 Ductal/NST 7/10 66 - No 0
L 34 2.2 (B) Ductal/NST 0/4 66 Post No 8
L 35 1.2(B) Tubular 0/3 66 Post No 275
L 40 7.5 Ductal/NST 4/7 49 - No 1
L 42 1.5 Ductal/NST 1/4 47 Peri No 82
L 57 1.9 Ductal/NST 4/4 66 Post No 79
L 59 2.7 (B) Ductal/NST 1/5 61 Post No 536
L 72 1.7 (B) Ductal/NST 0/3 56 Post No 658
L 79 1.8 (B) Ductal/NST 3/15 33 Pre No 7
L 91 3.2 Ductal/NST 1/11 33 Pre No 0
L 99 2.9 Ductal/NST 0/4 59 Post No 277
L 100 3.8 Tubular 0/12 48 Pre No 88
L 101 3.5 Comedo 0/12 59 Post No 0
NL 19 1.2 Carcinoid 3/10 79 Post No -
NL 20 1 Ductal/NST 0/3 72 Post No -
NL 24 1.9 Ductal/NST 0/15 59 Post Yes -
NL 26 3.0 Ductal/NST 0/21 75 - No 54
NL 29 1.8 (B) Ductal/NST 2/4 34 Pre No 36
NL 37 4.0 Squamous - 66 Post No 4
NL 45 3.8 Ductal/NST 0/2 51 Pre No 0
NL 63 3.8 Ductal/NST 0/3 33 Pre No 44
NL 65 2 Scirrhous 3/3 45 Post No 76
NL 74 -(B) - - 62 Post No 240
NL 75 1.9 Ductal/NST 0/7 51 Post No 3
NL 85 5.5 Ductal/NST 0/21 42 - No 4
NL 86 3.0 Ductal/NST 0/21 42 - No 51
NL 90 1.4 Ductal/NST 1/1 56 Post No 243
NL 93 1.4 Ductal/NST 1/4 57 - No 119
NL 103 2.5 Papillary 6/12 68 Post No 195
NL 107 2.3 Tubular 3/8 64 Post Yes 149
NL 108 1.7 Ductal/NST 0/14 64 Post Yes 321
NST - No Special Type
(B) - Biopsy
NL - No LOH, L - LOH
M/P - menopausal
ER - oestrogen receptor
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Table 6.3 Association between p53 mutation and clinical pathological parameters
Clinical Parameter Number of Number of Total
tumours with tumours number of




































































t 0.05 > P > 0.01
X2 - chi squared test
F.E. - Fisher exact test
NS - not significant
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Table 6.4 Association between LOH at the p53 locus and clinical pathological parameters



























































X2 0.5> P > 0.25
NS
X2 - chi squared test
F.E. - Fisher's Exact test - chi square test
NS - not significant
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6.3 Discussion
The association of p53 mutation and menopausal status (0.01 > P > 0.001) could reflect a
greater incidence of p53 mutations in tumours from post-menopausal patients. However it is likely
that it is a consequence of the paucity of information on menopausal status in the set of patients
presenting with tumours containing ap53 mutation (Table 6.1). Information on menopausal status
was available for 16/24 of these patients. Of the remaining 8 patients only one patient was aged over
50 years suggesting a lack of information on menopausal status among patients under 50. p53
mutation was associated with low levels of oestrogen receptor protein (0.05 > P > 0.01). As
oestrogen negative tumours have a poor prognosis a relationship between p53 mutation and
aggressive tumour behaviour is suggested.
Despite the number of groups that have characterised p53 mutations in breast tumour
samples only two have attempted to correlate p53 mutation with pathological/clinical parameters.
One study used 60 breast tumour samples, 16 of which had p53 mutations (Thompson et al., 1992).
Significant association was found between p53 mutation and low levels of oestrogen receptor protein
(p < 0.01) but not with tumour size, stage, nodal status, menopausal status or family history. The
other study analysed 96 breast cancer patients, 18 of which had presented with tumours containing a
mutant p53 gene (Mazars et al., 1992b). Mutation of the p53 gene was associated with low levels of
oestrogen (P = 0.044) and progesterone receptor protein (P = 0.012) but not with tumour grade, nodal
status or patient age. The results of the current study confirm the findings of Mazars et al. (1992b)
and Thompson et al. (1992) as a low level of oestrogen receptor protein was the only parameter to
show significant association with p53 mutation (0.05 > P > 0.01).
Considering the amount of effort in identifying and characterising p53 mutations at the
DNA level it is perhaps not surprising that efforts to assign a prognostic role to p53 have
concentrated on immunohistochemical detection of the over-expressed protein. In total 10 studies
have attempted to correlate pathological/clinical factors to p53 over-expression. Initial studies
estimated the extent of antibody staining in 40-200 breast tumour samples (section 5.3) and found
significant associations with a number of parameters (Cattoretti et al., 1988; Davidoff et al., 1991c;
Horak et al., 1991; Koutselini et al., 1991; Ostrowski et al., 1991; Walker et al., 1991). In
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concordance with the present study the majority of investigators found a statistically significant
association with low levels of oestrogen receptor protein as well as with other pathological/clinical
parameters associated with poor prognosis such as high tumour grade and axillary lymph node
involvement.
Consequendy the association of p53 over-expression and prognosis was investigated in four
large studies. The study by Poller et al. (1992) analysed 146 breast tumour samples and found a non¬
significant trend between p53 over-expression and poor patient survival. A larger study by Thor et
al. (1992), using 589 breast tumour samples, found a significant association with shorter metastasis
free survival and overall survival which was confirmed in both lymph node negative and lymph node
positive tumour populations. The two remaining studies investigated the potential of p53 over-
expression for the identification of ANN patients with a high risk of tumour recurrence. A
significant association with p53 over-expression and overall survival was found in 289 patients in a
study by Isoba et al. (1992). However proliferation rate and tumour size, but not p53 over-
expression, were shown to be independent predictors of survival. In contrast, a recent study by
Allred et al. (1993) grouped 700 breast tumour samples into three classes based on antibody staining:
non-expressors; low expressors; and high expressors. The study found significant differences
between all groups when considering reduced disease free survival and between non-expressors and
high expressors when considering overall survival. Over-expression of the p53 protein was also
found to be an independent predictor of poor prognosis despite a high correlation with tumour
proliferation rate.
Despite attempts to link p53 mutation at the DNA level to pathological parameters, the
association with tumour recurrence or overall survival has not been determined (Mazars et al.,
1992b; Thompson et al., 1992). Data on patient survival is currently being gathered to investigate
the usefulness of this genetic alteration as an indicator of prognosis. Since the detection of p53
mutations at the DNA level is both labour intensive and time consuming a major effort would needed
to analyse the p53 gene in numbers equivalent to those used in the immunohistochemical studies
(Thor et al., 1992; Isoba et al., 1992; Allred et al., 1993). In practical terms alone the determination
of p53 mutation at the protein level is a much simpler and more straightforward process. However,
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despite encouraging results much confirmatory work, in the form of studies standardised for
methods, patient populations and therapeutic treatments, needs to be undertaken before p53 over-






The experiments detailed in this thesis are a continuation of the work of Mackay et al.
(1988a) who observed a high rate of LOII at loci near the telomere of chromosome 17p in matched
control/breast tumour pairs. Using material from the same tumour bank the rates of LOH occurring
at other loci on chromosome 17p were investigated with two aims in mind. First to determine
whether the high frequency of LOH observed at the 17pl 3.3 locus extended to other more
centromeric loci. Secondly, due of the proximity of two of the probes used to the tumour suppressor
gene p53, to determine what role, if any, the p53 gene had in breast cancer development. Results
from the LOH studies revealed that the probes mapping near to the p53 locus showed a LOH
frequency of 49%. Furthermore two breast tumours were identified which showed LOH at 17pl3.1,
the site of the p53 gene, but retained heterozygosity at loci at 17pl3.3, implicating the p53 gene in
the development of these two tumours.
Consequently all the breast tumour DNAs were examined for p53 mutations in exons 5-9 of
the gene using the HOT mutation detection technique and it was estimated that approximately 40%
of breast tumours contained a mutant p53 gene. Most breast tumours with p53 mutations showed
accompanying LOH although many tumours with LOH had an apparently normal remaining p53
allele. Possible explanations for this observation include inactivation of the p53 protein by
mechanisms other than mutation in exons 5-9, failure of the HOT technique to detect all mutations
and the presence of additional tumour suppressor genes on chromosome 17. Somatically acquired
p53 mutations were found in 19 codons in exons 5, 6, 7, 8, and 9. Analysis of breast cancer p53
mutations detected in this and other studies revealed a preponderance of mutations at guanine
residues, suggesting a role for exogenous carcinogens in breast tumorigenesis. A preponderance of
mutations at codons 175, 194, 245, 248, 273, 280 and 285 was found but no particular hotspot was
identified. p53 mutation was shown to be associated with low oestrogen receptor levels but not with
patient age, nodal status, family history, tumour size. LOH at loci near the p53 gene was not
associated with any pathological/clinical parameter.
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7.2 Future studies.
The major problem with the present study, and one which is common with many studies
using breast tumour material, is that the cellular composition of the samples themselves is unknown.
Few studies using breast tumour tissue have undertaken to ensure that either the material analysed is
composed of tumour cells only or that the extent of normal cell contamination within the samples is
known (Lundberg et al., 1987; Devilee et al., 1990; Larsson et al., 1990). The ability to isolate pure
tumour cell populations would be invaluable for the molecular analysis of breast cancer. Methods
have been devised to isolate malignant cells from normal ones by immunological selection but these
techniques are costly and produce a yield of only 10% (Linehan et al., 1989).
A method that offers insight into the genetic alterations occurring in breast tumour samples
at a new level is the touch preparation method devised by Kovach et al. (1991). Using this method
clusters ofmalignant cells were able to be isolated from frozen or fresh breast tumours containing a
mixture of malignant and non-malignant tissue. Successful PCR amplification of tumour DNA from
as few as 10 malignant cells was achieved and mutations of the p53 gene were detected and analysed
without the need to consider the possibility of normal cell contamination. An addition benefit of this
technique is that isolating cells from the same part of the tumour increases the chances of obtaining
cells originating from the same clone. The possibility of tumour heterogeneity occurring within the
group of analysed cells is therefore reduced as cells within a cluster would be expected to share the
same genetic alterations.
By using a technique that can identify genetic alterations in breast tumour samples without
the need to consider normal cell contamination or tumour heterogeneity, the relationship between
p53 mutation and the loss of the remaining wild type allele can be investigated properly. Breast
tumours which show p53 mutation without accompanying loss of the wild type allele have been
found at a low frequency in a number of studies, including this one. This observation however may
simply be a result of either normal cell contamination or tumour heterogeneity within the analysed
sample (Mazars et al., 1992b). Studies using touch preparations offer the possibility of confirming
the identification of breast tumour samples showing p53 mutation without LOH. Of the 16 mutations
detected in breast tumour cells using this technique only one, a deletion of 3 base pairs, showed the
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presence of the normal allele on sequencing. This suggests that mutation of a single copy of the p53
gene can offer a selective advantage during breast tumorigenesis. However as 15/16 breast tumours
with a mutant p53 allele had loss of the accompanying wild type allele the importance of the removal
of both copies of the gene in the majority of breast tumours was demonstrated (Kovach et al., 1991;
Sommer et al., 1992).
The ability to isolate pure tumour cell populations would greatly improve both the analysis
of other tumour suppressor genes and the quality of LOH mapping data produced in future studies in
breast cancer. Normal cell contamination and tumour heterogeneity within the majority of tumour
samples in this study prevented the production of useful mapping data. The masking of LOH by
normal cell contamination has also been demonstrated in experiments using immunologically
selected renal carcinoma cells (Linehan et al., 1989). In this analysis the three informative samples
studied all showed little or no reduction in relative allele intensity before tumour cell selection.
After selection a greater than 90% reduction in allele intensity was observed. Despite this, any LOH
analysis using malignant cells isolated using this method would still have to take into account the
possibility of tumour heterogeneity.
The touch preparation technique is capable of analysing tumour tissue without the need to
consider the effects of either normal cell contamination or tumour heterogeneity although it does not
yield enough DNA to allow LOH assays by the southern blotting technique. However, the detection
of LOH using PCR markers is now possible and has been successfully used in lung, bladder, renal
and breast carcinomas (Merlo et al., 1991; Oka et al., 1991; Ganly et al., 1992). As when using the
southern blotting LOH assay, only those tumours containing less than 25-30% normal cell
contamination can be analysed visually (Vogelstein et al., 1988; Merlo et al., 1991). The use of both
PCR markers for the detection of LOH and the touch preparation technique would enable visual
evaluation of LOH data, without the need for quantitative densitometry, and could be carried out
using very small amounts of DNA, so helping to conserve valuable tumour samples. LOH studies
using PCR markers would also be less labour intensive, less expensive and less time consuming than
those based on conventional southern blotting techniques and would facilitate rapid identification of
tumour samples offering potential mapping information for the isolation of tumour suppressor genes.
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Investigation of LOH in this and other studies has previously depended on the use of RFLP
markers mapping up to several megabases away from the gene of interest. For example, YNZ22 is
commonly used to determine LOH at the p53 locus, 20 megabases away (Y. Nakamura, personal
communication). Intragenic polymorphisms identified though the study of a particular gene can be
easily used as allelic markers by PCR thus enabling LOH to be determined at the site of interest. A
PGR marker based on the codon 72 CGC>CCC polymorphism in the p53 gene has been used
successfully in the analysis of bladder and renal carcinomas (Merlo et al., 1991; Oka et al., 1991)
and additional polymorphism at codons 21 (Ahuja et al., 1990) and 72 (Harris et al., 1986) and in
introns 1 (Ahuja et al., 1989) and 6 (Prosser and Condie 1991) could also be utilised. PCR primers
identifying the YNZ22/D17S5 locus (Horn et al., 1989; Gecz 1991) have been determined and have
enabled rapid identification of deletions in the Miller-Dieker syndrome (Batanian et al., 1990).
These could potentially be of great use in the mapping of the putative 17pl3.3 tumour suppressor
gene in breast cancer.
These types of technique have the potential to investigate the extent of molecular changes
within breast tumour samples and the relationship between genetic alteration and tumour
characteristics. The high frequency of tumour heterogeneity observed in LOH studies (Larsson et
al., 1990; Chen et al., 1992) suggests the evolution of different clones within the same tissue occurs
in the majority of tumours. The touch technique could be used to analyse directly cells originating
from different areas of a single tumour for several genetic alterations in order to determine both the
extent of heterogeneity and the clonal relationship between different cell populations. In tumours
where more than one type of clone is found it would be of great interest to try and identify which
clones are capable of metastasising to axillary lymph nodes and distant organs. In this way genetic
changes important in the metastatic process, which may have potential as prognostic markers, could
be identified.
In a similar way the clonal relationship between the carcinoma in situ and invasive
carcinoma stages could be examined in tumours where both components are present. A definite
clonal relationship between the two stages could be established and the genetic changes important in
determining invasive characteristics identified. Paralleling the study by Davidoff et al. (1991b)
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tumours containing both carcinoma in situ and invasive carcinoma cells could be used to determine
whether the mutation of the p53 gene occurs before or after invasive properties are acquired.
Mutations occurring only in the invasive components of such tumours could be regarded as late
events while mutations present in both components could be considered as alterations occurring
earlier in the development of the tumour. A temporal ordering for p53 mutation and loss of the
remaining wild type allele could be determined by examining both these alterations in pure tumour
cell populations from a single tumour. Additionally, in tumours showing more than one histological
pattern, investigation at the tumour cell level could be used to identify genetic changes important in
determining histological differentiation.
The majority of these proposed studies require careful analysis of breast tumour samples at a
histological level. The breast tumour bank used in this current study has no data of this type and so
new tumour material would need to be collected and analysed before these experiments could be
attempted. Although the current tumour bank has been shown to be unsuitable for the generation of
mapping data it has been successfully used for the identification of mutations in the p53 gene (Coles
et al., 1992). As previously discussed, the p53 gene mutation spectrum observed in breast tumours
does not indicate any specific factor involved in the mutagenesis of the p53 gene. It is likely that the
p53 mutation spectrum is a product of several different factors and continuation of work of this type
may not be particularly productive. However breast tumours show LOH at a high frequency at a
number of loci and further mutation analysis experiments on newly identified tumour suppressor
genes could be carried out using material from the breast tumour bank. For example putative tumour
suppressor genes residing on lq, 3p, 6q, 17p, 17q and 18q could be analysed both to confirm their
role in breast tumorigenesis and to identify the types of alteration occurring within these genes.
Since analysis of the p53 mutation spectrum has not produced information in the way that a similar
analysis in hepatocellular carcinoma and squamous carcinoma of the skin has done, by analysing a
number of tumour suppressor genes in breast tumour samples it may be possible to identify a genetic
alteration which has the potential to indicate a specific factor involved in the development of breast
cancer.
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In this study 79 sporadic primary breast tumours were successfully screened using the HOT
technique for mutations in the p53 gene. However, despite the advantage of a 100% detection rate
and the ability to confirm mutations by the modification and cleavage pattern, the technique is time
consuming, labour intensive and requires the use of hazardous chemicals. Any further mutation
studies on other tumour suppressor genes using the current tumour bank would be probably be more
effectively carried out using the SSCP technique. As well as having a high mutation detection rate it
is rapid and less costly than either the HOT or DGGE/CDGE techniques, making it ideal for the
scanning of a large number of tumour samples. Unfortunately the less than 100% detection rate
poses problems when using the technique for mutation analysis as potential mutation hotspot sites
could remain undetected. This can be overcome by using overlapping SSCP fragments, so that, in
effect, each nucleotide base pair is screened twice, or by analysing a subset of the samples with the
HOT technique. Sufficient DNA from the breast tumours screened for p53 mutations remains for
similar mutation studies to be carried out. This makes the current tumour bank an excellent resource
for determining the frequency and types of mutation present in other tumour suppressor genes in
breast cancer. In addition, once information on patient outcome has been collected, such studies
could indicate the potential for newly discovered tumour suppressor genes as prognostic markers in
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Evidence implicating at least two genes on
chromosome 17p in breast carcinogenesis
C. Coles A. M. Thompson P. A. Elder B. B. Cohen
I. M. Mackenzie G. Cranston U. Chetty J. Mackay
M. Macdonald Y. Nakamura B. Hoyheim C. M. Steel
The DNA of paired tumour and blood leucocyte
samples from a large series of breast cancer
patients was analysed to map regions of loss of
heterozygosity on chromosome 17. The high
frequency of loss of heterozygosity on 17p was
confirmed, and a third of informative tumours had
also lost an allele at the long arm locus THH59. On
the short arm two distinct regions of loss of
heterozygosity were identified, in bands p13-3 and
p13-1. The latter probably involves the structural
gene p53, which has been implicated as an
oncogene or as a tumour suppressor in various
human cancers. 17p 13-3, however, showed a
significantly higher frequency of loss of
heterozygosity, and there was no correlation
between allele losses at the two sites.
Nevertheless, loss of heterozygosity at 17p 13-3 is
associated with overexpression of p53 mRNA,
suggesting the existence of a gene some 20
megabases telomeric of p53 that regulates its
expression. Lesions of this regulatory gene seem to
be involved in the majority of breast cancers.
Lancet 1990; 336:761-63.
Introduction
Loss of heterozygosity at specific loci in tumour tissue may
indicate deletion of tumour suppressor genes.1 Several sites
of loss ofheterozygosity have been reported in human breast
cancer, particularly on the short arm of chromosome 17."
The same chromosome arm shows loss of heterozygosity in
small-cell lung cancer,5 colon cancer,6 ovarian cancer,7
osteosarcoma,8 and astrocytoma.9 The occurrence of
"cancer families" showing clusters of two or more of these
disorders also suggests that the different tumour types share
at least one gene that when inactivated can initiate malignant
change. p53 is a strong candidate since it is located on
chromosome 17p, is overexpressed, mutated, or both in
at least a proportion of the tumours examined and can
function as a tumour suppressor, or when mutated, as an
oncogene.911 We now report the distribution of loss of
heterozygosity at multiple loci on chromosome 17 in breast
cancer.
Patients and methods
Fresh tumour tissue was obtained at operation from 168 patients
with breast cancer attending the Edinburgh breast unit. Most had
lesions less than 5 cm in diameter detected by self-examination or
through the breast cancer screening programme. a few patients had
received tamoxifen, but no other treatment had been given before
surgery. a venous blood sample was taken from each patient, with
informed consent, and high molecular weight dna was extracted
from tumour andwhole blood by a conventional phenol/chloroform
procedure. Samples of dna were digested with restriction
enzymes according to the manufacturers' instructions. Gel
electrophoresis and Southern blotting were carried out2J2 with
blood and tumour dna from the same patient in adjacent tracks
and control (placental or tonsil) dna of known genotype in the
outer tracks ofeach gel. The probes used and theirmap locations are
given in table I. They include pBHP53, derived from a cosmid
library of genomic p53.14 Because of the need to conserve dna,
particularly from the smallest tumour biopsy samples, we could not
analyse every tumour with every probe. However, this series is the
largest of breast tumours and the most comprehensive mapping of
loss of heterozygosity on chromosome 17 yet reported.
Results
The highest frequency of loss of heterozygosity (58%) was
detected by the probe YNZ22 (table I), in accord with
previous reports."12 For all the other loci examined on 17p
the rates of allele loss were significantly lower than that for
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D17S30 YNZ22 pl3.3 Taq I 142 98 57 (58%)
C3068* pl3.2 Hae III 81 51 17 (33%)
D17S31 MCT35.1 pl3.1 Msp I 113 54 24 (44%)
p53 pBHP53 pl3.1 Bam HI 138 81 22 (27% )
D17S4 pTHH59 q23-25.3 Taq I 67 47 16 (34%)
lei r
* = Y. Nakamura, unpublished.
LOH = loss of heterozygosity.
YNZ22 (p < 0-01, chi-square test) showing that the region of
17p most commonly deleted in human breast cancer does
not include the structural gene for p53. Nevertheless, the
frequency of allele losses at the other 17p loci was much
higher than that at randomly chosen sites on other
chromosomes.2-3 There was a similar frequency of loss of
heterozygosity (34%) at the long arm locus D17S4; this rate
is higher than we had reported previously and than that
found by two other groupswith different 17q probes.315 Our
earlier series of breast tumours2 forms a part of this larger
collection. The original autoradiographs were re-examined
and seven of the tumour/blood pairs were subjected to
reanalysis with probe pTHH59, on fresh samples ofDNA.
In no instance was our previous interpretation changed. The
change in the overall rate is therefore simply a consequence
of increasing the size of the population sampled.
When the data were tested by pairwise comparisons for
concordance of allele loss at any two loci (table il), it was
clear that loss of heterozygosity at YNZ22 was independent
of loss at any of the other loci. The status of MCT35.1
correlated significantly with that of pBHP53 and of C3068,
whereas allele losses at the latter two loci were independent
of each other. These findings support the map order
suggested from multipoint linkage analysis—3068-
MCT35.1-BHP53-cen. These observations are
incompatible with any single shortest region of overlap for
chromosome 17p deletions in this series of breast tumours.
When the data were combined with a conventional plot of
loss ofheterozygosity pattern for those tumours informative
at three or more of the loci (see accompanying figure) it was
apparent that there must be at least two shortest regions of
overlap on the short arm occurring independently and with
different frequencies—one close to YNZ22 and the other
close to MCT35.1. A deletion centred on either of these
subregions can include C3068 by extension, in one case
towards the centromere and in the other towards the








Patterns of loss of heterozygosity on chromosome 17 in 49
tumours informative at three or more loci.
• = loss of heterozygosity (usually complete loss of one allele,
otherwise > 50% reduction in relative intensity of one band on Southern
blot, confirmed by laser densitometry); C = heterozygosity retained;
& = uninformative (or not tested)
heterozygosity appears to be lost from the whole length of
the chromosome (implying probable monosomy or
isodisomy), allele loss of THH59 on the long arm of
chromosome 17 seems to be a further independent event,
suggesting the possibility of a third region of specific
deletion.
Discussion
This pattern of allele loss is quite different from that
recorded in other settings. For example, a large series of
colon tumours analysed in Edinburgh showed a very clear
single shortest region of overlap on the long arm of
chromosome 5 with the peak frequency of loss of
heterozygosity close to the ape locus.16 The pattern also
differs from those repotted for chromosome 17 in other















































* Fisher's exact test.
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tumours. In osteosarcoma8 and colon cancer6 deletions span
much of the short arm but give a single shortest region of
overlap centred on MCT35.1 (D17S31), whereas ovarian
cancer shows an even higher frequency of allele loss on the
long arm (at THH59) than on the short arm, with no
evidence as yet for separate clusters of deletions within
17p.17
The association between allele loss on 17p and mutation
of the retained copy of p53, shown in several tumour
types ,s'911 may require further scrutiny in the light of these
findings. Analysis of a subset of this series of tumours has
shown that p53 mutations can occur in association with
various patterns of allele loss at loci on 17p and are not
confined to those with demonstrable deletions close to p53
itself.18 Furthermore, many deletions centred on MCT35.1
exclude the locus identified by pBHP53. However, the
orientation of genomic p53 with respect to MCT35.1 is not
known, and it is possible that deletions affecting MCT35.1
but sparing pBHP53 remove portions of p53 coding or
regulatory sequences, inactivating that copy of the gene.
It is also interesting that allele losses at YNZ22 are
correlated with overexpression of p53 mRNA.12 Since the
loci are some 20 megabases apart and since allele losses at the
two sites are independent, we postulate a separate gene, close
to YNZ22, the function of which is to regulate p53
expression. Lesions involving that regulatory gene
constimte the commonest molecular changes in human
breast tumours. This hypothesis, ofcourse, does not detract
from the importance of p53 in relation to breast cancer but
introduces a new level of complexity into that relation.
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Antimicrobial actions of calcium binding leucocyte
L1 protein, calprotectin
Martin Steinbakk Carl-FredrikNaess-Andresen
Egil Lingaas Inge Dale Per Brandtzaeg
Magne K. Fagerhol
The calcium binding L1 protein was found to
inhibit growth of blood culture isolates of Candida
spp and cerebrospinal fluid isolates of
Cryptococcus neoformans. Minimum inhibitory
concentrations (MIC) were 4-128 mg/l, and
concentrations 2-4 times the MIC were fungicidal.
Blood culture isolates of Escherichia coli,
Klebsiella spp. Staphylococcus aureus, and
Staphylococcus epidermidis had MIC values of
64-256 mg/l. Antibacterial activity was strongly
influenced b^The nature of the culture medium. In
view of the biological activity of L1, the name
calprotectin is proposed to describe this
antimicrobial protein with calcium binding
properties.
Lancet 1990; 336: 763-65.
Introduction
Human leucocyte protein LI was first described in 1980,1 is
partly characterised,2-3 and is a cytoplasmic component of
neutrophils, mononuclear cells, and squamous epithelial
cells.4-5 This 36-5 kD molecule contains 13-3 kD heavy (L1h)
and 8-2 kD light (L1L) polypeptide chains, each ofwhich can
bind two calcium ions. Its quaternary structure probably
contains one LI
t and two L1h chains. Although the function
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2. MOLECULAR LESIONS IN BREAST CANCER
J. Mackay, A.M. Thompson, C. Coles and C.M. Steel
Experimental Studies Section, MRC Human Genetics Unit, Western General Hospital, Edinburgh, Scotland, UK.
An essential feature of malignancy is that the malignant phenotype is passed from the parent cell to its progeny
ad infinitum. This suggests that the fundamental lesion in malignancy resides in the DNA. Strong supporting
evidence for this theory comes from DNA instability syndromes (for example, ataxia-telangiectasia, Gatti et al.,
1988), in which DNA repair mechanisms are defective with an associated increased risk of malignant disease and
from inherited cancer syndromes such as retinoblastoma and familial adenomatous polyposis which behave as
autosomal dominant conditions. Breast cancer also has a heritable component as discussed in the "Etiology" section
of this Supplement.
Support for this molecular hypothesis of breast cancer has been derived from cytogenetic and molecular tech¬
niques. Despite the difficulties encountered in cytogenetic analysis of solid tumours, aberrations have been dem¬
onstrated on chromosomes 1, 3, 5, 6, 10, 11, 12 and 17 (Ferti-Passantonopoulou and Panani, 1987); a particular
association is reported with breakpoints on chromosome 1 at position q21 (Pathak and Goodacre, 1986).
Molecular lesions can be described under the headings of amplification, mutation, overexpression or deletion of
genetic material. However, molecular studies can only target limited regions of the genome. The choice of where
to begin the search may be based on a known oncogene (such as H-rax), a known functional gene (for example, the
oestrogen receptor gene) or the site of a specific chromosomal abnormality. Alternatively, chance may provide the
initial guide.
In breast cancer, several specific alterations in DNA or gene expression (mRNA or protein) in the tumour have
been demonstrated. Somatic changes in tumour DNA fingerprints have been demonstrated using mini-satellite probes
(Thein et al., 1987), and surveys of gene amplification (Masuda et al., 1987) and oncogene expression (Whittaker
et al., 1986) have led on to more detailed studies.
A variety of experimental approaches have been used to detect genes capable of contributing to a malignant
cellular phenotype in a dominant fashion at the cellular level, known as oncogenes. The normal human genome
contains homologous sequences (proto-oncogenes) which can be activated in different ways to produce oncogenes.
The oncogene c-myc on chromosome 8 (q24) is amplified in 20-30% of primary breast cancers (Escot and Theillet,
1986; Varley et al., 1987), and this is seen significantly more frequently in patients over 50 years of age at diagnosis
(Escot and Theillet, 1986). In the original series no other association was found, but a later study identified amplified
c-myc as a poor prognostic factor, being associated with early disease recurrence or death (Varley et al., 1987).
However, the significance of myc DNA amplification, as opposed to high levels of expression of the gene seen in
up to 80% of breast cancer patients (Kozbor and Croce, 1984; Lee et al., 1984), remains an unresolved question.
A better correlation between DNA amplification and level of gene expression has been found in studies on another
oncogene, erb B-2 on 17q (Coussens et al., 1985). Eighteen percent of primary tumours contain amplified erb B-2
(Slamon et al., 1987), but 40% of patients who are lymph-node-positive at presentation have tumours with an
amplified erb B2 gene (Slamon et al., 1987) and in this subgroup there is a strong association between erb B-2
amplification, a shorter disease-free interval and early death (Slamon et al., 1987, 1989; Wright et al., 1989).
Another oncogene, Int2 on 1 lql3 (Casey et al., 1986), is amplified in a small subset of tumours characterized by
very aggressive growth leading to early death despite intensive chemotherapy (Zhou et al., 1988). The current
evidence therefore suggests that specific oncogene amplification occurs in a subgroup of primary tumours biolog¬
ically more aggressive than the majority of breast cancers.
High levels of Ha-rax, a gene which encodes a protein p21 involved in signal transduction, have been found in
the majority of breast tumours (Horan-Hand et al., 1984). Although activating mutations of Ha-rax are probably rare
in breast cancer (Rochlitz et al., 1989), a concentration-dependent effect of p21 on tumorigenicity (Redmond et al.,
1988) and elevated Ha-rax mRNA levels in malignant compared to normal breast tissue (Spandidos and Agnatis,
1984; Slamon et al., 1984) have been demonstrated. Ha-rax may be involved in the metastatic phenotype (Agnatis
et al., 1986; Lundy et al., 1986). Certainly, in the experimental setting v-Ha-ras transfection induces oestrogen-
independent tumorigenicity in previously oestrogen-dependent MCF-7 cells (Kasid et al., 1987), suggesting that
Ha-rax is involved in progression rather than initiation of breast cancer.
Other oncogene abnormalities have been reported less frequently. A rare c-mos polymorphism has been described
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in breast cancer patients (Lidereau et al., 1985); amplification of myb (Masuda et al., 1987); overexpression offes
and fms (Slamon et al., 1984) and elevated c-fos expression (Biunno et al., 1988) are also recorded.
The concepts of tumour-suppressor genes and oncogenes are discussed elsewhere in this Supplement. It is
sufficient to point out here that some genes (tumour-suppressor genes) appear to be involved in the inhibition of
malignancy. The normal functions of such genes may be related to cell differentiation, growth control and genome
stability. However, only one, the retinoblastoma gene, has been isolated and cloned to date and its function is still
not entirely clear.
The use of highly polymorphic DNA probes to detect chromosomal lesions below the limit of visible resolution,
but involving deletion or inactivation of particular genes, has permitted identification in primary breast tumour cells
of at least 3 areas of the genome likely to be of fundamental importance. The first is on chromosome lip. Allelic
loss of the Harvey ras locus at 1 lpl5 is found in 20-27% of human primary breast tumours (Mackay et al., 1988a;
Theillet et al., 1986) and is reported to be associated with low oestrogen receptor status (Mackay et al., 1988a;
Lidereau, 1988) larger tumour size (Mackay et al., 1988a) and high histological grade (Lidereau, 1988), suggesting
that it could be taken as a feature of poor prognosis. However, more detailed examination of several loci on 1 lp has
confused rather than clarified the picture in that it has not been possible to identify a single segment of the
chromosome arm that is lost consistently. Lesions were found on 1 lp in about 50% of a small series of tumours fully
characterized for 6 loci (Mackay et al., 1988a).
The second potentially important locus is on 13q, which contains the first tumour-suppressor gene to be identified,
the retinoblastoma (Rb) gene (Cavenee et al., 1985). Forty percent of ductal tumours have allelic loss at 13q
(Lundberg et al., 1987), and rearrangements at the retinoblastoma locus have been found in 19% of primary breast
tumours (Varley et al., 1987) although the significance of these findings, in terms of prognosis for individual
patients, remains unclear.
The third important locus is on 17p. Recent studies have demonstrated allelic loss at the locus identified by a
highly polymorphic sequence YNZ22 in up to 60% of breast tumours (Mackay et al., 1988b; Devilee et al., 1989).
Initially, no significant clinical or pathological associations were found (Mackay et al., 1988£>) but a larger series has
identified a correlation between YNZ22 allelic loss and low oestrogen receptor status (Thompson et al., 1990). These
findings have been extended by studies on p53, a gene located on 17p (Isobe et al., 1986). It can evidently behave
either as an oncogene or a tumour suppressor, depending on whether its structure is normal or mutant (Green, 1989).
p53 protein is also expressed in 15—25% of breast tumours (Cattoretti et al., 1988), and a high level of p53 mRNA
has been found in 30% of primary tumours (Thompson et al., 1990). There is a significant association between a high
level of p53 mRNA and YNZ22 allelic loss, raising the possibility that a p53-controlling element on 17p has been
lost in some breast tumours.
Another important locus appears to be the ataxia-telangiectasia gene (11 q22—24; Gatti et al., 1988) since female
carriers of the A-T gene have an increased risk of breast cancer (Swift et al., 1987).
Failure to express oestrogen receptor has been associated with absence of an oestrogen-receptor DNA allele (Hill
et al., 1989) and an ER protein/ER mRNA ratio of >1.5 correlates with short time to relapse in ER-containing
tumours (May et al., 1989). The oestrogen-regulated mRNA pS2 (Masiakowski et al., 1982) correlates closely with
the effects of oestrogen on cell proliferation (Johnson et al., 1989).
Multiple molecular lesions in individual tumours
The techniques used for defining changes at specific genetic loci are so much more sensitive than conventional
cytogenetics that is has been possible to demonstrate a series of consistent DNA lesions present in many primary
breast tumours. These lesions are very unlikely to be mutually exclusive, and it is probable that malignant cells
accumulate 2, 3 or more of them in the course of tumour evolution as has already been demonstrated in colorectal
cancer (Vogelstein et al., 1989).
Thus, in breast cancer, it appears that some combination of oncogene over-activity (as demonstrated by activation,
amplification or over-expression) and loss of tumour suppressor function (by mutation, deletion or reduced expres¬
sion) occurs as the underlying mechanism for breast carcinogenesis. However, the number of lesions required, the
order in which they occur and the relationship of these multiple steps to tumour progression and metastasis remain
unknown.
Future studies
Identification of the breast cancer genes or DNA sequences
Indentification of the actual genes or DNA sequences of fundamental importance will come from more detailed
mapping studies in tumours.
This is the approach that led to isolation of the Rb gene and is currently homing in on the adenomatous polyposis
coli "ape" gene, implicated in colorectal cancer and located on chromosome 5q. If a particular locus is shown to
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be lost in a high proportion of breast tumours, this will be very strong evidence that it is the site of a crucial
tumour-suppressor gene. Careful analysis of tumours at different stages in the natural history of the disease from
carcinoma in situ right through to metastatic deposits will be required to elucidate the sequence of molecular events
that underlies initiation and progression of breast cancer.
A different approach, which can contribute to the mapping of "breast tumour genes" is the application of linkage
analysis to families with a high incidence of breast cancer. A preliminary study on one large family in Edinburgh
has recorded an inconclusive lod score (+ 1.8 at 0 recombination) for YNZ22, but no linkage was observed between
heritable breast cancer and the Harvey ras gene. More extensive studies on 13q have also produced negative results
but the major part of the human genome has yet to be surveyed.
Ultimately the question must be asked "what contribution can molecular analysis make to the prevention and/or
treatment of breast cancer'' The immediate prospect is that the prognosis for individual patients may be defined much
more precisely and hence that the choice of aggressive or relatively conservative management may be made with
more confidence. In the longer term we can envisage a much more profound understanding of the process of
carcinogenesis which should open up the prospect of completely new approaches to treatment. It would, however,
be misleading to suggest that gene therapy {i.e., direct manipulation of the genome of malignant cells) will have a
place in the foreseeable future. The problem of inducing a targeted change in the DNA of every tumour cell appears
insurmountable, on the basis of current knowledge, and anything less would be bound to fail. It is more realistic to
anticipate the identification of new biological pathways providing opportunities for specific and effective pharma¬
cological intervention.
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SHORT COMMUNICATION
Constitutional p53 mutation in a non-Li-Fraumeni cancer family
J. Prosser', D. Porter', C. Coles', A. Condie1, A.M. Thompson2, U. Chetty3, C.M. Steel' &
H.J. Evans'
lMRC Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU;2Department of Surgery, Raigmore Hospital,
Inverness IV2 3UJ; 3Department of Surgery, Royal Infirmary, Edinburgh EH3 9YW, UK.
Two recent reports have described inherited mutations in p53
associated with the predisposition to develop early cancers
(Malkin et al., 1990; Srivastava et al., 1990). These germ-line
mutations were found in affected members of families with
the Li-Fraumeni syndrome in which soft-tissue sarcomas in
related children were associated with cancers of the breast
and other organs among parents and relatives (Li & Frau-
meni, 1969). In addition, a germ-line mutation in p53 has
been identified in a 5-year-old patients with an intra-cranial
malignancy and a strong family history of cancer (Metzger et
al., 1991). Finally, there are a further ten constitutional
mutations reported for the Li-Fraumeni syndrome in a
recently complied list of p53 mutations (Caron de Fromentel
& Soussi, 1991). We now report a germ-line mutation of p53
in a non-Li-Fraumeni cancer family.
We detected a constitutional mutation in p53 while using
the HOT technique (hydroxylamine/osmium tetroxide modi¬
fication of mismatched basepairs (Cotton et al.. 1988; Prosser
et al., 1990, 1991)) to screen for alterations in this gene in a
series of sporadic breast tumours. In one of these patients the
p53 mutation was present in both the tumour and white
blood cell DNA. This is an incidence of one in 136 patients,
or 0.7%. Sequencing confirmed that both normal and mutant
alleles were present in each sample. Interestingly, the tumour
DNA showed loss of heterozygosity with the probe YNZ22
but no loss with pBHp53. The mutation is in exon 8 at
codon 267 (Figure 1), changing arginine to glutamine, a basic
to an uncharged amino acid. The mutation lies in the general
region of previously published germ-line mutations in the p53
gene (amino acids 242-307, Malkin et al., 1990; Srivastava et
al., 1990; Metzger et al., 1991; Caron de Fromental & Soussi,
1991), although, unlike the majority of these mutations, it is
not found in the conserved regions of the gene (one in region
III, 13 in region IV and three in region V), but lies between
conserved regions IV and V at an arginine codon which is
invariant in all species studies (Xenopus, trout, chicken, rat,
mouse, human) (Soussi et al., 1989). The remaining codon at
position 307 does not lie within a conserved region of the
gene but is invariant in mammals. In data collated by Holl-
stein et al. (1991) which included 280 base substitutions
distributed over 90 codons of the p53 gene, codon 267 was
not reported mutated. In approximately 350 single base alter¬
ations in 93 codons collated by Caron de Fromentel and
Soussi (1991) codon 267 was once reported mutated from
CGG to CCG. The mutation we report is CGG to CAG.
Family studies and examination of medical records showed
that the patient is indeed a member of a cancer family, but a
family in which the age of onset of malignancy is not re¬
markably early (Figure 2). Information is available for a five
generation pedigreefn which it would appear that the consti¬
tutive mutation was either present five generations ago or
arose as a germ-line mutation at that time. There are four
recorded cancer deaths in the pedigree: breast cancer at age
53, breast cancer at age 67, lung cancer at age 66, ovarian
cancer at age 63. The proband is alive with breast cancer at
age 53. We have found the mutation in the proband, in her
sister who is unaffected by cancer at age 37 years, and in a
first cousin of the mother of the proband who is alive and
unaffected by cancer at age 74 years. We have not been able
to PCR archival material from the mother's lung tissue
(which had been preserved in Bouin's fixative) and have
therefore been unable to show the mutation in this woman
who would appear to be an obligate carrier of the mutation.
Because the mutation is found in a 74 year old cancer-free
relative of the proband, it would be difficult to argue that the
mutation segregates with affected family members in the
pedigree, while being absent from unaffected relatives. What
we can say is that we have found a constitutive p53 mutation
in the proband of a cancer family in which a variety of
cancers have been noted over three generations. The muta¬
tion has been looked for and is present in two other family
members, neither of whom has developed cancer. There are
no cases of childhood or early cancer in this five generation
pedigree. No member affected by cancer had remarkably
early onset of the disease (at ages 42, 49, 53, 63 or 67 years),
and, indeed, one member of the pedigree with the mutation
remains unaffected in her 8th decade.
At the time of discovery of the Li-Fraumeni constitutive
mutations, the median age of tumour development in affected
family members was noted to be approximately 30 years and
it was argued that the mutations were, from the cell's point
of view, weak mutations (Vogelstein, 1990). Judging by the
observed age of onset of disease in affected family members
and by the absence of disease in a 74 year old carrier of the
mutation, the mutation at codon 267 in this family is even
weaker. It may be relevant to note that at least one parent
and one grandparent in the six families originally reported to
possess a constitutional p53 mutation were themselves
obligate carriers of the respective mutations but had not
developed cancer (Malkin et al., 1990).
It may be expected that mutations in p53 which are com¬
patible with viability and normal early development must be
'weak' mutations which confer only a small growth advan¬
tage to the cell and which cannot act as dominant negative
mutations. On the other hand, no such constraint is imposed
on the somatically acquired mutations in tumours which
might be expected to show a greater variation and include
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Figure 2 Five generation pedigree showing incidence of cancer
(black circles). Numbers below circles represent age at which
cancer was diagnosed, age at death, current age, as appropriate.
Arrow indicates the proband. Individuals tested for the p53
mutation are shown as wt/267 (carriers) and wt/wt (non-carriers).
'strong" mutations conferring considerable growth advantage.
There is evidence (Milner & Medcalf, 1991) for the 'strength'
of only one of the constitutionally mutated codons, 248,
where a CGG->TGG mutation does not behave in a
dominant-negative way when co-translated in vitro with wild-
type p53 protein. This contrasts with the in vitro demonstra¬
tion of the dominant-negative effect of proteins carrying
various other sporadic mutations. Milner and Medcalf also
looked at mutations at codon 273 (CGT->CCT and CGT-
>CTT) but did not investigate the particular recorded con¬
stitutional mutation at this site (CGT->CAG).
If we look at the overall frequency of total recorded
mutations in those codons of p53 found constitutionally
mutated (181, 242, 245, 248, 252, 258, 273, 282, 286, 307 and
now 267), it is apparent that four of the sites are hyper-
mutable (codons 245, 248, 273 and 282) where mutations
account for approximately 25% of all those recorded in the
p53 gene, codon 248 accounting for greater than 10% on its
own (Caron de Fromentel & Soussi, 1991). Each of these
sites contains a CpG dinucleotide (245 contains half a CpG
dinucleotide) and 77% of the recorded mutations involve
C->T changes at the CpG configuration. Although there is
an under-representation of CpG dinucleotides in the verte¬
brate genome (Sved & Bird, 1990), "ft is known that 60-90%
of them are methylated (Bird, 1986) and it is generally
accepted that methylcytosine mutates at a high rate to
thymine (Coulondre et al., 1978). This type of spontaneous
mutation, which occurs at 12 times the normal transition
rate (Sved & Bird, 1990), is responsible for a high proportion
of all p53 mutation found at these four hypermutable
codons.
If we look only at the recorded constitutional mutations,
half (10/19) occur at the four frequently mutated codons and
nearly all of these (8/10) involve C->T mutations. Of the
remaining nine (at codons 181, 242, 252, 258, 267, 286 and
307), two involve C->T changes at CpG dinucleotides.
Three are at sites so far unique to constitutional mutations
(181, 252) and the remaining six are at sites which are
infrequently mutated (242, 258, 267, 286 and 307) and where
the constitutional changes alone account for 53% of the
recorded mutations.
In summary, more than half (10/19) of all constitutional
p53 mutations appear to be spontaneous C->T changes at
CpG dinucleotides and are frequently found at hypermutable
sites (8/10). The codons of the remaining constitutional
mutations are only infrequently mutated and have no consis¬
tent mutational pattern. (Five are C->T [G->A] in non-
CpG dinucleotides, two are T->C [A->G], one is A->C
[T->G], constituting seven transitions and one transversion,
and one is loss of a single base.) The particular changes at
the constitutional p53 mutations so far recorded are therefore
consistent with the conclusion that endogenous spontaneous
mutation could account for these events. The data are still
too sparse to discuss 'hotspots' for constitutional mutations,
but two codons (245 and 248) are responsible for eight of the
19 changes (42%). These are frequently mutated codons of
the p53 gene in any case and are responsible for about 13%
of all recorded mutations in the gene.
The authors would like to thank Mrs Rhona De Mey of the MRC
Human Genetics Unit registry for construction and verification of
the pedigree. Calculations of incidence of specific mutations in the
p53 gene used data from Caron de Fromentel and Soussi (1991).
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abstract
We have identified and analyzed 41 mutations in p53 in sporadic
breast tumors from 136 unselected breast cancer patients and estimate
that approximately 40% of such tumors contain p53 mutations. The
frequency of G-T transversions and the incidence of guanosine muta¬
tions in the nontranscribed strand of the pS3 gene were found to be
higher than expected, and we suggest, therefore, that exogenous carcin¬
ogens have an etiological role in sporadic breast cancers. Mutations
wer ■ recorded in 44 codons of the p53 gene, with no obvious mutational
hot-spots, although mutations at codons 175, 194, 273, and 280 ac¬
counted for 25% of the changes. One germ-line mutation was found in
136 patients and so we conclude that constitutional mutation ofp53 may
be an uncommon etiological factor in breast cancer.
introduction
For female nonsmokers, cancer of the breast is the most
important malignancy in Western society, and by the age of 75
ap proximately 10% of women in the United States will have
developed the disease. There is evidence for a genetic contribu¬
tion to the risk of developing breast cancer, as well as an asso¬
ciation with modern affluence (diet and alcohol consumption).
In addition, the influence of reproductive factors supports a
hormonal role in the etiology of the disease (1,2). Breast cancer
is, however, a heterogeneous disease (3) and for this reason
linkage studies to pinpoint a genetic locus or loci responsible
for the inherited suceptibility have been beset with difficulties.
Studies on LOH3 in sporadic breast tumors have shown loss of
genetic material at a number of loci including lq, 3p, 6q, 16q,
17p, and 18q in >50% and at lp, 7q, 8q, 9q, 1 lq, 13q, 15q, 17q,
and 22q in >30% of tumors (4-17), suggesting the possible
involvement of a number of tumor suppressor genes. In addi¬
tion, several oncogenes (myc, neulHER-2/c-erbB-2, and int2)
have been implicated in the development of the disease (re¬
viewed in Refs. 18 and 19). The etiology of breast cancer is,
therefore, complicated both by disease heterogeneity and by the
number and variety of genetic changes which appear to be im¬
portant. However, one gene which is clearly involved in the
development of both sporadic and some hereditary breast tu¬
mors is p53 (20-34), a gene which in its unmutated form be¬
haves as a tumor suppressor gene but which in at least several
mutant forms acts as an oncogene (35).
Mutations in the p53 gene are the most common genetic
alterations in all human cancers (35, 36) and have been found at
numerous sites in >100 of the 393 amino acids that comprise
the protein (37, 38). Such a variety of mutations has permitted
inalyses for significant differences in the mutational spectra
jetween different cancers (37) and has led to the postulation of
itiological roles for particular mutagens, e.g., the role of afla-
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toxin B1 and the hepatitis B virus in the G-T transversion of
p53 codon 249 in hepatocellular carcinomas from southern
Africa and east Asia (39, 40). The nature ofmolecular change is
often specific for a given mutagen, e.g., UV light predominantly
causes cyclobutane dimers (41) and TV-methylnitrosourea pro¬
duces G-A transitions (42). The nature of the mutations in p53
may, therefore, point to the mutagen(s) involved. In skin can¬
cers p53 mutations at dipyrimidine sites (43) were indicative of
the role of UV light, and in lung and esophageal cancers base
pair changes in p53 were characteristic of those produced by
mutagens in tobacco and alcohol (44). The spectrum of muta¬
tions in radon-associated lung cancer in uranium miners is dif¬
ferent from that usually seen in lung cancers and may reflect the
genotoxic effects of radon (45). p53 mutations in colon cancer
are characterized by a very high incidence of C-T changes,
mainly at CpG dinucleotides (37), although etiological reasons
for this have not been advanced.
We have estimated the incidence of p53 mutations in two
series of sporadic breast tumors, based on mutation detection
by the HOT detection technique (46). Using our own data on
137 tumors and published results of others, we discuss the
overall incidence of p53 mutations in sporadic breast tumors,
the nature of these mutations, and their possible etiology. We
have compared the spectrum of p53 mutations in sporadic
breast cancer with the germ-line mutations found in the Li-
Fraumeni syndrome and with similar analyses in colon and
other tumors.
MATERIALS AND METHODS
Tumor samples were collected from patients undergoing Patey mas¬
tectomy or wide local excision. All patients had presented with palpable
breast lumps and had been referred by their general practitioners to the
breast clinic in the Royal Infirmary of Edinburgh. Patients with T4
tumors or with distant metastases at presentation were excluded, be¬
cause they were usually treated by chemotherapy in the first instance.
Two sets of tumors resulted from serial admissions collected by two
successive surgeons. All DNA preparations were made from whole
blood or tumor tissue by standard techniques. PCR amplification, se¬
quencing of PCR templates, and the HOT technique (HA and osmium
tetroxide modifications) were carried out as previously described
(21, 47). Scanning for mutations in exons 5 and 6 of the first 60-tumor
set (mutations 1-8; Table 1) was carried out using HA modification
only and labeled wild-type DNA; for mutations in exons 7, 8, and 9 of
the 60-tumor set (mutations 9-16) both HA and Os04 modifications
and labeled wild-type DNA were used. This was also done for exons 5
and 6 of the second 77-tumor set (mutations 17-32). HA and Os04
modifications and both wild-type and potential mutant labeled DNAs
were used for exons 7-9 in the 77-tumor set (mutations 33-41); there¬
fore, these fragments were scanned twice to ensure that all mutations
were detected. The exact mutation in each instance was determined by
direct sequencing of independently amplified PCR fragments. The leu¬
kocyte DNAs from patients with tumors carrying p53 mutations were
subsequently checked for germ-line mutations.
When estimating the frequency ofp53 mutations in breast tumors, a
problem arises regarding the counting ofmultiple tumors from a single
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Table 1 p53 mutations found in 137 sporadic breast tumors, with LOH results for the same samples
LOH
Mutation Tumor Nucleotide Protein
no. no. Codon change change BHp53 MCT35 YNZ22
1 8 164 AAG—'CAG Lys—Gin U U L
2 21 136" CAA—GAA Gin—Glu L U N
3 32 187° GGT—TGT Gly—Cys L U L
4 34 175 CGC—CTC Arg—Leu L u U
5 36 201 TTG—TT- Frameshift U N L
6 43 179 CAT—-GAT His—Asp L L L
7 51 152 CCG—TCG Pro—Ser N L U
8 85 157 GTC—TTC Val—Phe U L
9 4 250 CCC—GCC Pro—Ala N L N
10 8 265 CTG-CCG Leu—Pro U U L
11 9 281 GAC—GGC Asp—Gly N L L
12 20 307 GCA—ACA Ala—Thr L L L
13 33 283 CGC-CCC Arg—Pro U N
14 47 280 AGA—GGA Arg—Gly N U L
15 57 242 TGC—TTC Cys—Phe L L L
16 80 267 CGG—CAG Arg—Gin N U L
17 8 208 GAC—GTC Asp—Val — — —
18 10 194 CTT—CGT Leu—Arg — — —
19 11 140 GAC—G-C Frameshift — —
20 18 179 CAT—TAT His—Tyr L U L
21 21 192 CAG—TAG Gin—Stop L L L
22 25 186 GAT—TAT Asp—Tyr — — —
23 34 182 TGC-TGA Cys—Stop U L N
24 36 178 CAC-CCC His—Pro U U L
25 57 175 CGC—CAC Arg—His L L
26 64 213 CGA—TGA Arg—Stop N U L
27 67 163 TAC—AAC Tyr—Asn U U L
28 71 141 TGC—TAC Cys—Tyr — — —
29 72 194 CTT—CGT Leu—Arg L u
30 95 213 CGA—TGA Arg—Stop U u L
31 113 194 CTT—CGT Leu—Arg — — —
32 114 175 CGC—CAC Arg—His — — —
33 8 285 GAG—AAG Glu—Lys —
34 12 276 GCC-CCC Ala—Pro — —
35 61 273 CGT—CAT Arg—Leu — — —
36 84 273 CGT—CTT Arg—Leu — — —
37 88 237 ATG—ATT Met—lie — —
38 92 255 ATC— lie—Del u — —
39 98 239 AAC—GAC Asn—Asp N u —
40 101 245 GGC—GAC Gly—Asn L u L
41 110 282 CGG—CTG Arg—Leu — — —
a Thompson et al. (32) give incorrect sequence changes for mutations at codons 136 and 187. In addition, no mutations were found in tumors 65 and 81 (codons 194
and 67) of their list. L, loss; N, no loss; U, uninformative; —, not done.
individual. If multiple tumors unequivocally represented multiple
primaries, then, for the purposes of estimating mutation frequency,
each tumor would be considered independently. But differentiating be¬
tween multiple independent primaries and multiple deposits of a single
primary is difficult. We consequently made the following decision: six
of the 136 patients had multiple tumors (total of 14 tumors); in five
individuals the p53 mutation status of each of the multiple tumors was
identical and these were, therefore, counted as five tumors in total; in
one individual with two tumors, one tumor contained mutant p53 and
one did not, and these were counted as two separate tumors.
RESULTS AND DISCUSSION
Incidence of p53 Mutations in Sporadic Breast Cancer. We
have found 41 mutations in sporadic tumors from 136 unse-
lected breast cancer patients (137 tumors, as detailed in
"Materials and Methods"). The precise codon alterations are
listed in Table 1 and sequence data on a number of mutations
are shown in Fig. 1. Two tumors contained two independent
mutations. In a separate study,4 it was determined that the
HOT technique as used (see "Materials and Methods") detects
90% of all mutations. For the purpose of estimating mutation
frequency, we consider only the second 77-tumor set, in which
25 tumors (31%) contained mutations in exons 5-9 of the p53
4 Condie, A., Eeles, R., Bdnreseu, A-L., Coles, C., Cooper, C., and Prosser, J.
Detection of point mutations in the p53 gene: comparison of SSCP, CDGE, and
HOT, submitted for publication.
gene. An allowance for the incomplete detection of mutation
suggests a probable frequency closer to 36%.
Our study does not take into account the total number of
possible mutations in the entire p53 gene. In collated published
data regarding alterations to p53 in a wide variety of cancers
(38), 6% of all mutations (22 of 368) were recorded outside
exons 5-9, in exons 1-4, 10, and 11 and in introns 3, 4, 5, 6, 7,
and 9, despite a heavy bias in the literature against analyzing
these regions. The 6% of mutations found outside exons 5-9
could, therefore, be a notable underestimate. Although few such
studies have been undertaken, the sequencing of several entire
p53 cDNA copies in a variety of tumors and tumor cell lines did
not reveal mutations which lie outside this region (20, 48-50).
In addition, although we have included introns 5, 7, and 8 in the
PCR fragments of our survey, we have found no splicing mu¬
tations in 137 tumors. If approximately 10% of all p53 muta¬
tions lie outside.exons 5-9, then the incidence of mutation in
the entire p53 gene in sporadic breast tumors must be on the
order of 40%. This estimate is in accord with, and extends,
published findings on smaller series using nonimmunohis-
tochemical methods (single-strand conformation polymor¬
phism, HOT, constant denaturing gel electrophoresis, etc.) for
mutation detection (see Table 2).
Published estimates of mutations detected by immunohis-
tochemical techniques suggest that on the order of 60% of
sporadic breast tumors have mutations in the p53 gene (23, 27,
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Fig. 1. Sequencing data for 10 tumors in which the relative contributions of normal and wild-type alleles can be assessed. For example, in tumor 8 the amount of
wild-type DNA is greater than that ofmutant DNA, in tumor 61 the amount ofmutant DNA is greater than that ofwild-type DNA, and in tumor 57 only mutant DNA
is present.
Table 2 Proportion ofsporadic breast tumors with mutations in the p53 gene (nonimmunohistochemical methods ofdetection)
Using DNA-based methods of mutation detection [constant denaturing gel electrophoresis (CDGE), (single-strand conformational polymorphism (SSCP),
HOT, direct sequencing], various regions of the p53 gene in breast tumors have been examined. The incidence of mutations has been compared in exons 5-8. In
order to compare these estimates with those achieved by antibody staining, we have estimated mutation incidence in the entire p53 gene (see text).
Estimated Estimated
Tumors Tumors with Exons Reported mutations in mutations in all
Method examined mutation studied mutations (%) exons 5-8 (%) exons (%) Ref.
HOT 77 25 5-9 32 36a 40 This paper
HOT 60 16 5-9 27 33" 37 21, 32
CDGE 32 10 5, 7, 8 31 34c 38 29
SSCP 24 9 5-8 38 42 30
SSCP 59 10 5-9 17 19 31
PCR 11 4 5-9 36 36 28
RNase protection 26 3 Entire gene 12 30
PCR 59 21 2-11 36 31
a If 25 represents 90% of mutations present, then 28 mutations would be the probable actual incidence in these 77 tumors (36%) (see text).
b Prosser et al. (21) used the HOT technique with HA modification and wild-type labeled DNA. This theoretically detects 50% ofall possible mutations but in sporadic
breast tumors, where 74% of mutations occur in GC base pairs, approximately 70% are detected. Therefore, the 8 mutations found in exons 5 and 6 would represent 11
probable mutations. The HOT technique with wild-type DNA labeled using both HA and Os04 modifications detects 90% ofmutations.4 Consequently, the 8 mutations
found in exons 7, 8, and 9 (32) would represent 9 probable mutations, giving a total of 20 probable actual mutations in the 60-tumor set (33%).
c Exons 5, 7, and 8 were studied. Mutations in exon 6 account for 13% ofp53 mutations recorded between exons 5 and 8 in all cancers surveyed (38). This estimate
has, therefore, been adjusted to include potential exon 6 mutations.
51, 52). Immunohistochemical staining uses p53-specific anti¬
bodies which recognize various epitopes on the p53 protein.
The increased stability of many mutant p53 proteins permits
their detection in tissue sections with antibodies such as
pAb421, pAbl801, and polyclonal CM-1. Antibody pAb240
specifically recognizes an epitope characteristic ofmany mutant
proteins (53).
There is clearly a serious discrepancy in the estimates of
mutation based on the two sorts of technique, one an analysis at
the DNA level (~40%) and the other at the protein level
(—60%). This might suggest that sampling bias in the DNA
studies may be greater than estimated and that >10% of muta¬
tions may occur outside exons 5-9. On the other hand, the
assumption that detection of expression of p53 protein means
overexpression of mutant as opposed to wild-type protein may
be open to question. Indeed, some tumorigenic cell lines over-
express wild-type p53 (54), and it is known that there are dif¬
ferences in p53 protein levels due to factors affecting differen¬
tiation (55) and cell cycle progression (54). Moreover, in four
undifferentiated neuroblastoma-derived cell lines high-level ex¬
pression of a stable, apparently wild-type, protein was found
(56). It is of course possible that a gene outside the p53 locus is
involved in the increased half-life of some proteins. Milner and
Watson (57) observed that the wild-type murine p53 protein
could be expressed in a form immunologically similar to a
mutant protein, within 1 h after addition of fresh growth me¬
dium. If their observations hold true in human material, it is
possible that not all the p53 which stains with mutant-specific
antibody is mutant. Interestingly, the temperature-sensitive p53
mutant (Val-135) fluctuates between normal and mutant pro¬
tein conformation depending on the growth temperature (58).
Overall, there would appear to be good reason to question the
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assumption that elevated expression of p53 is synonymous with
expression of mutant p53.
Notwithstanding the qualifications given above, in studies of
24 positively staining breast tumors and cell lines known to
overexpress mutant p53, 22 were shown to possess mutations in
the gene (22, 24, 25, 27, 29), and similar findings have been
reported for tumors and cell lines of lung, colon, ovary, and
esophagus (44, 59-62). In fact, there are a number of reasons to
suppose that some mutant p53 genes would be undetected by
antibody staining, i.e., those with stop codons truncating the
gene before the recognized epitope, those with deletions of both
alleles, and those with protein degraded by the human papillo¬
mavirus E6 protein. Some investigators have, indeed, found
mutations in negatively staining material (29, 44, 60). At
present, therefore, in the absence of direct comparison within a
large series of mutations detected both at the DNA level and at
the protein level, it is unclear whether DNA studies underdetect
mutations or antibody-staining techniques overdetect them.
Relationship between p53 Mutation and LOH on Chromo¬
some 17p. The p53 gene is located at 17p 13, and data on p53
mutation and LOH for this region can indicate a temporal
order for the two events in tumor development. Our results
show that, of 20 tumors which are both mutant at the p53 gene
and informative for markers at BHp53 or MCT35 (loci near
p53), 75% show LOH (Table 1) and may conform to the se¬
quence of events of mutation in p53 followed by loss of the
normal allele on the partner chromosome. This value is similar
to those found in other breast cancer studies also using markers
near the p53 gene (24, 29, 30). Evidence for two independent
loci showing significant LOH on the short arm of chromosome
17, one at 17pl3.1, the site of p53, and one more telomeric to
this at 17p 13.3, has been found in a number of cancers includ¬
ing breast (8, 11), liver (63), and kidney (64). Unless the pattern
of genetic loss on 17p has been shown to involve only one locus,
as is the case with colon cancer (48), LOH over the p53 gene
cannot be assumed by loss at a more telomeric site (e.g., that
defined by the probe YNZ22).
Several investigators have directly addressed the question of
the presence or absence of a wild-type allele in tumors contain¬
ing a mutation in p53, using sequence data or single-strand
conformation polymorphism autoradiographs. Since whole tu¬
mor DNAs from our breast tumor series were PCR amplified
and sequenced with no consideration for the relative amounts of
tumor and normal tissue in each of the samples, in many in¬
stances it was difficult to determine whether the mutations in
p53 were accompanied by loss of the wild-type p53 allele. In our
77-tumor series, sequencing data showed that the mutant allele
was at least twice the intensity of the wild-type allele in 11 of the
25 mutations, evidence that, in the tumor tissue, the mutant
allele was accompanied by loss of the normal allele. In the
remaining 14 mutations, however, the wild-type allele was ei¬
ther equal to or greater than the mutant allele in intensity. In
the literature, a high proportion of homozygous or hemizygous
mutations in breast tumors and cell lines has been found
(24, 28, 30, 31), and a similar high proportion of homo/hemi-
zygosity pertains to tumors of the ovary, brain, liver, lung,
uterus, and gut, as well as leukemia (39, 65-71). In the two
tumors containing two independent p53 mutations, no LOH
data are available; neither is it known if the mutations are on
separate alleles.
While in a proportion of sporadic breast tumors, as in colon
cancer (20, 48, 72), p53 mutation may occur before loss of the
wild-type allele, there are a substantial number in which loss is
not accompanied by mutation. Of 34 tumors in our series with
LOH near the p53 gene 56% apparently have only normal p53
DNA, suggesting that in many tumors loss of the normal wild-
type allele may occur without concomitant p53 mutation. Other
studies with similar results (20, 24, 30, 48, 70) suggest several
possible explanations for this: that loss on 17p may be a ran¬
dom or nonselective loss, that the screening technique used may
not have detected the corresponding p53 mutation, that p53
mutation may occur outside the region screened, that there may
be a dosage effect such that 50% dosage ofp53 confers a selec¬
tive growth advantage to the cell, or, finally, that the allele loss
may involve a second tumor suppressor gene.
Mutation of one copy of p53 and loss of the wild-type allele
conform to Knudson's two-hit hypothesis of tumor suppressor
genes, and our results support the role of p53 as a tumor sup¬
pressor gene in a number of breast tumors. Nevertheless, it
should be remarked that we, and others (25, 30), have found
evidence for a proportion of tumors with p53 mutation and no
concomitant loss of the remaining wild-type allele (five in this
study with no LOH of adjacent 17p markers). It is known that
certain mutant forms ofp53 behave as oncogenes (73-75), and
it would be interesting to address the question of whether
strongly oncogenic mutations require no loss of the wild-type
p53 allele in order to effect a growth advantage, while mutations
which are either weakly oncogenic or not oncogenic (simply
loss of function) need to be associated with loss of the normal
allele. The relative oncogenicity of only a few mutant p53 genes
has been determined. Hinds et al. (73) and Halevy et al. (74)
have compared different mutant p53 genes for their ability to
transform primary embryo rat cells in culture. Milner and Med-
calf (75) have compared mutant p53 genes for their ability to
drive wild-type p53 into the mutant conformation. From these
studies, a number of mutations have been catergorized as
strongly oncogenic (Phe-132, Val-135, Ser-151, His-175, Ile-
247, and Pro-273) or weakly oncogenic (Trp-248, Cys-270,
His-273, and Gly-281). Only two samples from our breast tu¬
mor series contain mutations of tested oncogenicity. Tumors 25
and 32 (Table 1) both have the 'strong' His-175 mutation and
so might be expected to have retained the wild-type p53 allele,
but tumor 25 shows LOH at BHp53 and MCT35.1 and se¬
quencing data show complete and partial loss of the wild-type
allele in tumors 25 and 32, respectively.
Analysis of the p53 Mutational Spectrum in Sporadic Breast
Tumors. A total of 84 mutations in sporadic breast tumors
from our series and from the literature are listed in Table 3.
When the specific types of mutations are analyzed (Table 4),
there are some notable observations. There is an excess of point
mutations at G/C base pairs (75%). (The overall content of
GC in the p53 gene is 56%.s) It is possible that 50% (42 of 84)
of all breast tumor mutations are point mutations occurring at
guanosines in the noncoding strand. This bias is seen in GC-
CG, GC-AT, and GC-TA mutation events, although it is most
pronounced for GC-TA transversions (14 of 16 or 88%). Eleven
of 14 GC-AT transitions at CpG dinucleotides may be more
realistically viewed as C-T alterations in the coding strand, but
the remaining 31 of 84 mutations (37%) which could have
occurred at guanosines in the noncoding strand are in excess of
expectation. This is significant in view of the fact that the
nucleoside guanosine is a preferential target for most chemical
5 P. M. Chumakov, EMBL Accession Number is X54156 for HSP53G.
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Table 3 Codon number and specific alteration for breast tumor mutations
(mutations from this paper and from the literature)
Single nucleotide substitutions
Codon Codon Nucleotide CpG
number change change dinucleotide Source Ref.
128 CCT—CCG T—G Tumor 29
128 CCT—TCT C—T Non Tumor 29
132 AAG—CAG A—C Cell line 22
134 TTT—CTT T—C Tumor 29
136 CAA—GAA C-G Tumor 21
141 TGC—TAC G—A Non Tumor This paper
151 CCC—TCC C—T Non Tumor 26
152 CCG—TCG C—T Non Tumor 21
157 GTC—TTC G—T Tumor 21
157 GTC—TTC G—T Cell line 28
163 TAC—AAC T—A Tumor This paper
163 TAC—TGC A—G Tumor 24
164 AAG—CAG A-C Tumor 21
175 CGC—CAC G—A CpG Tumor This paper
175 CGC—CAC G—A CpG Tumor This paper
175 CGC—CAC G-A CpG Tumor 27
175 CGC—CAC G—A CpG Tumor 29
175 CGC—CTC G—T Tumor 21
175 CGC—CAC G—A CpG Cell line 28
178 CAC—CCC A—C Tumor This paper
179 CAT—TAT C—T Non Tumor This paper
179 CAT—GAT C-G Tumor 21
182 TGC—TGA C—A Tumor This paper
186 GAT—TAT G—T Tumor This paper
187 GGT—TGT G—T Tumor 21
192 CAG—TAG C—T Non Tumor This paper
193 CAT—CCT A—C Tumor a
194 CTT—CGT T—G Tumor This paper
194 CTT—CGT T—G Tumor This paper
194 CTT—CGT T—G Tumor This paper
194 CTT—TTT C—T Non Cell line 20
196 CGA—CCA G-C Tumor a
208 GAC—GTC A—T Tumor This paper
213 CGA—TGA C-T CpG Tumor This paper
213 CGA—TGA C—T CpG Tumor This paper
234 TAC—TAA C—A Ceil line 31
237 ATG—ATT G—T Tumor This paper
237 ATG—AAG T—A Tumor 29
237 ATG—ATA G—A Non Tumor 24
238 TGT—TTT G—T Tumor 30
238 TGT—TTT G—T Tumor 29
239 AAC—GAC A-G Tumor This paper
242 TGC—TTC G—T Tumor 32
245 GGC—GAC G-A Non Tumor 24
245 GGC—GTC G—T Tumor 29
245 GGC—GAC G-A Non Tumor This paper
248 CGG—TGG C—T CpG Tumor 29
248 CGG-CAG G—A CpG Tumor 24
248 CGC—CAG G—A CpG Tumor 25
249 AGG—AGC G-C Cell line 22
250 CCC—GCC C-G Tumor 32
254 ATC—AAC T—A Tumor 25
265 CTG—CCG T—C Tumor 32
266 GGA—GTA G—T Tumor 25
267 CGG—CAG G-A CpG Tumor 32
273 CGT—CAT G—A CpG Cell line 20
273 CGT—CTT G—T Tumor This paper
273 CGT—CAT G-A CpG Tumor This paper
273 CGT—CAT G-A CpG Tumor 29
276 GCC—CCC G—C Tumor This paper
278 CCT—GCT G—C Tumor 24
280 AGA—ACA G—C Tumor 30
280 AGA—ACA G-C Tumor 28
280 AGA—'GGA A—G Tumor 32
280 AGA—AAA G—A Non Cell line 22
281 GAC—GGC A-G Tumor 32
281 GAC—GGC A-G Tumor 29
282 CGG—CTG G—T Tumor This paper
282 CGG—CCG G-C Tumor 27
282 CGG—CTG G—T Tumor 24
283 CGC—CCC G-C Tumor 32
285 GAG—AAG G—A Non Tumor This paper
285 GAG—AAG G-A Non Tumor 30
285 GAG—AAG G-A Non Cell line 22
307 GCA—ACA G-A Non Tumor 32
Table 3—Continued
Deletions
Codon Codon change Deletion Source Ref.
140 GAC—G-C AT base pair Tumor This paper
167 CAG—CA- GC base pair Tumor 27
172 GTT—GT TA base pair Tumor 29
175-180 Deletion of 6 codons 18 base pairs Tumor 24
201 TTG—TT- GC base pair Tumor 21
235-239 Frameshift deletion 14 base pairs Tumor 28
255 ATC deletion 3 base pairs Tumor This paper
329 ACC—AC- CG base pair Tumor 28
Exon 11 Deletion of 30 30 base pairs Tumor 30
base pairs
a P. Devilee, unpublished observations.
carcinogens (76) and that the nontranscribed strand is more
commonly the site of damage (possibly because of a bias in the
rate of DNA strand repair such that the coding strand is pref¬
erentially repaired over the noncoding strand) (77).
Two categories of mutation are, therefore, noticeably preva¬
lent in sporadic breast tumors: CG-TA transitions and GC-TA
transversions. The increased incidence of CG-TA changes oc¬
curs both at CpG dinucleotides (19%) and at cytidines and
guanosines not contained in this sequence conformation (20%).
Although CG-TA changes at CpG dinucleotides are common,
they are not as frequent as in colon cancer, where they account
for 67% of the total changes (37). With GC-TA transversions,
it is apparent that they are more frequent in sporadic breast
cancer than expected. Hollstein et al. (37) found that GC-TA
changes occur at high frequency in lung cancer (non-small cell
lung cancer, 57%), liver cancer (74%), and esophageal cancers
(24%), where a number of specific mutagenic factors are be¬
lieved to be important. Aflatoxin B1 is a potent liver carcinogen
which induces G-T transversions, and carcinogens in tobacco
(for example, benzo[a]pyrene) are also known to elicit G-T
transversions. However, in other solid tumors (colon, bladder,
ovary, sarcomas, and brain) GC-TA transversions constitute a
small proportion of all mutations (5-13%). Of 75 point muta¬
tions in breast tumors in our series, 16 (21%) are GC-TA
transversions. The increased frequency ofGC-TA transversions
and the high incidence of mutation of guanosines in the non-
coding strand of the gene might, therefore, imply that external
carcinogens have a role in the development of sporadic breast
tumors.
The germ-line mutations to p53 found in the Li-Fraumeni
familial cancer syndrome (which includes breast tumor) have a
mutational spectrum with a preponderance of CG-TA transi¬
tions and few GC-TA transversions (Table 4). Forty-four % of
the germ-line mutations are at CpG dinucleotides, a change
that is frequent in mammalian genomes (78) and may be attrib¬
uted to spontaneous deamination of cytosine. It, therefore, ap¬
pears that different factors predispose cells to the somatic p53
mutations found in a large proportion of sporadic breast tumors
and to the germ-line p53 mutations which occur as part of the
Li-Fraumeni inherited cancer syndrome.
When the mutational spectra between breast cancer and co¬
lon cancer are compared, there are obvious differences. A high
proportion (67%) of all p53 mutations in colon cancer are
CG-TA transitions at CpG dinucleotides. There are no re¬
corded GC-TA transversions (37, 38) and three codons are
indisputably hot-spots for mutation: codons 175, 248, and 273
p53 MUTATIONS IN BREAST CANCER
Table 4 Frequency ofspecific mutations in breast tumors, in Li-Fraumeni patients, and in cancers other*than breast
GC-AT
GC-CG GC-TA (CpG, non) AT-GC AT-CG AT-TA Total
Published breast mutations except those from 6 7 16 (8,8) 3 3 2 37
this laboratory (20, 22, 24-31)"
Breast mutations from this laboratory (this paper; 5 9 13 (6,7) 4 5 2 38
Refs. 21 and 32)
Total breast tumor mutations 11 16 29(14, 15) 7 8 4 75
Percentage of specific mutations in breast tumors 15 21 39 (19. 20) 9 11 5 100
Germ-line p53 mutations (mainly Li-Fraumeni) 0 2 15 (10,5) 3 1 0 21
Percentage of specific germ-line mutations 0 10 71 (47, 24) 14 5 0 100
Percentage of specific p53 mutations in all cancers 9 21 48 (36, 12) 11 5 5 100
other than breast (38)
Percentage of specific p53 mutations in all cancers 8 11 56 (42, 14) 13 6 5 100
other than breast, liver, and lung (38)
a P. Devilee, unpublished observations.
(accounting for >50% of all the alterations). In contrast, in
breast cancer the picture is very different; of the 75 point mu¬
tations analyzed, only 19% occur at CpG dinucleotides, 21%
are GC-TA transversions, and only 24% of breast cancer mu¬
tations occur at four codons: 175 (six), 194 (four), 273 (four),
and 280 (four). Overall, CG-TA transitions at CpG are less
frequent, GC-TA transversions are more frequent, and there are
not such pronounced hot-spots for mutation as found in colon
cancer.
Analysis of the Particular Mutations and Codons Involved.
Data from a number of studies show that the most frequent type
of change occurring in the p53 gene is a single-base missense
substitution which alters a single amino acid in the protein (e.g.,
Refs. 20, 37, and 38), and this is true in breast tumors also,
where 89% (75 of 84) are single-nucleotide substitutions (84%
result in amino acid substitutions and 5% in stop codons). The
remaining 11% (9 of 84) are deletions. The locations of all point
mutations in sporadic breast cancer published to date (Refs.
20-32, 37, and 38 and this paper) have been in conserved
codons of the gene; 68% are in conserved domains II to V, 8%
in domain II, 12% in domain III, 23% in domain IV, and 25%
in domain V. Of the remaining mutations, 17 of 24 occur at
codons conserved from Xenopus to mammals and the rest are
found in codons conserved among mammals. A number of neu¬
tral mutations and polymorphisms have been reported for p53
in the literature. In 76 patients we have found two samples with
the CGA-CGG neutral mutation constitutionally present at
codon 213 (79, 80).
One of the 41 mutations in 136 patients was found to be a
constitutional change, CGG-CAG at codon 267, giving an in¬
cidence of constitutional mutations in p53 in sporadic breast
cancer of 0.7% (81). The patient carrying this constitutional
mutation was subsequently found to have come from a cancer-
prone family, although not a Li-Fraumeni family. We have
reanalyzed the five breast cancer-prone families previously re¬
ported (47) and confirm our inability to find constitutional p53
mutations in these individuals. In our 77-tumor set we found no
relationship between p53 mutation and tumor size, disease
stage, or menopausal status. This was also true for the 60-tumor
set (32).
Conclusions, (a) From our study of 136 breast cancer pa¬
tients we estimate that 40% of sporadic breast tumors carry
mutations in the p53 gene. A review of the data on incidence of
p53 mutations in sporadic breast cancer shows that the esti¬
mates ofmutation frequency are significantly different depend¬
ing upon whether the measurements are made by DNA analysis
(~40%) or by immunohistochemical methods (~60%). There
are theoretical reasons for both techniques to underestimate the
actual incidence, but there is good evidence to suggest that
immunohistochemical staining may well result in an overesti-
mation. Until a body of material selected on the basis of im¬
munohistochemical screening is extensively analyzed by non-
immunohistochemical methods and/or sequencing, it will be
difficult to account for the observed differences.
(b) In sporadic breast tumors, the increased frequency of
GC-TA transversions, together with a very high incidence of
guanosine mutations in the nontranscribed strand of the p53
gene, leads to the conclusion that exogenous carcinogens may
have an etiological role in these tumors. Information was not
available on what proportion of the breast cancer patients
were smokers and whether this was relevant in accounting for
some G-T transversions. Carcinogenic hormones are generally
inefficient in the production of point mutations at the gene
level (82), but increased estrogen levels are known to pro¬
mote cell growth and may indirectly increase the incidence of
mutation.
(c) Germ-line p53 mutations in the Li-Fraumeni family can¬
cer syndrome (which includes breast cancer) are mainly CG-TA
transitions at CpG dinucleotides. These may be naturally oc¬
curring endogenous events.
(d) Somatic mutations in breast tumors have been found in 44
codons of the p53 gene between exons 5 and 9. A preponder¬
ance ofmutations was found at codons 175, 194, 273, and 280,
but no particular mutational hot-spot was identified.
(e) Analysis of the data for LOH and mutation in p53 in
sporadic breast tumors suggests that in a proportion of tumors
mutation may occur before allele loss but this sequence of
events is not followed in a substantial number of tumors.
(/) In breast cancer patients an autosomal dominant mode of
inheritance accounts for approximately 5-10% of cases (83).
Based on our finding of one germ-line mutation in sporadic
breast tumors from 136 patients (81) and on our finding of no
apparent p53 mutation in five families with breast cancer (47),
we conclude that mutation in p53 is a rare etiological factor in
hereditary breast cancer.
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